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This thesis investigated a buprenorphine (BUP) and naltrexone (NTX) combination 
therapy for the prevention of relapse to heroin and cocaine. Delivery of the 
combination by transdermal iontophoresis was also explored. 
 
In the first half of the thesis, experiments were carried out using Sprague Dawley 
rats; an assay of analgesia (the tail withdrawal assay) and a behavioural assay 
(conditioned place preference; CPP) were employed. It was found that 1.0 mg/kg of 
NTX (but not 0.3 mg/kg NTX) blocked the analgesic and rewarding properties of 0.3 
mg/kg BUP. Interestingly, 0.3 mg/kg BUP with 3.0 mg/kg NTX, but not the same 
dose of NTX alone, was aversive. Using a CPP-extinction-reinstatement method, it 
was shown that the combination (0.3 mg/kg BUP and 1.0 mg/kg NTX), administered 
10 minutes before a priming dose, prevented reinstatement of both morphine- and 
cocaine-seeking. 
 
In the second half of the thesis, iontophoresis (0.3 or 0.4 mA/cm2) was used to 
transport BUP and NTX across the skin; experiments were carried out using excised 
pig skin in side-bi-side glass cells. NTX transport was efficient and consistent with 
the standard mechanisms (electrorepulsion and electroosmosis) of iontophoresis. 
BUP was less efficiently delivered and accumulated in the skin; the size of the BUP 
skin depot increased with pH and with the concentration of BUP in the donor 
solution. BUP’s presence in the skin reduced convective solvent flow (indicated by a 
neutral marker) which had a negative impact on its flux, and also on that of NTX. 
 
The BUP/NTX combination has real potential as a relapse prevention therapy, and it 
is particularly exciting that it seems to be efficacious against cocaine, as treatments 
for cocaine dependence are desperately needed. Delivery of a therapeutically 
relevant amount of the combination by transdermal iontophoresis is achievable, but 
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Chapter 1. Introduction 
 
1. Treatment of addiction 
 
Addiction is widespread and costly to the individual and to society. Globally, around 200 
million people use psychoactive substances (not including alcohol) each year (WHO 2015). 
In the UK, around 1600 people die per year as a result of using illegal drugs (Office for 
National Statistics), and around 1600 people are living with HIV as a result of intravenous 
drug use (Health Protection Agency).   
 
It is reported that 42 % of patients with substance abuse problems never achieve a 
sustained recovery (defined as one year with no symptoms) (Dennis et al. 2005). Treatment 
is difficult at least in part because a large number of drug users have psychiatric conditions 
(Dennis et al. 2005) and because concurrent use of multiple drugs of abuse is common (Leri 
et al. 2003).  
 
Heroin and crack cocaine are the two most harmful illegal drugs of abuse to the user as well 
as to others (Nutt et al. 2010). Treatment for dependence upon heroin and crack cocaine is 
the focus of this thesis.  
 
Characteristics of addiction  
The action of drugs of abuse is often described as a ‘hijacking’ of the natural reward systems 
of the brain. These reward systems exist because they reinforce fundamental behaviours 
such as eating, drinking, mating, and bonding with offspring. The effects of drugs of abuse 
are powerful because they do not simply mimic the natural reward, they far exceed it 
(Kalivas & O’Brien 2008). The effects of different addictive substances (alcohol, nicotine, 
amphetamines, cocaine, opioids) are mediated by distinct pharmacological mechanisms, but 
many behavioural commonalities can be observed. Indeed, clinical diagnosis of addiction 
does not distinguish between substances involved. Addiction is characterised by the 
following points (Redish et al. 2008; Badiani et al. 2011):  
 
o Some people are predisposed to addiction 
 
o People often first use drugs of abuse to self-medicate 
 
o Poly-drug use is common (such as alcohol with nicotine, or cocaine with 
heroin) 
 
o The motivation behind drug use changes from using the drug because it 
makes you feel good (‘positive reinforcement’) to because without the drug 




o Drug use evolves from a choice to a compulsion (this is associated with bad 
decision-making) 
 
o Drug use continues despite the experience no longer being pleasurable (liking 
changes to wanting) 
 
o Drug use continues despite negative consequences (such as significant 
detrimental effect on the user’s personal life, work, health) 
 
o The association between objects/people/places and the drug becomes 
strengthened  
 
o There is a high propensity to relapse (to resume drug use even after long 
periods of abstinence) 
 
It is generally believed that for all drugs of abuse dependence is related to an increase in 
levels of dopamine in the nucleus accumbens (Kreek et al. 2012). This commonality 
between different classes of drugs of abuse means that it is theoretically possible for a single 
pharmacological treatment to be effective against all drugs of abuse. 
 
Current strategies for pharmacological treatment of addiction 
Many relapse prevention therapies mediate their effect by blockade or substitution. These 
strategies can be illustrated by differing approaches to smoking cessation. Bupropion, 
available in tablet form, provides an example of the blockade mechanism. It does not elicit 
nicotine-like effects, and blocks the pleasurable effects of nicotine if the patient smokes. 
Nicotine, available as patches or gum, acts by substitution. The nicotine diminishes 
withdrawal symptoms, reducing (or eliminating) the need to smoke and therefore avoiding 
the associated health problems.  
 
Some relapse prevention therapies have aspects of both blockade and substitution.  For 
example, varenicline, which is sold as tablets for smoking cessation, blocks the effects of 
nicotine, but itself gives a low level nicotine-like effect.  
 
Current pharmacological treatments for heroin  
Methadone is the mainstay of heroin treatment in the UK. It acts primarily as a substitution 
therapy, by activating the same receptors as heroin, and thus reducing withdrawal symptoms 
(Farid et al. 2008), allowing patients to regain some control of their lives (Nutt & Lingford-
Hughes 2008). Methadone treatment has some shortcomings. Methadone is itself a very 
addictive drug, and can be fatal in overdose, by respiratory depression. Furthermore, it does 
not eliminate heroin use, and a patient on methadone is not protected from a fatal heroin 
7 
 
overdose. Lastly, many fatalities of children have occurred following accidental ingestion of 
methadone (Milroy & Forrest 2000). 
 
Naltrexone (NTX) is prescribed to heroin-dependent patients as an abstinence-promoter. 
Although NTX is safe, and effective at blocking the euphoric effects of heroin (Schuh et al. 
1999; Comer et al. 2006), treatment success is hindered by low compliance (Kirchmayer et 
al. 2002).  
 
A third treatment option for heroin-dependence is buprenorphine (BUP). It acts both as a 
substitution therapy, similar to methadone, and as a blockade therapy, similar to NTX 
(Greenwald et al. 2003). BUP can be rewarding (Greenwald et al. 2007; Marquez et al. 
2007) therefore concerns exist over abuse liability. 
 
As mentioned, this thesis focuses not only on the treatment of dependence on heroin but 
also on crack cocaine. Unfortunately, whilst the symptoms associated with ceasing long-term 
use of cocaine (such as sleeplessness and anxiety) can be treated, no treatment to reduce 
the likelihood of relapse is currently available.  
 
Euphoria and reward 
The brain areas involved in both acute and chronic effects of rewarding substances include 
the amygdala, hippocampus, hypothalamus, several regions of the frontal cortex, the VTA 
(ventral tegmental area), and the NAc (nucleus accumbens). The pathway from the VTA in 
the midbrain to the NAc in the limbic forebrain (the mesolimbic dopamine pathway) is 
considered particularly important, and an increase in dopamine release in the NAc appears 
to be a common effect of both drugs of abuse and of natural rewards such as food and sex 
(Berridge & Robinson 1998). 
 
Figure 1.1 illustrates that despite diverse pharmacology, all drugs of abuse (including opiates 
and cocaine) have convergent effects at the mesolimbic dopamine pathway, resulting in a 






Figure 1.1: Simplified diagram of the acute actions of several drugs of abuse on the ventral 
tegmental area (VTA) and the nucleus accumbens (NAc). Cocaine is represented here 
under the description ‘stimulants’. Adapted from Nestler (2005), and reproduced with kind 
permission of Nature Publishing Group. 
 
Opiates 
The opioid system comprises three classical receptors: mu, kappa, and delta, plus the more 
recently characterised NOP (Nociceptin/Orphanin FQ). NOP is also known as ORL-1 (Opioid 
Receptor-Like). The primary ligands of the mu, kappa and delta receptors are the 
endogenous peptides β-endorphin, dynorphin, and met- and leu-enkephalin (Mucha et al. 
1985). The endogenous ligand of NOP is nociceptin (Meunier et al. 1995; Reinscheid et al. 
1995).  
 
The opioid receptors are G-protein-coupled receptors, and are broadly expressed throughout 
the central and peripheral nervous system (Le Merrer et al. 2009). Binding sites of mu, 
kappa and delta overlap in most brain structures, although higher expression of one receptor 
type may be seen in some regions. 
 
The mu receptor is well studied, partly because many analgesics, such as morphine, 
mediate their therapeutic effects (and indeed their side-effects such as respiratory 
depression) via the mu receptor. Agonism of the mu receptor can also produce euphoria 
(see next section).  
 
Agonism of the kappa receptor also has analgesic effects. However, unlike mu agonism it 
does not cause respiratory depression, and instead of euphoria can elicit dysphoria 
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(negative mood state). Antagonism of the kappa receptor can have an anti-depressant or 
anti-stress effect (Almatroudi et al. 2015). The kappa/dynorphin system and the mu system 
oppose and balance each other to maintain a baseline normal mood state (Shippenberg & 
Herz 1986).  
 
The importance of the delta receptor in the treatment of addiction is the least well studied 
and remains unclear. The effect of agonism of the NOP receptor by the endogenous peptide 
nociceptin is complex, but as its name suggests, it has some pain-producing effects (Lutfy & 
Maidment 2000).  
 
Activation of the opioid receptors causes inhibition of adenylate cyclase, hyperpolarisation 
due to the opening of potassium channels, and inhibition of transmitter release due to the 
inhibition of the opening of calcium channels. Opioids bind to opioid receptors on GABAergic 
interneurons in the VTA. This results in a disinhibition of VTA dopaminergic neurones that 
project to the NAc, and an increase in dopamine levels. Opioids also bind to opioid receptors 
on neurons in the NAc itself.  
 
Cocaine 
Cocaine increases levels of dopamine, noradrenaline and 5-HT in the synapse in the central 
and peripheral nervous system (Phillips et al. 2014). This is generally attributed to the 
binding of cocaine to the respective reuptake transporters of dopamine, noradrenaline and 5-
HT (DAT, NET and SERT) and consequent blocking of their activity delaying clearance of 
those neurotransmitters from the synapse back into the pre-synaptic neurone. A mechanism 
whereby dopamine transport by DAT is actually inverted has also been more recently 
described (Badiani et al. 2011; Heal et al. 2014). Either way, an increased level of 
extracellular dopamine is probably the most important mediator for cocaine’s stimulating and 
euphoric properties (Heal et al. 2014). 
 
Changes in the brain due to chronic drug use 
Physiological changes occur during chronic drug use (Wise & Koob 2014). Sustained high 
levels of mu agonism (due to chronic heroin use, for example) cause endogenous systems 
to shift toward normal pre-drug levels (classical homeostasis). The mu system is down-
regulated and the kappa/dynorphin system is up-regulated (Bruchas et al. 2010). This up-
regulation of the kappa/dynorphin system is also observed following chronic cocaine use 
(Shippenberg 2009). When a drug user abstains from using drugs, agonism of the mu-opioid 
receptor is dramatically reduced, but the kappa/dynorphin system is still in “overdrive”; the 
resulting imbalance causes dysphoria. Ceasing chronic use of drugs of abuse can therefore 
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leave patients in a very unpleasant physical and psychological state (Rothman et al. 2000). 
Furthermore, during periods of abstinence, patients’ pre-existing pathologies (such as 
depression or anxiety) may emerge. This state of mind leaves patients vulnerable to relapse 
triggered by stress, people/objects/places strongly associated with previous drug-taking, or 
by a small intake of the drug of abuse (Aguilar et al. 2009). 
 
The mood state of patients is critical to retention in treatment programs, and therefore critical 
to likelihood of relapse (Rothman et al. 2000). As abstinent patients may be dysphoric due to 
kappa overdrive, administration of a kappa antagonist is a rational treatment strategy (Carroll 
& Carlezon 2013). Unfortunately, no selective kappa antagonists are currently licensed. 
Rothman et al. (2000) suggested that delivering two currently licensed compounds, BUP and 
NTX, together was a way of achieving the desired pharmacological profile of kappa 




NTX is an antagonist at the mu and the kappa receptors, and binds with comparable affinity 
at both these receptors (Toll et al. 1998). The low compliance documented for NTX may be 
related to the fact that it provides no pleasure (Kirchmayer et al. 2002). Furthermore, as an 
antagonist of the mu receptor it is likely to block natural rewards (Mucha et al. 1985) and 
exacerbate the patient’s dysphoria. The idea that mu antagonists can block endogenous 
rewards appears to be supported by preclinical work (Mucha et al. 1985) that showed that 
removing the brain region of rats that produce β-endorphin eliminated the observed aversive 
effect of naloxone. 
 
Poor adherence to NTX is a serious concern; if the patient does not take the medication for a 
day or two, blockade of heroin will not be effective, because NTX has a half-life of around 24 
hours (Nutt & Lingford-Hughes 2008). Lastly, it is interesting to note that NTX is also used 
for treatment of alcohol-dependence. It is suggested that in the event of a lapse the pleasure 




BUP is a partial agonist of the mu receptor, and an antagonist of the kappa receptor 
(Husbands 2013). As a partial agonist at the mu receptor, BUP can act as an agonist or an 
antagonist, depending on the dose and the specific test conditions (Schuh et al. 1999). As 
an agonist, BUP can be described as a substitution therapy. It follows that it can cause a 
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positive mood state, and can be rewarding (Greenwald et al. 2007; Marquez et al. 2007). 
BUP has high affinity but low efficacy at the mu receptor, and can therefore act to block the 
actions of other mu agonists, such as hydromorphone (Schuh et al. 1999) and heroin (Law 
et al. 2004).  
 
As previously stated, BUP is a partial agonist at the mu receptor. This means that it can 
never elicit the same response as full opioid agonists (such as morphine, for example) even 
at high doses. Consequently, compared to full agonists, BUP exhibits a ceiling effect for 
respiratory depression, and for its rewarding properties (Lewis 1985). Although the ceiling 
effect on respiratory depression does mean that BUP alone is very safe, intravenous 
injection in conjunction with other drugs such as benzodiazapenes may be harmful (Nutt & 
Lingford-Hughes 2008).  
 
BUP and NTX combination 
This approach could be considered as a NTX therapy in which BUP is included to make it 
more attractive to patients; this is critical to encourage individuals to remain in treatment 
(Nutt 2010). Alternatively, the combination can be viewed as a BUP therapy in which NTX is 
included to limit abuse liability. Inclusion of sufficient NTX should be able to limit BUP’s mu-
opioid receptor agonism (Dum & Herz 1981; McAleer et al. 2003) thus increasing regulatory 
acceptability, and feasibility of its use in cocaine addicts. Overall it is desired that the 
combination of BUP and NTX be neither rewarding nor aversive. 
 
Though not mentioned in Rothman’s original rationale for the combination (2000), BUP is 
also a partial agonist of the NOP receptor (Huang et al. 2001). Selective NOP agonists are 
neither rewarding nor aversive (Le Pen et al. 2002) and, although the mechanism is poorly 
understood, they have been shown in rodents to oppose the effects of both cocaine and 
morphine (Kotlinska et al. 2002; Sakoori & Murphy 2004).  
 
Rothman presented the BUP/NTX combination primarily as a treatment for heroin-dependent 
patients. McCann (2008) also championed a BUP/NTX combination for relapse prevention, 
but with a slightly different rationale. There is some evidence that BUP might reduce cocaine 
use (Kosten et al. 1989) but it might not be appropriate to administer even a partial mu 
agonist to opioid-naïve cocaine-dependent patients. Inclusion of NTX in the combination 
would address that concern. Lastly, McCann pointed out that the majority of cocaine-
dependent patients also abuse alcohol, and NTX is already licensed for alcohol 
dependence. Overall, a mixed very low efficacy mu receptor agonist, kappa receptor 
antagonist, NOP receptor agonist is a desirable target as a novel anti-addiction therapy. 
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Note that the rationale for combining BUP with the mu antagonist naloxone in the analgesic 
sublingual tablet Suboxone® is completely different from the rationale for combining BUP 
with NTX for relapse prevention here described. In Suboxone®, naloxone is included as an 
anti-abuse strategy. Due to low bioavailability, naloxone has no pharmacological effect if the 
product is used as indicated, but if the tablet is crushed and injected, the naloxone blocks 
the potentially rewarding effects of the BUP. Naloxone is not well suited to long-term 
treatment of heroin dependence due to its relatively short duration of action (van Dorp et al. 
2006) and is more commonly used to treat opiate overdose.  
 
Clinical evidence for a BUP/NTX combination as a relapse prevention therapy 
A small study involving drug users was carried out to test whether a BUP/NTX combination 
was effective as a relapse prevention treatment (Rothman et al. 2000). In these studies, 
NTX and BUP were administered as oral tablets and sublingual tablets respectively. The 
results were encouraging; a significant reduction of both heroin and cocaine use was 
demonstrated. A second, slightly larger study was therefore carried out (Gerra et al. 2006), 
in which the BUP/NTX therapy was directly compared with NTX alone. The effect of the 
combination was superior to that of NTX alone. Retention rates were higher in the 
combination group (22 out of 30 completers compared to 12 out of 30 completers for the 
NTX-only group). Patients taking the combination showed reduced drug use (figure 1.2), 
and reduced scores for craving and psychiatric symptoms including depression and anxiety.  
 
 
Figure 1.2: Treatment with NTX/BUP resulted in lower rates of positive urine samples than 
treatment with NTX only (p < 0.05) after 12 weeks of treatment. Drawn from data from Gerra 
et al. (2006). 
 
Both Rothman and Gerra attribute the success of the BUP/NTX combination primarily to 
kappa antagonism restoring the balance between the mu and kappa systems, thus 
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restoring mood. Gerra concedes that a small amount of mu agonism from BUP might also 
aid outcomes. Regardless of the mechanism responsible, overall the combination probably 
works because it reduces the need to self-medicate (Gerra et al. 2006). 
 
Effect of BUP/NTX on cocaine use 
Interestingly, a reduction in cocaine use in the combination group was observed in both 
clinical studies (Rothman et al. 2000; Gerra et al. 2006). This effect has also been observed 
when BUP (Kosten et al. 1989) and NTX (Schmitz et al. 2001) are administered separately. 
If the rewarding effects of cocaine are mediated by dopamine, it is not immediately obvious 
why treatment with opioids should be effective. However it has been reported that human 
polymorphisms at the mu receptor influence predisposition to cocaine addiction (Kreek et al. 
2012; Yuferov et al. 2010), and preclinical evidence indicates that cocaine use results in 
region-specific activation of both the mu and kappa systems (Yoo et al. 2012). 
 
The reduction in cocaine use observed in the Rothman (2000) and Gerra (2006) studies 
could be a result of antagonism of mu receptors attenuating the positive reinforcing effects of 
cocaine (Bilsky et al. 1992), or a result of antagonism of kappa receptors conferring stress 
resilience (Redila & Chavkin 2008), or a consequence of more generalized anti-addictive 
effects of agonism of the NOP receptor (Shoblock et al. 2005; Kuzmin et al. 2007). 
Alternatively, the observed reduction in cocaine use in these two clinical studies could simply 
be a consequence of reduction in heroin use; these two drugs of abuse are often used by 
addicts to ‘complement’ each other (Leri et al. 2003). Therefore, the impact of BUP/NTX on 
the effects of cocaine in a controlled experiment has been assessed in Chapter 2 of this 
thesis.  
 
2. Delivery strategy for buprenorphine and naltrexone 
 
Formulation of BUP and NTX together in a single medicine is likely to be fundamental to the 
success of this combination therapy. As BUP can be rewarding when not blocked by NTX, 
physical incorporation of the two compounds together is necessary to minimise the chance 
of abuse or diversion of BUP. Furthermore, adherence is a particular concern in this patient 
group, and would be facilitated with a simpler therapy. 
 
Oral tablets, though cheap and convenient, are not a straightforward option for co-
formulation of BUP and NTX. NTX can be administered orally, but BUP has low oral 
bioavailability due to significant first pass effect (McQuay & Moore 1995). Conversely, BUP 
can be administered as a sublingual tablet (or sublingual film), but NTX has low 
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bioavailability by the sublingual route (Lewis & Lloyd-Jones 1987). Therefore, in the clinical 
studies already mentioned (Rothman et al. 2000; Gerra et al. 2006), BUP and NTX were 
administered sublingually and orally respectively. A similar situation is seen for a clinical trial 
of BUP and NTX for reduction of cocaine use currently underway (planned study design 
described in Mooney et al. 2013), where NTX is being administered as a long-acting 
parenteral (Vivitrol®) and BUP is being delivered as a sublingual tablet (Suboxone). 
 
Co-formulation of BUP and NTX in an injectable depot or a surgically-inserted depot (with 
each depot lasting several months, for example) has obvious advantages related to patient 
compliance (Sigmon et al. 2006), and NTX implants have achieved some success in patients 
compared to oral tablets (Carreno et al. 2003). However, there are several drawbacks to 
depots. Administration of the drug/s cannot be easily discontinued in the event of adverse 
reactions. Specifically, there is concern over how to provide acute (opioid) pain relief to 
patients with an NTX implant. Lastly, no titration of dose can be carried out (until the next 
depot is administered). 
 
Rationale for the transdermal route for a BUP/NTX therapy 
In this thesis, the administration route selected for co-delivery of BUP and NTX was the 
transdermal route. Transdermal delivery can be used to achieve a continuous input of drug. 
It is envisaged that BUP/NTX patches would be replaced every few days. 
 
General advantages of the transdermal route include avoidance of first-pass metabolism and 
of food effects, less frequent dosing for drugs with very short half-lives, ability to discontinue 
the medication immediately, and suitability for patients who cannot swallow or who are 
vomiting (Cleary 1993; Berner & John 1994). The possible advantages of delivery of NTX by 
the transdermal route have been previously discussed. Oral NTX is associated with 
gastrointestinal disturbances, which would potentially be avoided by delivering NTX 
transdermally (Paudel et al. 2005; Valiveti et al. 2005). The low patient retention rates 
reported for NTX (Kirchmayer et al. 2002) may be due, at least in part, to its side effects 
(nausea, headache, anxiety). It is thought that the side effects of NTX are caused by its 
primary metabolite, 6-beta-naltrexol (6ß-NTX) (King et al. 1997), though the mechanism is 
unknown. Transdermal delivery would address this in two separate ways. Firstly, a slow 
steady input of NTX would avoid plasma peaks of 6ß-NTX. Secondly, the ratio of the parent 
drug to the metabolite is larger when NTX is delivered transdermally compared to orally 
(Wermeling et al. 2008), the authors suggest that this might be due to avoidance of 




Transdermal patches for delivery of BUP alone have already been commercialised 
(Transtec, Norspan, Butrans), for provision of analgesia. The rationale for this administration 
route for BUP included steadier plasma concentrations than can be achieved with the 
sublingual route (Lanier et al. 2007). In a relapse prevention therapy, a slow input rate of 
BUP is particularly important. The speed with which a drug enters the brain is very important 
to its subjective effects (Gorelick 1998; Samaha & Robinson 2005). A critical aspect of 
substitution therapy is that the therapeutic drug effect occurs more slowly than for the drug of 
abuse. For example, the slow onset of methadone (thought to be a consequence of both oral 
consumption and slow binding to receptors) is critical to its use (Bailey & Husbands 2014). 
The slow input of BUP that can be expected from a transdermal patch means that the 
treatment itself is unlikely to be rewarding. 
 
Specific advantages of formulating a BUP/NTX combination as a transdermal patch are as 
follows. It is likely that a relatively constant ratio of NTX:BUP plasma levels would be more 
easily achieved using continuous drug release from a patch than from the concurrent release 
of BUP and NTX from daily administration of tablets or films. Secondly, BUP incorporated 
into an adhesive patch (in the presence of NTX) would be relatively tamper-proof. Despite 
these advantages, to the author’s knowledge, no attempt has previously been made to 
deliver NTX and BUP together via the transdermal route.  
 
The skin as a site for drug delivery 
Three distinct tissue layers lie between the surface of the skin and the cutaneous blood 
supply (a distance of 200 µm or so; Bronaugh & Stewart 1986): the stratum corneum, the 
viable epidermis, and the dermis (see figure 1.3). 
 
The stratum corneum is a tough, flexible, waxy layer around 10 µm thick (Kligman 1964), 
and is the layer of the skin that hinders water loss. The corneocytes (the cells of the stratum 
corneum) are flattened, relatively impermeable, dead cells filled mainly with keratin, largely 
devoid of lipids, stacked in interdigitated columns. Each corneocyte is around 1 µm thick, 
and ~ 40 µm wide (Prausnitz et al. 2004). The corneocytes are embedded in a matrix of 
extracellular, highly ordered lipid bilayers composed of cholesterol, ceramides and free fatty 
acids. 
 
Below the stratum corneum is the viable epidermis. This is a cellular, aqueous environment, 
around 50-100 µm thick (van Smeden et al. 2014). Underneath the epidermis is the dermis, 
which is a largely acellular, aqueous, gel-like connective tissue that contains mainly collagen 
in a matrix of glycosaminoglycans. The capillaries of the cutaneous microcirculation extend 
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Figure 1.3: Schematic representation of a cross section through human skin. a, b and c 
show theoretical routes for skin permeation; a = intracellular, b = intercellular, c = 
appendageal (i.e., via a hair follicle or sweat gland). Redrawn from Prausnitz et al. 2004, and 
Jepps et al. 2013. 
 
Although this thesis is concerned with iontophoretic delivery, a brief description of passive 
permeation is included for completeness and is focussed on transdermal delivery of drugs 
for systemic action, i.e., penetrating the skin to reach the cutaneous microcirculation.  
 
It is widely accepted that the stratum corneum is very effective at hindering the movement of 
drug molecules from the surface of the skin into the body. However, despite extensive 
research, a clear consensus on the route that drugs take across this barrier has not been 
reached. There are three theoretical options (Scheuplein 2013). Drug molecules could take 
the shortest route through the skin (shown as a in figure 1.3). This would involve repeatedly 
passing alternately through the corneocytes and the lipid cement around them, and is 
therefore considered by many to be thermodynamically unfeasible (Cullander 1992; Guy 
2013). Drug molecules could pass through the stratum corneum, but only move through the 
lipid cement (shown as b in figure 1.3). This is often referred to as the ‘tortuous’ pathway 
because to move around 10 to 15 layers of the flat wide corneocytes, the drug molecules 
may travel up to 500 µm (Hadgraft 2004) to cross the ~10 µm thick stratum corneum. For 
exponents of this pathway, the unique geometry of the cells of the stratum corneum helps to 




Lastly, drug molecules could enter the hair follicles or sweat ducts (shown as c in figure 1.2). 
The sweat duct route is often largely ignored, because they occupy such a small area of the 
skin surface (Edwards & Langer 1994), and furthermore, are either closed, or there is an 
outward movement of sweat, which would hinder drug ingress (Robson 1988). Hair follicles 
also occupy a small area of the skin surface (hair follicles on the chest and upper arm 
occupy ~0.2% of area, Otberg et al. 2004). To be clear, the hair follicle route does not 
circumvent the stratum corneum; the follicles are lined with stratum corneum, albeit thinner 
(Jepps et al. 2013). Obviously, these three routes across the skin are not mutually exclusive, 
and a drug may travel via all of these routes, at different rates, dependent on the 
physicochemical properties of the drug, the condition of the skin, and perhaps the stage of 
drug permeation (Keister & Kasting 1986; Scheuplein 2013). 
 
The influence of the physicochemical properties of compounds on their rate of passive 
permeation through the skin has been well studied (Naik et al. 2000; Wiedersberg & Guy 
2014). Not surprisingly, all things being equal, smaller molecules permeate faster than larger 
molecules, and, as a rule of thumb, molecules over 500 Da are not considered good 
candidates for transdermal delivery. Molecules can cross the skin easier in the unionised 
form. A balance of lipophilicity and hydrophilicity is important; a decent water solubility (≥ 
1mg/ml) and a logP between 2 and 3 are optimal. Some water solubility is desirable because 
transdermal formulations may be formulated as a hydrogel, for example. The balance of 
lipophilicity and hydrophilicity is important because a drug molecule must permeate the lipid 
barrier of the stratum corneum, before moving into the aqueous environment of the viable 
tissue (Guy 2013). 
 
The transdermal products currently available are used for quite varied clinical indications, for 
example: testosterone gel (testosterone replacement), rotigotine patches (Parkinson’s 
disease), oxybutynin patches (overactive bladder), fentanyl patches (analgesia), 
scopolamine patches (travel sickness), and nicotine patches (smoking cessation). Not only 
do these compounds display sufficient permeability through the skin, but they have another 
unifying feature: they are all relatively potent. Passive permeation across the skin is slow, 
therefore only drug compounds with therapeutic plasma concentrations of a few ng/ml are 
likely to be successfully delivered via the transdermal route (Kalia et al. 2004). 
 
Target transdermal fluxes for a BUP and NTX relapse prevention therapy 
A minimum required transdermal flux (input rate) can be calculated from the clearance of the 
drug and the therapeutic plasma concentrations required at the steady-state, if known 





Clearance (L/h) x plasma concentration (µg/L) = Required steady-state flux (µg/h)  
  
The optimal plasma concentrations of BUP and NTX for the treatment of opioid dependence 
are not yet precisely known, but there are studies in the literature that indicate required 
therapeutic plasma levels of the two drugs separately. Table 1.1 shows the predicted 
required input rates for BUP and NTX, calculated from the predicted therapeutic plasma 
concentrations and on literature values of clearance. Note that this calculation assumes 
100% bioavailability. In reality, bioavailability for the transdermal route may be less than 
100% because some drug may be metabolised in the skin, or sequestered in the outer 
layers of the skin and never reach its target (Berner & John 1994).  
 
Unfortunately, in the studies in man by Rothman (2000) and Gerra (2006), plasma 
concentrations of NTX and BUP were not measured. Thus table 1.1 shows therapeutic 
concentration values from other sources. For NTX, the predicted therapeutic plasma 
concentration comes from a handful of studies in man where NTX’s ability to block the 
effects of heroin was assessed (Farid et al. 2008). For BUP, the predicted therapeutic 
plasma concentrations come from studies measuring withdrawal symptoms in opioid-
dependent volunteers (Kuhlman et al. 1998; Lanier et al. 2008) and from a study measuring 
extent of blockade of hydromorphone challenges (Sigmon et al. 2006). The predictions in 
table 1.1 are based on the therapeutic plasma concentrations of BUP and NTX when 
administered separately, so the plasma concentrations required as part of a combination 
therapy may well be lower. 
 
The selection of a patch size of 50 cm2 for the calculation of predicted fluxes was arbitrary, 
but was considered to represent an acceptable size for the patient.  
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Table 1.1: Transdermal passive fluxes of BUP and NTX required to keep a therapeutic 
steady-state concentration to treat opioid dependence. Values were predicted using 
equation 1.1 (Jtrans = Css x Cl) and reported clearance values. 
 
 
To put these target fluxes into context by comparison with some commercial (passive) 
products, the flux of estradiol is 0.09 – 0.42 μg/cm2/hr, of granisetron (to treat chemotherapy-
induced nausea and vomiting) is 2.5 μg/cm2/hr, and of methylphenidate (for treatment of 
attention deficit hyperactivity disorder) is 88 μg/cm2/hr. So, the required fluxes of BUP and 
NTX are within the range attainable for other drugs. It is now considered whether they are 
feasible for BUP and NTX. Table 1.2 shows the fluxes of NTX in vitro reported in previous 
work.  
















(Wall et al. 1981) 
 
157  
(Wall et al. 1984) 
2 




(Bullingham et al. 1980) 
 
76.8 
(Kuhlman et al. 1996) 
0.7 
(Kuhlman et al. 1998) 
 
0.74  
(Sigmon et al. 2006) 
 
0.60 




Table 1.2: Previous in vitro studies on transdermal delivery of NTX.  
a
values estimated from measured flux of the prodrugs, assuming complete conversion into 
NTX. 




Hammell et al. 
2004 
NTX prodrugs Human skin 2.8
a
 
Hammell et al.  
2005 
NTX prodrugs Human skin 2.3
a
 
Paudel et al.  
2005 
Delivering the active 
metabolite of NTX 
Guinea pig and human skin. 
75 % propylene glycol in the 
donor solution 
4.2 & 1.8 
Valiveti et al. 
2005 
NTX prodrugs 
Hairless guinea pig skin, 





Wermeling et al. 
2008 
Microneedles, NTX as 
HCl salt 
Human skin. Similar fluxes 
observed in vivo. 
14.7 
Banks et al.  
2008 
Microneedles, NTX as 
base and as HCl salt, 
and the active 
metabolite of NTX 
Guinea pig and human skin. 
75 % propylene glycol in the 
donor solution 
13.3 
Vaddi et al.  
2009 
NTX prodrugs Human skin 1.4
a
 
Milewski et al.  
2013 
Microneedles, 
NTX as HCl salt 
Yucatan pig skin 1.8 
Ghosh et al.  
2013 
Microneedles, NTX as 
base 
Yucatan pig skin 16.4 









It can be seen that conventional passive fluxes of NTX are lower than the predicted flux 
required for our application. NTX does not cross intact skin easily by passive diffusion, most 
likely due to its relative hydrophilicity (Paudel et al. 2005), having a logP of 1.7, and a water 
solubility of > 60 mg/ml, and 378 Da in size. The structure of NTX (and BUP) is shown in 
figure 1.4.  
 
 
Figure 1.4: Structure of naltrexone hydrochloride (left) and buprenorphine hydrochloride 
(right).  
 
Strategies explored by other groups include delivering prodrugs of NTX (Vaddi et al. 2009) 
and delivering the active metabolite of NTX (Paudel et al. 2005), and have had limited 
success. A strategy of compromising the barrier of the stratum corneum using microneedles 
(Wermeling et al. 2008; Ghosh et al. 2013) did result in fluxes higher than the target. 
However, it was considered that for this project, where chronic use of patches was 
anticipated, a microneedle system was not the most suitable option. 
 
The fluxes of BUP (base) from marketed passive patches for analgesia are 0.8 - 1.4 
µg/cm2/h (product information). This indicates that, unlike NTX, passive delivery rates might 
be sufficient to deliver BUP for relapse prevention. For completeness, table 1.3 shows some 




Table 1.3: Previous in vitro studies on passive transdermal delivery of BUP.  
Author Approach Details 
Maximum flux achieved 
(µg/h/cm2) 
Roy et al. 
1994 




50% ethanol in 
receiver solution 
2.8 for the base and 8.2 for 
the salt,  
both from 90 % propylene 
glycol  
Stinchcomb 
et al. 1996 




0.1 for BUP, all prodrugs 
lower 






Nude mouse skin, 
50% ethanol in 
receiver solution 
6.4 (BUP control) to 8.3
a
 
(best BUP nanoparticle 
formulation) 
Prodrugs all lower fluxes than 
BUP 
 
Rationale for iontophoretic delivery of NTX and BUP  
The literature indicates that NTX is not a strong candidate for passive transdermal delivery, 
and that predicted required fluxes might be difficult to achieve. The strategy selected here for 
optimising its flux was iontophoresis. Iontophoresis involves application of an electrical field 
across the skin at a low current density (up to 0.5 mA/cm2). A transdermal iontophoretic 
device consists of two electrodes (drug is present at one, the other is a ‘return’ electrode) 
typically incorporated into a small patch containing microelectronics and a battery. 
Compared to passive delivery, iontophoresis can greatly increase the rate at which drugs 
can be delivered across the skin (Merino et al. 1997). It does so by applying a driving force 
to the drug molecule, and not by decreasing the barrier properties of the skin. 
 
During iontophoresis, molecules move across the skin by three mechanisms: 
electrorepulsion (ER), electroosmosis (EO), and passive diffusion. Electrorepulsion drives 
ions into the skin away from the electrode of the like sign. For example, a cationic drug 
present at the anode can be transported into the body. Electrosmosis is a convective solvent 
flow that occurs when a current is passed across the skin. Electrorepulsion concerns only 
ionised molecules, whilst electrosmosis concerns both ionised and unionised molecules. 
Lastly, of course passive diffusion still occurs during iontophoresis, though obviously in a 
system optimised for iontophoretic delivery, the contribution of passive flux to total flux is 
likely to be negligible. 
 
NTX has been previously identified as a good candidate for iontophoretic delivery (Giannola 
et al. 2007), due to its hydrophilicity and the fact that it is charged at a physiological pH (it is 
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a weak base with a pKa of ~8), however, in that work, the suggested site of iontophoresis 
was the buccal cavity.  
As mentioned, it has already been demonstrated that BUP can be delivered transdermally by 
passive diffusion alone. However, in this thesis, BUP will be delivered by iontophoresis in 
order to be formulated together with NTX. It is important that BUP is physically incorporated 
into a product with NTX. As an opioid agonist, BUP is abusable in the absence of the 
antagonist NTX. Furthermore, transdermal delivery by iontophoresis offers increased control 
over input rate. Flux during iontophoresis is controlled by the current passed and not by the 
efficiency of the skin barrier (Harper Bellantone et al. 1986), consequently, variability 
(between body sites, and between individuals) is smaller than for passive transdermal 
delivery (Phipps et al. 1989). Iontophoresis also offers the possibility of faster attainment of 
therapeutic plasma levels compared to passive delivery (Thysman et al. 1994; Brand & Guy 
1995; Singh et al. 1995). Lastly, unlike passive patches, iontophoresis offers the possibility 
of manipulating or titrating the dose during patch use. The main disadvantage of 
iontophoresis compared to the conventional oral route, and indeed compared to passive 
transdermal delivery, is likely to be an increased cost. 
What type of molecule can be delivered by iontophoresis? 
Clearly, for drugs to be delivered by electrorepulsion, they must be ionisable over the pH 
range of the skin (Kalia et al. 2004). In contrast, electroosmosis will act on all molecules, 
ionised or unionised. 
 
It is easier for smaller molecules to cross the skin by electrorepulsion than larger molecules 
(Yoshida & Roberts 1992). However, the upper size limit of the permeant is significantly 
higher for iontophoresis than for passive, and peptides of a few kDa have been delivered 
(Green 1996).  
 
A minimum aqueous solubility of 1 mg/ml is desirable to formulate for iontophoresis, and 
lipophilic molecules are not easily delivered (Prausnitz et al. 2004). In experiments 
performed using homologous series of compounds iontophoretic flux has been observed to 
decrease with increasing logP and molecular weight (Del Terzo et al. 1989; Lopez et al. 
2003). Although in these studies it is not possible to dissociate effect of molecular weight 
from effect of logP, it is likely that effect of molecular size dominates (van der Geest et al. 
1996; Mudry et al. 2007). Figure 1.5 shows the relationship between molecular weight and 





Figure 1.5: Cationic transport numbers in the single-carrier situation as a function of 
molecular weight. Transport number is simply the fraction of charge carried by the permeant 
and is therefore a measure of the efficiency of delivery. Taken from Mudry et al. (2007) and 
reproduced with kind permission from Elsevier. 
 
Lastly, in contrast to passive delivery, it is likely that for iontophoresis the hair follicle route 
provides a major pathway for transport (Uitto & White 2003). That said, the contribution of 
this route during iontophoresis is probably system- and molecule-dependent, with preference 
for the follicle route increasing with hydrophilicity of the permeant (Cullander 1992). 
 
Commercially available transdermal iontophoretic devices 
Some iontophoretic devices have been approved for drug delivery. The Iomed Phoresor® 
system uses a small power pack in conjunction with disposable, fillable patches (provided 
without drug), and is commonly used to deliver dexamethasone to treat sports injuries. 
Prefilled patches are available for local delivery of lidocaine (for anaesthesia), for systemic 
delivery of fentanyl (for analgesia), and for systemic delivery of sumatriptan (for treatment of 
migraines). The lidocaine device is interesting as it also delivers epinephrine (a 
vasoconstrictor) to prolong local drug levels of lidocaine.  
 
Table 1.4 shows the iontophoretic transdermal drug delivery products that have reached the 
market, and some properties of the drug molecules therein, alongside NTX and BUP for 
comparison. It can be seen that in terms of physicochemical properties, NTX and BUP are 
reasonable candidates for iontophoretic delivery.  
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Table 1.4: Selected physicochemical properties of molecules in marketed iontophoresis 
products, compared with properties of NTX and BUP. *Patch is provided without drug, 
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NTX is similar in size and lipophilicity to compounds demonstrated to be suitable for 
iontophoretic delivery. BUP is slightly larger and has a lower aqueous solubility. 
 
Target iontophoretic transdermal fluxes for a BUP/NTX relapse prevention therapy 
For the prediction of required passive fluxes, a patch size of 50 cm2 was used. However, for 
an iontophoretic patch of 50 cm2, the delivery electrode would occupy only half of that area 
(the other half would be the return electrode). The required iontophoretic fluxes are therefore 
calculated based on a 25 cm2 delivery electrode area. The required iontophoretic flux of NTX 
is 15.2 μg/cm2/hr, and the required iontophoretic flux of BUP is 2.2 μg/cm2/hr.  
 
No studies of transdermal iontophoresis of NTX have been published. The table below 
shows studies on transdermal iontophoresis of BUP. The authors of these studies did not 
discuss the advantages of iontophoretic delivery of BUP, but Banga (2011) suggests that 
transdermal iontophoresis of BUP (for analgesia) could offer higher plasma levels, better 






Table 1.5: Previous studies on iontophoretic transdermal delivery of BUP. 
Author Approach Details 
Maximum flux achieved 
(µg/h/cm2) 












as hydrochloride salt 
Nude mouse skin 
in vitro 
10.1 (iontophoresis) and 6.1 
(electroporation)  
Denuzzio  




In vivo in pig 
Flux not given, 0.7 ng/ml 
Cplasma reached 
 
Studying iontophoresis in vitro 
For development and mechanistic studies, in vitro experiments are performed, commonly 
with human, pig or mouse skin (WHO 2006; Seto et al. 2010). The skin can be used ‘as is’ or 
sectioned to a uniform thickness with a dermatome (a surgical instrument that is used to cut 
skin for grafts). For a permeation experiment, the skin is mounted in a cell with the outer 
surface of the skin in contact with the drug (whether in a gel, cream, patch, or drug solution), 
and the inner surface of the skin in contact with a ‘receiver’ chamber. The receiver chamber 
is filled with buffer that can be sampled at intervals and assayed to quantify how much drug 
has crossed the skin in a given period of time. 
 
When performing iontophoresis in vitro, ‘side-bi-side’ cells (see figure 1.6) are commonly 
used. Most often, cells with two chambers are used (the donor, which contains the drug, and 
the receiver); the return electrode sits in the receiver compartment. Both compartments can 





   
 
 
Figure 1.6: Photograph showing an example of an in vitro iontophoresis cell. Pig skin is 
clamped between the two glass compartments. Ag/AgCl electrodes are immersed in the fluid 
bathing the skin, without contacting the tissue. The side arms of the cell compartments can 
be used to withdraw samples from the receiver (or donor) during the experiment.  
 
Following iontophoresis, the entire piece of skin can be assayed for drug; more precise 
information about the distribution of drug in the skin can be obtained by tape stripping. Tape 
stripping is a technique whereby successive layers of the stratum corneum are collected 
using adhesive tape, and from which drug can be extracted and assayed (Herkenne et al. 
2006).  
 
Overall, the background literature makes a compelling case for the combined iontophoretic 
delivery of BUP and NTX as a potential relapse prevention treatment to be explored.  
 
3. Aims and organisation of the thesis 
 
The first aim of the thesis was to assess the efficacy of a BUP/NTX combination to protect 
against relapse following a morphine or cocaine drug prime. In Chapter 2, the ratio of 
buprenorphine/naltrexone which was neither aversive nor rewarding was determined. 
Experiments were performed in vivo, using Sprague Dawley rats, with drug administered by 
intraperitoneal injection. The tail flick assay and the conditioned place preference method 
were used. In Chapter 3, it was demonstrated that buprenorphine/naltrexone may be 
effective at reducing both morphine- and cocaine-seeking. This was achieved using a 
conditioned place preference method which was extended to include an extinction and 




The second aim of the thesis was to assess the transdermal route as an administration 
option for BUP and NTX together. Chapters 4 and 5 concern the co-formulation of 
buprenorphine and naltrexone for delivery by transdermal iontophoresis. Experiments were 
performed in vitro, using pig skin. Chapter 4 demonstrated that these two drugs can be 
transported across the skin by iontophoresis, and showed the effect of pH, drug 
concentration, and current density. Chapter 5 characterised the effect of receiver solution 
and current profile. 
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An important feature of a buprenorphine/naltrexone (BUP/NTX) combination is that it should 
be neither rewarding nor aversive. Too much BUP could lead to a therapy that is rewarding, 
via agonism of the mu receptor (Marquez et al. 2007). This might be unacceptable from a 
regulatory point of view, and would be inappropriate for use in opioid-naïve cocaine-
dependent patients. Too much NTX could lead to a therapy that is aversive, possibly via mu 
antagonism effects on mood (Parker & Rennie 1992; Suzuki et al. 1992; Miotto et al. 2002); 
this would probably result in low retention rates (compliance currently being a major problem 
with NTX alone). The aim of this chapter was, therefore, to determine the ratio of BUP/NTX 
that was neither rewarding nor aversive.  
 
In the small clinical studies carried out by Rothman et al. (2000) and Gerra et al. (2006), 
NTX and BUP were administered at a ratio of approximately 10:1. Based on observations of 
the pupil diameters of patients, it was reported that at this ratio (and dose), the combination 
produced no overall mu agonism. It is possible that a ratio of 10:1 represents a cautious 
approach, and that more mu agonism could be tolerated without resulting in rewarding 
effects. Further, a low level of mu agonism might be desirable for improved compliance (Nutt 
2010).  
 
In man, information about levels of mu agonism produced by different doses or different 
ratios of drugs can be relatively easily obtained by self-reporting; study participants are 
administered the drug/s then asked questions such as “How high are you?” or “Do you feel 
any drug effect?” (Schuh et al. 1999). In the present study, experiments to determine the mu 
agonism produced by various combinations of NTX:BUP were performed in rats. In animal 
models, reward produced by a drug or combinations of drugs can be studied using self-
administration studies or conditioned place preference (CPP). Alternatively, the amount of 
mu agonism produced by a drug or combinations of drugs can be indirectly determined by 
measuring analgesia or mu antagonist-precipitated withdrawal. 
 
In an assay of analgesia, the animal is exposed to a pain-producing stimulus (such as heat 
or mild electric shock), and the response is measured (such as time taken to react to the 
heat stimulus, or the magnitude of electric shock which elicits vocalization). The mu 
antagonist-precipitated withdrawal assay takes advantage of the fact that if a drug produces 
significant mu agonism, then subsequent administration of a sufficient dose of mu antagonist 
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will produce signs of withdrawal such as diarrhoea and teeth-chattering that can be scored 
by the experimenter; greater withdrawal indicates greater prior mu agonism (Wee et al. 
2012). In self-administration studies, rodents or non-human primates can be trained to press 
a lever to receive a dose of a mu agonist, typically via an intravenous catheter (Shalev et al. 
2002). Lastly, CPP is a behavioural method commonly used in rodents for measuring drug-
induced reward (Cunningham et al. 2006; Tzschentke 2007). The animal is conditioned to 
associate a reward (the subjective effects of a drug) with a particular compartment. The 
compartments will be referred to as the drug-paired (DP) compartment and the saline-paired 
(SP) compartment. The strength of conditioning can be quantified by measuring the amount 
of time spent in the drug-paired compartment when the animal is allowed to choose between 
compartments in a drug-free state.  
 
It is generally accepted that whilst both self-administration and CPP have good predictive 
validity of whether a substance will be abused in man, they measure slightly different things. 
CPP is thought to measure the rewarding (or aversive) motivational properties of a drug 
(Cunningham et al. 2006, Tschentke 2007). Self-administration measures how reinforcing a 
drug is, and how hard an animal will work to receive the drug (Epstein et al. 2006). 
 
In this chapter, analgesia was selected to measure mu agonism, and CPP was selected to 
measure drug reward, following administration of various ratios of NTX:BUP. The specific 
analgesia assay chosen was the hot water tail withdrawal assay. The tail of the rat was 
placed in hot water and the time taken for the tail to be withdrawn was recorded. Any 
analgesic effect observed was attributed to mu agonism by BUP (Dum & Herz 1981; Lutfy et 
al. 2003). The CPP method has been used successfully in the past to measure the 
rewarding properties of differing doses (Bardo et al. 1995) and combinations (Canestrelli et 
al. 2014) of drugs, including mu agonists. CPP is a good predictor of rewarding 
properties/abusability in man (Bardo et al. 1995). Lastly, the CPP method also allows 
measurement of aversion (Cunningham et al. 2006). If the compound tested is aversive, the 
animal will spend less time in the drug-paired compartment than at baseline; this is referred 
to as conditioned place aversion. 
 
Rodent studies in which indicators of mu agonism were measured following co-
administration of BUP and NTX are shown in table 2.1. Overall, these studies indicate that 
ratios of NTX:BUP less than 10:1 are not necessarily rewarding. The ratios of NTX:BUP 




Table 2.1: Rodent studies in the literature that measured indicators of mu agonism produced 
following co-administration of BUP and NTX.  
*A discrimination assay is generally performed using a two-lever operant procedure 
(Huskinson et al. 2014). The animal is trained to press lever A when it receives an infusion of 
the training drug (delivered by the experimenter) and to press lever B when it is receives an 
infusion of saline (delivered by the experimenter). This training is accomplished by reward of 
correct responses with food, for example. Once training is complete, a test drug can be 
administered. Pressing of lever A would then indicate that the test drug has a similar 
subjective effect to the training drug. 




Dum & Herz 
1981 
Rats, analgesia 5:1 
mu agonism still evident,  
NTX administered first 
Walker et al. 
1994 
Rats, analgesia 3:1 no mu agonism observed 
Walker et al. 
1994 
Rats, discrimination* 3:1 no mu agonism observed 
Holtzman 
1997 
Rats, discrimination* 3:1 no mu agonism observed 
Kögel et al. 
2005 
Mice, analgesia 3:2 
mu agonism blocked if NTX 
administered first, or 
unchanged if BUP 
administered first  
Wee et al. 
2012 
Rats, analgesia  1:10 mu agonism still evident 




1:10 mu agonism still evident 
Almatroudi 
et al. 2015 





2. Materials and methods 
 
Drugs and chemicals 
Naltrexone hydrochloride dihydrate was from Fluka (UK). Buprenorphine hydrochloride was 
prepared in-house. Saline (sodium chloride 0.9%) was from Dechra (UK). All injections were 
intraperitoneal (1 ml/kg).  
 
Animals 
All experiments were performed in accordance with the U.K. Animals (Scientific Procedures) 
Act of 1986 and the University of Bath’s ethical review documents. Male Sprague Dawley 
rats (Charles River, UK) were used; 260-420g (7-11 weeks old) for tail withdrawal, 235-345g 
(7-9 weeks old) for conditioned place preference experiments. All rats were housed four per 
cage with ad libitum access to food and water and maintained on a 12:12 h light-dark cycle 
(lights on 07:00, lights off 19:00).   
 
Tail withdrawal assay 
A water bath (Grant Instruments, UK) was maintained at a constant temperature. 52ºC was 
selected, after demonstrating that at 55ºC 0.3 mg/kg BUP did not elicit any measurable 
analgesia. The rats were held firmly in a vertical position, and lowered until the distal third of 
the tail was in the water. The time taken for the rat to withdraw the tail was recorded. A 20 
second cut-off was imposed to avoid tissue damage. All rats were opioid naïve, and were not 
reused. A saline-only control was included.  
 
Conditioned place preference apparatus 
CPP boxes (Tracksys, UK) were three-chambered shuttle boxes comprising a small central 
compartment (10 x 10 cm) where rats were placed at the start of a test session, and two 
larger compartments (40 x 40 cm), one with horizontal black and white stripes, and one with 
vertical black and white stripes. Floors were made of stainless steel sheeting with punched-
out shapes (circles, 12 mm hole, and squares, 10 mm hole) resulting in distinct textures 
(Novametals, UK). Removable partitions allowed the boxes to be used either to restrict the 
rats to a particular compartment for conditioning, or to allow the rats to be ‘free-to-explore’ 
during a test session. Experiments were performed between 8 am and 5 pm under dim 
white light (light intensity approximately 15 lux). During all test sessions, the time each rat 








Figure 2.1: Layout of CPP boxes. DP = drug-paired compartment. SP = saline paired-
compartment. The flooring of the CPP apparatus was selected with the aim of the two 
compartments being distinct enough for the rats to be able to acquire a place preference, 
but equivalent enough that no innate preference for either compartment would be observed. 
One rat was placed in each CPP box; four tests were run simultaneously.  
 
Within each cohort, half the rats were trained to associate the compartment with the circle 
flooring with a drug reward, and half the rats were trained to associate the compartment 
with the square flooring with a drug reward (figure 2.1). 
 
The CPP data throughout are presented after multiplying by a correction factor (following 
Brenhouse & Andersen 2008). The correction factor is useful when the CPP apparatus 
includes a neutral central compartment, because a change in the time that a rat spends in 
the drug-paired compartment does not necessarily mean that a change in preference has 
occurred. This is illustrated in table 2.2. If only the uncorrected time spent in the drug-paired 
compartment is examined it appears that the preference of the rat for the drug-paired 
compartment is very different across the three sessions. In actual fact, in this example, the 
preference of the rat for the drug-paired compartment over the saline-paired compartment is 




Table 2.2: An illustration of the correction factor employed to remove any influence of time 
spent in the central compartment on the apparent preference of a rat for the drug-paired 













Corrected time in 
drug-paired 
compartment (s) 
Test session A 400 300 200 600 
Test session B 600 0 300 600 
Test session C 200 600 100 600 
 
Equation 2.1 shows how the corrected value was calculated. Effectively, the time spent in 
the neutral central compartment is divided proportionally between the two conditioning 
compartments (Brenhouse & Andersen 2008). 
 




A value of 900 is used in this equation (and in equation 2.2) because there are 900 seconds 
in a 15 minute test period.  
 
The corrected values of time spent in the drug-paired compartment were used to generate a 
preference score (equation 2.2). If a rat spent zero time in the saline-paired compartment 
during a test session the preference score was 50. If a rat spent zero time in the drug-paired 






Individual rats which spent more than 600 or less than 300 seconds in the drug-paired 
compartment (equivalent to a preference score of >16.7 or < -16.7) during the baseline 
session were excluded (following Ribeiro Do Couto et al. 2006). Groups were organised 
such that mean baseline preference scores were close to zero. 
43 
 
Assessment of the mu agonism/antagonism of the NTX/BUP combination  
In these experiments, the amount of BUP administered was fixed at 0.3 mg/kg per dose 
(after Tzschentke 2004). The same BUP dose was administered alone to serve as a 
positive control, and it was expected that BUP’s mu agonism effects would be observable at 
this dose in both the tail withdrawal assay (Walker et al. 1994) and in the CPP method 
(Rowlett et al. 1994). BUP was also administered (in separate cohorts) in combination with 
NTX. For the tail withdrawal assay, doses of NTX were either 0.3 or 1 mg/kg, resulting in 
approximate ratios of NTX:BUP of 1:1 or 3:1. For the CPP method, doses of NTX were 
either 0.3, 1 or 3 mg/kg, resulting in approximate ratios of NTX:BUP of 1:1, 3:1 or 10:1. 
Lastly, for the CPP method, one group of rats was administered 3.0 mg/kg NTX only. 
 
Tail withdrawal assay. Five baseline measurements were taken, one immediately after 
another, for each rat. Baseline tail-withdrawal time was taken as the mean of the last 2 
baseline measurements. 0.3 mg/kg BUP was then administered in combination with either 
0, 0.3 or 1.0 mg/kg NTX (n = 5, 4, 7). Following injection of the drugs, measurements (as 
described previously) were taken once every 7.5 minutes, up to 60 minutes; data collected 
at the 60 minute time-point was used in subsequent analyses. For the saline control group 
(n = 4), measurements were taken up to 30 minutes. For each rat, analgesia was quantified 
as Δt (increase in tail-withdrawal time compared to baseline measurement). The Δt group 
means were compared using one-way ANOVA with the Bonferroni post-test. 
 
CPP assay. Rats were conditioned with BUP (0.3 mg/kg) administered in combination with 
either 0, 0.3, 1 or 3 mg/kg NTX (n = 16, 8, 8, 16). One group of rats were conditioned with 




Figure 2.2: Schematic of an example time course of the conditioned place preference 
method. Filled-in circles represent drug injections and empty circles represent saline 
injections.  
 
On day 1, rats had a 15 minute exploratory session; on day 4, they had a 15 minute 
baseline preference test. On days 5-8 and 11-14, the rats received drug or saline on 
alternate days, thus, each rat had 4 drug injections and 4 saline injections. Injections were 
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administered at least 24 hours apart to ensure that the effects of BUP had dissipated before 
subsequent saline injections (Tzschentke 2004). Following injections, the rats were 
immediately confined to a compartment for 40 minutes. On day 15, % preference was 
obtained exactly as for baseline preference; i.e., the preference for each drug treatment was 
measured by recording the time spent in the drug-paired chamber in a free-to-explore test 
lasting 15 minutes. To assess conditioning, a 1-tailed Wilcoxon matched pairs signed-rank 
test was used (each group’s preference score after drug treatment compared to its 
baseline).  
 
In an optimal study design, only groups of equal sample size (n numbers) should be 
compared, to avoid confounding. However, throughout this thesis groups of unequal sizes 
were used (for example in figure 2.3 and table 2.3). This represents a compromise due to 
time and cost factors. 
 
3. Results and Discussion 
 
The aim of this chapter was to find out the minimum amount of NTX required to block the 
rewarding effects of BUP. Two separate assays were selected; the first was a measurement 
of analgesia and therefore an indirect measure of mu agonism, and the second was a 
behavioural assay and a direct measure of drug reward.   
 
Using NTX to block the rewarding effects of BUP 
Tail withdrawal assay. Table 2.3 and figure 2.3 show that, as expected, when administered 
alone, 0.3 mg/kg BUP elicited marked analgesia. This can be seen by the increase in time 
taken to withdraw the tail compared to baseline (Δt). The full analgesic effect from BUP 
emerged after approximately 20 minutes. This analgesic effect was blocked by the inclusion 
of 1.0 mg/kg NTX; Δt at 60 minutes was statistically different from the BUP only group (one-
way ANOVA with the Bonferroni post-test, p < 0.05). Inclusion of 0.3 mg/kg NTX resulted in 
a Δt that was intermediate between that observed for 0 and 1.0 mg/kg NTX, and was not 








Figure 2.3: Analgesic effects of 0.3 mg/kg BUP administered in combination with 0, 0.3 or 
1.0 mg/kg NTX (n = 5, 4 and 7 respectively). Time (mean ± SEM) taken for rats to withdraw 
tail during the hot water assay was measured. A saline control was also performed (n = 4). 
The 60 minute Δt values were compared (one-way ANOVA with the Bonferroni post-test) 
and the 0.3 mg/kg BUP group was significantly different (p < 0.05) from the 0.3 mg/kg BUP 
& 1.0 mg/kg NTX group.  
 
Table 2.3: Analgesic effects of 0.3 mg/kg BUP administered in combination with 0, 0.3 or 
1.0 mg/kg NTX (n = 5, 4 and 7 respectively). Time (mean ± SEM) taken for rats to withdraw 
tail during the hot water assay was measured. Withdrawal times shown are measured 60 
minutes after administration of drug/s. 
BUP & NTX (mg/kg) 0.3 & 0 0.3 & 0.3 0.3 & 1.0 
Withdrawal time at baseline 
(s) 
4.0 ± 0.4 5.5 ± 0.6 5.2 ± 0.6 
Withdrawal time after 
administration of BUP/NTX  
(s) 
12.6 ± 2.1 9.0 ± 1.7 4.6 ± 0.3 
Δt (s) 8.7 ± 2.2 3.5 ± 1.6 -0.6 ± 0.6 
 
 
The results from this analgesia assay indicated that 1.0 mg/kg of NTX could block the mu 
agonism of 0.3 mg/kg BUP. This was then tested in the CPP assay, which is used to 
measure drug reward. 
 
CPP assay. One rat in the 0.3 mg/kg BUP group, one rat in the 0.3 mg/kg BUP with 0.3 
mg/kg NTX group, and one rat in the 3.0 mg/kg NTX only group were excluded for having a 
preference at baseline. The results of the baseline test are shown in figure 2.4, and the 
results of the post-conditioning test are shown in figure 2.5; table 2.4 summarises the 
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results. As expected, 0.3 mg/kg BUP alone elicited drug-seeking behaviour in the CPP 
method. This can be seen as a significant increase in the time spent in the drug-paired 
compartment by that group compared to its baseline (1-tailed Wilcoxon matched pairs 
signed-rank test, p < 0.05). 
 
Table 2.4: Rewarding effects of 0.3 mg/kg BUP administered in combination with 0, 0.3, 1.0 
or 3.0 mg/kg NTX (n = 15, 7, 8, 16 respectively), and 3.0 mg/kg NTX alone (n = 7). Time 
(mean ± SEM) spent in the drug-paired compartment at baseline, and after conditioning. 
The test session was 15 minutes, so a score of 450 indicates equal time spent in each 
compartment.  
BUP & NTX 
(mg/kg) 
0.3 & 0 0.3 & 0.3 0.3 & 1.0 0.3 & 3.0 0 & 3.0 
Baseline (s) 447 ± 16 465 ± 41 465 ± 18 448 ± 15 418 ± 28 
After conditioning 
(s) 
544 ± 34 508 ± 62 436 ± 60 355 ± 42 455 ± 23 
After conditioning 
(preference score) 





Figure 2.4: Time spent in the drug-paired compartment during the baseline test (mean + 
SEM of n = 15, 7, 8, 16, 7). The dotted line at 450 indicates equal time spent in both 






Figure 2.5: Time spent in the drug-paired compartment after conditioning (mean + SEM of n 
= 15, 7, 8, 16, 7). * indicates preference score was significantly different from baseline  
(1-tailed Wilcoxon matched pairs signed-rank test, p < 0.05). The dotted line at 450 
indicates equal time spent in both compartments; test duration being 15 minutes. 
 
For the groups which received 0.3 or 1.0 mg/kg NTX, time spent in the drug-paired 
compartment was not significantly different from their respective baselines. The group which 
received 0.3 mg/kg BUP with 1.0 mg/kg NTX showed very little change from its baseline, 
indicating that this dose combination was neither rewarding nor aversive. 
 
Interestingly, NTX countered the rewarding effects of BUP to the extent that co-
administration of 0.3 mg/kg BUP with 3.0 mg/kg NTX actually elicited aversion (rats spent 
significantly more time in the saline–paired compartment compared to baseline test). 
Previous studies have indicated that mu antagonists can be aversive. Mucha et al. (1985) 
reported observing a conditioned place aversion in rats following administration of naloxone. 
Hollister et al. (1981) reported that NTX caused “intolerably unpleasant” effects including 
“loss of energy, gastrointestinal disturbances and mental depression” in healthy volunteers 
with no history of illicit drug use. The apparent aversive effects of mu antagonists has been 
attributed to blockade of endogenous opioid activity (Colasanti et al. 2011). 
 
To determine if the aversion observed after administration of 0.3 mg/kg BUP with 3.0 mg/kg 
NTX was due to mu antagonism by NTX, a conditioned place preference experiment was 
carried out in which only 3.0 mg/kg NTX was administered. Unexpectedly, no aversion was 
observed when NTX was administered alone, and the time spent in the drug-paired 
compartment was not different from baseline. A similar result has been seen by Canestrelli 
et al. (2014) who used CPP to assess the effect of administering BUP in combination with 
the mu antagonist, naloxone. They observed that combinations of BUP and naloxone could  
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be aversive, whereas the same dose of naloxone on its own was not. Canestrelli’s 
hypothesis was that naloxone masked the mu agonism of BUP, allowing the actions of BUP 
on another receptor, NOP, to be observed. Indeed, they showed that administration of an 
NOP antagonist blocked the aversive properties of the BUP/naloxone combination. Our data 
seem to support their hypothesis. Intriguingly, there is a growing body of evidence that NOP 
has anti-addictive actions (Kotlinska et al. 2002; Sakoori & Murphy 2004), though no 
mechanism has been demonstrated to date.  
 
It is not known to what extent the data reported here, collected in rats, will translate to 
humans. As mentioned in the introduction, CPP models have good predictive validity for 
which substances will be rewarding in man, but in terms of dose and ratio, there are likely to 
be some pharmacokinetic and pharmacological interspecies differences.  
 
The clearance of BUP and NTX in the rat is 1.41 and 4.02 L/kg/h respectively (Ohtani et al. 
1995 & 1997; Akala et al. 2008). The clearance of BUP and NTX in humans assuming a 60 
kg body weight is 1.28 and 3.16 L/kg/h respectively (Bullingham et al. 1980; Kuhlman et al. 
1996; Lictko 1981; Wall et al. 1981 &1984). Although the reported clearances in rat are 
slightly higher than those for humans, the relative proportions of the clearance values for the 
two drugs are very similar. Yassen et al. (2007) described rate constants of BUP for 
association and dissociation at the mu receptor as identical in rat and man.  
 
Lastly, there are metabolic differences between the two species; in contrast to man, 
significant levels of the metabolites norbuprenorphine or 6-β-naltrexol are not observed in 
rats (Ohtani et al. 1997; Akala et al. 2008). Overall, clearly the findings of this chapter would 
need to be confirmed in man. 
4. Conclusions of the chapter 
There was good agreement between the findings of the tail withdrawal assay and the CPP 
assay. Taken together, it was clear that, in these rats, when administered via the 
intraperitoneal route, 1.0 mg/kg NTX blocked the mu-opioid receptor agonism of 0.3 mg/kg 
BUP (a ratio of 3:1 NTX:BUP). Additionally, the CPP assay demonstrated that this 
combination is non-rewarding and non-aversive. 
 
In the previous studies in man (Rothman et al. 2000; Gerra et al. 2006), NTX and BUP were 
administered at a ratio of approximately 10:1. Our finding hints that this ratio may represent 
an overly cautious approach, and that patients may be able to receive less NTX and still 
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have adequate blockade of BUP’s rewarding effects. Furthermore, our finding suggests that 
in this combination, if too much NTX is administered, the combination may be aversive. This 
would need to be considered before new trials in man were planned. 
 
In this work, the combination was administered by intraperitoneal injection whereas our long 
term aim was to deliver these compounds by the transdermal route. As stated previously, a 
critical feature for a potential anti-addiction therapy is that the treatment itself is not 
rewarding (Manlandro 2007). Subjective positive effects are linked with speed of onset 
(Samaha & Robinson 2005), and if no rewarding effects were observed when the 
combination was administered via the intraperitoneal route, it is unlikely that any rewarding 
effects would be present if the drug was delivered as a continuous input (as would be the 
case from a transdermal patch). 
 
Lastly, the finding that 0.3 mg/kg BUP with 1.0 mg/kg NTX is not rewarding means that in 
chapter 3, when the ability of BUP/NTX to block relapse is tested using the conditioned 
place preference reinstatement model, we can expect that the BUP/NTX treatment itself will 
not act as a priming dose and trigger relapse. 
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Chapter 3. Blocking reinstatement to drug-seeking behaviour with buprenorphine 
and naltrexone  
 
1. Introduction  
Relapse (resumption of drug use after a period of abstinence) can be triggered by stress, by 
cues that have become associated with drug-taking, or by a single, small dose of drug 
(Shalev et al. 2002; Aguilar et al. 2009). Current therapies protect against relapse to varying 
extents. For example, if NTX treatment is adhered to it will provide pharmacological 
blockade against heroin therefore will reduce the likelihood of a single drug use triggering a 
relapse (Schuh et al. 1999). Arguably the substitution therapies BUP and methadone 
reduce the likelihood of relapse by reducing the need to use heroin (Gerra et al. 2009). 
However, there is no evidence that any of these therapies are protective against relapse in 
the event of cocaine use. 
 
The Rothman (2000) and Gerra (2006) clinical studies showed that a BUP/NTX combination 
is a potential relapse prevention therapy against both heroin and cocaine use. However, 
those studies were conducted using a ratio of 10:1 NTX:BUP, whereas the results in 
chapter 2 showed that (in rats at least) a ratio of 3:1 NTX:BUP was optimal in terms of the 
therapy itself being neither rewarding nor aversive. The first aim of this chapter was, 
therefore, to determine whether this smaller ratio of 3:1 NTX:BUP retained enough mu 
antagonist activity to block relapse following a morphine prime. Morphine was used here in 
place of heroin because heroin is quickly deacetylated to morphine in the body and in 
solution (Jones et al. 2013). 
 
It is not possible to tell from the Rothman (2000) and Gerra (2006) studies whether the 
observed reduction in cocaine use was a direct effect of the BUP/NTX therapy on cocaine 
use, or a consequence of reduced heroin use. The pharmacological interaction between the 
opioids BUP/NTX and heroin is reasonably well understood, but a mechanism for the effect 
of BUP/NTX on cocaine use is not as clear. There is only one study (to the author’s 
knowledge) that attempts to assess directly the effect of co-administered BUP/NTX on 
cocaine-seeking. Wee et al. (2012) trained rats to self-administer cocaine, then 
administered BUP, alone and with increasing amounts of NTX; their rationale for inclusion 
of NTX in the therapy was similar to ours. They observed that administration of BUP alone 
reduced self-administration for cocaine, but that increasing amounts of NTX reversed the 
effect of BUP. They concluded that as long as the amount of NTX in the combination was 
kept low, this combination reduced cocaine-seeking. However, these results could be 
explained equally well by the rewarding properties of BUP. The doses of BUP used in the 
54 
 
Wee study (2012) were relatively high (3 mg/kg for two consecutive days) and this dose has 
been shown to be rewarding (Walker et al. 1994, Rowlett et al. 1994). Therefore perhaps 
when the rat was administered BUP, it was satiated and did not need to self-administer 
cocaine. This explanation would fit with the observation that increasing doses of NTX 
cancelled BUP’s effect on self-administration of cocaine. Overall, the effect of a BUP/NTX 
combination on cocaine-seeking is not clear, and therefore the second aim of this chapter 
was to measure the effect of BUP/NTX on drug-primed reinstatement to cocaine-seeking. 
 
In this chapter, the CPP (conditioned place preference) method was used to measure the 
effect of the BUP/NTX treatment on cocaine-seeking and morphine-seeking in rats 
(separate cohorts). There are (at least) two different ways the CPP method can be used to 
measure the efficacy of anti-addiction therapies. The simplest is to measure if prior 
administration of the therapy can block acquisition of CPP to rewarding drugs (Sakoori & 
Murphy 2004). This approach can provide useful information, but obviously does not have 
strong construct validity. Therefore we chose the CPP-extinction-reinstatement method 
which we believe has more relevance to relapse prevention in an abstinent drug-dependent 
patient. Firstly, rats are conditioned to associate a particular compartment of the CPP 
apparatus with a drug reward. After that, the drug-seeking behaviour is extinguished 
(‘extinction’ is said to have occurred). Extinction is the loss of the drug-seeking behaviour, 
and occurs when the reward is no longer presented; the rats learn to stop a behaviour that 
has ceased to be productive, and drug-seeking falls to baseline levels (Rutten et al. 2011b; 
McNally 2014). The last stage of the model is reinstatement, the animal model equivalent of 
relapse. Reinstatement is simply resumption of drug-seeking after a period of extinction and 
occurs if the animal is exposed to a trigger such as stress or a single, small dose of drug. 
The CPP-extinction-reinstatement paradigm is frequently used to assess the efficacy of 
potential relapse prevention therapies (Aguilar et al. 2009). 
 
In this work, reinstatement triggered by a drug prime was investigated. The term ‘drug 
prime’ is generally understood to mean a lower dose than that used for conditioning, and is 
commonly (but not always) the same drug as that used for conditioning. Drug-primed 
reinstatement is thought to occur because it gives a reminder of the subjective effects of the 
rewarding drug (Shalev et al. 2002). Drug-primed reinstatement was chosen for 
investigation because whilst there is a decent body of literature suggesting that kappa 
antagonists can block stress-triggered reinstatement to cocaine (reviewed by Bruchas et al. 
2010), less is known about the effect of kappa antagonism on drug-primed reinstatement to 





The CPP-extinction-reinstatement paradigm is relatively time-consuming (for example, one 
data set can take up to 3 weeks), so it was prudent to find another means of checking 
whether the proposed doses/ratio of BUP/NTX would be likely to block a priming dose of 
morphine before commencing behavioural work. Therefore, the tail withdrawal assay (which 
is relatively quick and simple compared to CPP) was used to measure the ability of 0.3 mg 
BUP with 1.0 mg/kg NTX to block 10 mg/kg morphine (which was anticipated to be larger 
than the priming dose used in the behavioural work). If no analgesia was observed, it would 
indicate that the BUP/NTX combination blocked the mu agonism of the morphine; this could 
then be tested in the CPP method.  
 
Additionally, in order to know the plasma and brain concentrations of BUP and NTX in the 
rats at the time that the drug-prime was administered, a separate cohort of rats were 
administered the combination, and samples were collected and assayed. Lastly, receptor 
occupancies of BUP and NTX at the mu receptor and kappa receptor were predicted from 
the observed plasma and brain concentrations. 
 
2. Materials and methods 
 
Drugs and chemicals 
Naltrexone hydrochloride dihydrate was from Fluka (UK). Buprenorphine hydrochloride was 
prepared in-house. Cocaine hydrochloride and morphine sulphate were from MacFarlan 
Smith (UK). Saline (sodium chloride 0.9%) was from Dechra (UK). Buffer components and 




All experiments were performed in accordance with the U.K. Animals (Scientific Procedures) 
Act of 1986 and the University of Bath’s ethical review documents. Male Sprague Dawley 
rats (Charles River, UK) were used; 260-420g (7-11 weeks old) for tail withdrawal, 250-320g 
(7-9 weeks old) for conditioned place preference experiments. All rats were housed four per 
cage with ad libitum access to food and water and maintained on a 12:12 h light-dark cycle 
(lights on 07:00, lights off 19:00).   
 
Tail withdrawal assay 




Conditioned place preference apparatus 
The conditioned place preference assay is described in the previous chapter; see pages 40-
42. 
 
Measuring the antagonism of morphine by the BUP/NTX combination 
Before behavioural work was undertaken, the tail withdrawal assay was used to establish 
whether the BUP/NTX combination could block the mu agonism of morphine. Five baseline 
measurements were taken, one immediately after another, for each rat. Baseline tail-
withdrawal time was taken as the mean of the last 2 baseline measurements. Latency to 
withdrawal was measured following administration of 10 mg/kg morphine only (n = 4), and 
when both 0.3 mg/kg BUP and 1.0 mg/kg NTX (n = 5) or 1.0 mg/kg NTX alone (n = 7) were 
administered 30 minutes prior to the morphine. Following injection of the morphine, 
measurements were taken once every 5 minutes, up to 30 minutes. Data collected at the 30 
minute time point was used in subsequent analyses. For each rat, analgesia was quantified 
as Δt (increase in tail-withdrawal time compared to baseline measurement). The Δt group 
means were compared using one-way ANOVA with the Bonferroni post-test. 
 
Effects of BUP/NTX on reinstatement of cocaine and morphine conditioned place 
preference 
To test the ability of a BUP/NTX combination to block drug-primed reinstatement, a CPP-
extinction-reinstatement method was established (figure 3.1).  
 
Figure 3.1: Schematic of the time course of the conditioned place preference extinction and 
reinstatement method. Filled-in circles represent cocaine or morphine injections and empty 
circles represent saline injections. During conditioning the order of drug and saline 
injections alternated daily. This schematic shows the reconditioning style of extinction, 
where each rat received 2 saline injections per day. The arrow indicates that BUP/NTX 
treatment (or saline, in the control groups) was administered 10 minutes prior to the priming 
dose. 
 
The rats had one 15 minute exploratory session and one 15 minute baseline preference test. 
Next, animals were conditioned using either 3 mg/kg cocaine or 5 mg/kg morphine, receiving 
drug and saline on the same day (at least 4 hours apart) for 3 consecutive days. The 
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selection of the conditioning doses reflected a balance between the desire to observe a 
robust conditioning response, yet achieve extinction within a reasonable amount of time, and 
then easily retrieve the CPP during reinstatement.  
 
Immediately after injection, rats were confined to a particular compartment (drug-paired or 
saline-paired) in the CPP box for 20 minutes or 40 minutes, for cocaine and morphine 
respectively. A shorter conditioning time was used for cocaine because of the expectation 
that the rewarding properties of cocaine are relatively short-lived, and it was important that 
the rats were out of the boxes before the rewarding effect dissipated, and before any 
aversive effects emerged.  
 
Following conditioning, preference scores were obtained exactly as for baseline preference. 
Individual rats which showed less than a 30-second increase in time spent in the drug-
paired side during the post-conditioning test compared to their baseline preference were not 
included in the extinction and reinstatement data (after Mueller et al. 2000 and Ribeiro do 
Couto et al. 2005). To assess conditioning before exclusions, a 1-tailed Wilcoxon matched 
pairs signed-rank test was used (each group’s preference score after drug treatment 
compared to its baseline). 
 
Four cohorts of rats were used: cocaine-conditioned control (n = 20), morphine-conditioned 
control (n = 24), cocaine-conditioned BUP/NTX treatment (n = 16), and morphine-
conditioned BUP/NTX treatment (n = 16). 
 
For all cocaine-conditioned rats, extinction was achieved by reconditioning. This involved 
injection of saline followed by confinement to each compartment for 20 minutes a day for 4 
days (4 hours apart). During extinction training, if a rat was placed in the drug-paired 
compartment in the morning session one day, it would be placed in the saline-paired 
compartment in the morning session the following day. Extinction was confirmed by a 15 
minute free-to-explore test. 
 
For the morphine-conditioned rats, two styles of extinction were used: a reconditioning style 
and a retesting style. The reconditioning style involved a saline injection with 15 minutes 
confinement in each compartment (as described for cocaine). The retesting style of 
extinction involved daily retesting, with 15 minutes per test. Both styles of extinction training 
are commonly used (Aguilar et al. 2009). Of the animals subsequently tested for 
reinstatement, 5 rats in the control group underwent extinction training using the 
58 
 
reconditioning style, and 9 underwent extinction using the retesting style. All rats in the 
BUP/NTX treatment group underwent extinction training using the reconditioning style.  
 
For both extinction styles, extinction training was deemed complete if group mean 
preference score was <5. For the retesting style of extinction, this was taken from the 
average of 2 consecutive days.  
 
Following extinction, rats were administered a priming dose of 3 mg/kg cocaine or 1.25 
mg/kg morphine. The selection of the priming doses reflected a balance between the desire 
to observe a robust reinstatement in the control groups, and having the sensitivity to 
measure any possible effect of the BUP/NTX treatment on reinstatement. Furthermore, as 
reinstatement is a reflection of drug-seeking behaviour, the priming dose should not be so 
high that the animal is satiated. 
 
The control groups received a saline injection 10 minutes prior to drug priming and the 
treatment groups received a BUP/NTX injection (0.3 and 1 mg/kg respectively) 10 minutes 
prior to drug priming. Following administration of the priming dose, rats were placed 
immediately into the CPP boxes and were free-to-explore during a 30-minute test.  
 
Conditioning and reinstatement were assessed using the Friedman test followed by Dunn's 
multiple comparison test (each group’s preference score compared to its baseline). A Mann-
Whitney U test was used to compare the preference during the reinstatement test for rats 
that had undergone a retesting style of extinction and for rats that had undergone a 
reconditioning style of extinction. 
 
Blood and brain tissue concentrations 
BUP and NTX (0.3 and 1 mg/kg respectively) were administered by intraperitoneal injection. 
After 30 minutes, animals were killed by cervical dislocation and trunk blood and whole 
brains were collected and placed on ice. 
 
Plasma sample preparation - Blood samples (~400 µl) were centrifuged at 3300 rpm for 10 
minutes (Boeco, Germany), and the plasma recovered. The plasma samples were basified 
using an ammonium hydroxide solution of pH 10 and loaded onto a solid phase extraction 
(SPE) cartridge (Waters Oasis HLB) previously conditioned with 1 ml methanol and 1 ml 
water. The cartridge was washed with 1 ml 2 % methanol in ammonium hydroxide solution 





Brain tissue sample preparation - The brain tissue was prepared using the same SPE 
process as the plasma samples. Prior to the SPE process 1.8 ml water per gram of brain 
tissue was added to facilitate homogenisation (Tissue Master 240, OMNI International, US), 
the sample was centrifuged, and the supernatant fluid was collected.  
 
BUP and norbuprenorphine LC-MS method - Separation was performed using a GeminiNX 
column (3µm C18 110A 50 x 2mm) from Phenomenex, maintained at 25°C, on a Shimadzu 
LC-2010AHT HPLC. The mobile phase was 18:82 acetonitrile: 0.1% acetic acid at a flow 
rate of 0.2 ml/min. 30µl of sample was injected. The sample was passed through a nylon 
0.45 µm syringe filter before injection into the LC-MS. Samples were injected undiluted to 
analyse BUP, then diluted 1:1 with water to analyse NTX. The retention times for BUP and 
norbuprenorphine were 9 and 3 minutes, and the masses per charge were 468 and 414. 
Standards were prepared in SPE eluent. Limit of quantitation was 0.18 ng/ml for BUP and 
0.8 ng/ml for norbuprenorphine. 
 
NTX and 6ß-naltrexol LC-MS method - The method for analysis of NTX and 6ß-naltrexol 
was adapted from Valiveti et al. (2004). Separation was performed using a Symmetry 
column (5µm C18 110A 150 x 2.1 mm) from Waters, maintained at 23°C, on a Shimadzu 
LC-2010AHT HPLC. The mobile phase was 12:88 acetonitrile: 0.1 % ammonium acetate at 
a flow rate of 0.25 ml/min. 30µl of sample was injected. The retention times for NTX and 6ß-
naltrexol were 4 and 3 minutes, and the masses per charge were 342 and 344. Standards 
were prepared in SPE eluent. Limit of quantitation was 3.8 ng/ml for NTX and 0.28 ng/ml for 
6ß-naltrexol.  
 
Receptor occupancy calculations 
From the observed plasma and brain concentrations, receptor occupancy levels of each 
drug could be estimated using affinity values (equilibrium dissociation constants). 





% occupancy of drug A = 100 * ([A]/KA) / (([A]/KA) + ([B]/KB) + 1) 
 
where [A] = the tissue concentration of drug A, [B] = the tissue concentration of drug B, KA = 
the equilibrium dissociation constant of drug A, and KB = the equilibrium dissociation 
constant of drug B. 
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The equilibrium dissociation constants for BUP and NTX at the mu receptor were 0.41 nM 
and 1.26 nM respectively (Ridzwan 2012). The equilibrium dissociation constants at the 
kappa receptor for BUP and NTX were 0.8 nM and 0.4 nM respectively (Toll et al. 1998). 
3. Results and Discussion 
 
The aim of this chapter was to assess the ability of the BUP/NTX combination to reduce the 
likelihood of relapse following a cocaine or morphine prime. Firstly, the tail withdrawal 
method, an assay of analgesia, was used to confirm that 0.3 mg/kg BUP with 1.0 mg/kg 
NTX could block the mu agonism produced by 10 mg/kg morphine. Subsequently, the CPP-
extinction-reinstatement method was used to measure the effect of the BUP/NTX 
combination on drug-primed reinstatement to morphine and to cocaine. The results are 
presented below. 
 
Measuring mu receptor antagonism of a BUP/NTX combination 
Prior to commencing behavioural work, the ability of 0.3 mg/kg BUP and 1.0 mg/kg NTX to 




Figure 3.2: Tail withdrawal assay to measure antagonism of morphine by NTX, with and 
without BUP. Data shows measurements taken 30 minutes after administration of 10 mg/kg 
morphine, and 60 minutes after administration of BUP and/or NTX (n = 5, 4, 7). Baseline 
values were in the range 4 - 5 seconds. Mean + SEM; * indicates significantly different (p < 
0.05) vs. morphine alone group; ** indicates significantly different (one-way ANOVA with the 
Bonferroni post-test, p < 0.05) vs. morphine control group and vs. 0.3 mg/kg BUP and 1.0 
mg/kg NTX group. 
 
As expected, 10 mg/kg morphine elicited a measurable analgesia. Clear mu receptor 
antagonism was observed following administration of BUP/NTX (morphine-induced 
analgesia decreased from 16 ± 0 to 3 ± 1 seconds, mean ± SEM). Administration of NTX 
alone blocked morphine-induced analgesia to a greater extent than the BUP/NTX 
61 
 
combination. This result provided justification to test the combination at these doses in the 
CPP behavioural model. 
 
CPP extinction and reinstatement model 
The CPP-extinction-reinstatement method was used to observe drug-primed reinstatement 
in cocaine- and morphine-conditioned rats, and the effects thereon of treatment with a 
BUP/NTX combination. Table 3.1 shows the number of rats used in the experiments, the 
number of rats excluded, and the time taken to reach extinction. Conditioning was 
statistically significant in each cohort before individual rats were excluded for insufficient 
conditioning.  
 
Table 3.1: Number of rats used in the experiments, and excluded at each stage, and time 












At start 20 16 24 16 
Excluded for baseline 
preference 




8 5 8 7 
Time taken to reach 
extinction 
1 week 1 week 




It was observed that in the control cocaine-conditioned group, preference for the drug-
paired compartment emerged at 13-15 minutes of the 30 minute reinstatement test period 
(see figure 3.3, left panel). Mueller and Stewart (2000) also observed an emergence of 
drug seeking during the reinstatement test (see figure 3.4, left panel) following a cocaine 
drug prime in cocaine-conditioned rats, though over a shorter period of time. 
 
Unlike the cocaine-conditioned rats, the morphine-conditioned rats showed the greatest 
preference during the first 15 minutes of the reinstatement test (figure 3.3, right panel). This 
is in contrast to Mueller et al. (2002) who saw an emergence of drug-seeking in morphine-
conditioned rats at around 20 minutes (figure 3.4 right panel). The data presented here are 
more comparable with Bozarth (1987) who showed that rats reinstated to seek heroin 
decreased their drug-seeking behaviour over the duration of a 15 minute test. The data 
from 0-30 minutes of the reinstatement test were used for the cocaine-conditioned rats, 







Figure 3.3: Preference for the 3 CPP compartment types across the 30 minutes of the 
reinstatement test. Left: Following a 3.0 mg/kg cocaine prime. Right: Following a 1.25 




Figure 3.4: Preference for the 3 CPP compartment types across the reinstatement test. 
Left: following a 5.0 mg/kg cocaine prime (taken from Mueller and Stewart 2000). Right: 
following a 2.5 mg/kg morphine prime (taken from Mueller et al. 2002). Data shown in 3 
minute bins. Mean ± SEM. Figures reproduced with kind permission from Elsevier. 
 
Figure 3.5 (top panel), figure 3.6 (top panel), and table 3.2 show that for the control groups, 
conditioning, extinction and then reinstatement were successfully achieved. The preference 
post-conditioning and following a drug prime was significantly different from baseline for 
both drugs. As there was no significant difference in preference score during the 
reinstatement test between the morphine-conditioned rats, which underwent the two styles 
of extinction training used (reconditioning 11 ± 7, n = 5; retesting 19 ± 9, n = 9; mean ± 




Achieving conditioning, extinction and drug-primed reinstatement using the conditioned 
preference method has been previously reported for morphine (Parker & McDonald 2000) 
and cocaine (Mueller & Stewart 2000). The novel aspect of the work reported here is the 
effect of the BUP/NTX combination on reinstatement; these results are shown in figure 3.5 






Figure 3.5: Effect of BUP/NTX treatment on reinstatement to cocaine-seeking. Preference 
scores (left to right in each panel: baseline, post-conditioning, post-extinction and drug-
primed reinstatement). Drug prime was 3 mg/kg cocaine. Top panel cocaine-conditioned 
control group (n = 12); Bottom panel cocaine-conditioned BUP/NTX treated group (n = 9). 
Mean + SEM; * indicates significantly different from baseline (Friedman test followed by 
Dunn's multiple comparison test, each group’s preference score compared to its baseline, p 
< 0.05). Arrows indicate that BUP/NTX treatment (0.3 mg/kg/1.0 mg/kg) was administered 
10 minutes prior to the priming dose.  
 
For the BUP/NTX treated groups, conditioning and extinction were successfully achieved. 
The effect of the combination on drug-primed reinstatement in both the cocaine- and 
morphine-conditioned rats is clear. Preference during reinstatement test was not 
significantly different from baseline for either drug. In the cocaine-conditioned rats, the 
BUP/NTX treatment completely blocked reinstatement (preference score of -9 ± 5 mean ± 
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SEM compared to 11 ± 5 in the control group). In the morphine-conditioned rats, the 
BUP/NTX treatment attenuated the preference observed following administration of a drug 





Figure 3.6: Effect of BUP/NTX treatment on reinstatement to morphine-seeking. % 
preference of rats (left to right in each panel: baseline, post-conditioning, post-extinction and 
drug-primed reinstatement). Drug prime was 1.25 mg/kg morphine. Top panel morphine-
conditioned control group (Mean + SEM of n = 14). Bottom panel morphine-conditioned 
BUP/NTX treated group (Mean + SEM of n = 8); * indicates significantly different from 
baseline (Friedman test followed by Dunn's multiple comparison test, each group’s 
preference score compared to its baseline p < 0.05). Arrows indicate that BUP/NTX 
treatment (0.3 mg/kg/1.0 mg/kg) was administered 10 minutes prior to the priming dose. 
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Table 3.2: Time spent in the drug-paired compartment at the different stages of the CPP 
experiment (n = 12, 9, 14, 8). As the test session is 15 minutes, a score of 450 indicates 
equal time spent in each compartment. Data shown as mean ± SEM. 












Baseline 427 ± 20 449 ± 27 431 ± 18 396 ± 28 
After conditioning 562 ± 16 547 ± 39 604 ± 19 610 ± 23 
After extinction 482 ± 26 455 ± 55 482 ± 38 421 ± 47 
After reinstatement 553 ± 47 365 ± 54 596 ± 55 502 ± 92 
 
The work presented here is a clear advance with respect to previous knowledge. There is 
preclinical data showing that BUP on its own (Kosten et al. 1991; Suzuki et al. 1992; Comer 
et al. 1993) and NTX on its own (Bilsky et al. 1992; Suzuki et al. 1992) can reduce the ability 
to acquire a conditioned place preference to cocaine. However, here, the ability of BUP and 
NTX to block drug-primed reinstatement to cocaine-seeking following extinction was 
demonstrated. Furthermore, the two compounds were administered as a combination that by 
itself induces neither conditioned place preference nor aversion. Importantly, the observed 
reduction in cocaine-seeking implies that the decrease in cocaine use reported in clinical 
trials (Rothman et al. 2000; Gerra et al. 2006) was probably not a simple consequence of 
reduced heroin use.  
 
The blocking of drug-primed reinstatement to morphine by a BUP/NTX combination has not 
been shown before, but is expected and can be explained by pharmacological blockade of 
the mu agonist effect of morphine. In contrast, the novel observation that a BUP/NTX 
combination can block drug-primed reinstatement to cocaine has no simple explanation. 
Some hypotheses are given below. 
 
1. It is possible that the overall mu antagonist activity of the combination could prevent 
reinstatement by blocking endogenous opioids that are indirectly activated by cocaine 
(Soderman & Unterwald 2008; Le Merrer et al. 2009), or that the mu activity of the 
combination somehow normalises the dysregulated opioid system observed following 




2. It generally expected that kappa antagonism should not influence drug-primed 
reinstatement to cocaine (Beardsley et al. 2005), but should only reduce stress-induced 
reinstatement to cocaine (Beardsley et al. 2005; Carey et al. 2007; Land et al. 2009). 
However, Wee et al. (2012) argues that the negative mood state that occurs following 
chronic use of cocaine is caused by kappa overdrive, and that kappa antagonsim could 
reduce cocaine use in general, regardless of whether in response to stress or to a drug 
prime. 
 
3. The third receptor that the combination (only BUP) binds to is NOP. There is convincing 
evidence that NOP is anti-addictive (Marquez et al. 2008a; Rutten et al. 2011a), for 
substances of abuse including cocaine (Kotlinska et al. 2002; Marquez et al. 2008b; 
Bebawy et al. 2010). However, the affinity of BUP for the NOP receptor measured in vitro is 
relatively low; equilibrium dissociation constants from 8.4 nM (Wnendt et al. 1999) to 77.4 
nM (Spagnolo et al. 2008) have been reported. Therefore it is not yet known what dose of 
BUP would be required for NOP agonism to become relevant to drug-seeking behaviour. 
 
4. The last explanation proposed for the observed blocking of drug-primed reinstatement to 
cocaine by the BUP/NTX combination is that it is an experimental artefact. It is conceivable 
that BUP/NTX could somehow prevent the recall of the association between the cocaine 
reward and the cocaine-paired compartment. In this case, reduced time spent in the drug-
paired compartment during the reinstatement test would not indicate a true reduction in drug-
seeking. Overall, this explanation for the observed result is considered unlikely; neither BUP 
nor NTX are known to effect spatial memory retrieval. 
 
Finally, a caveat of the findings of this chapter is that the BUP/NTX combination was given 
acutely, within minutes of the priming dose. Obviously as a relapse prevention therapy it 
would be administered chronically. 
 
Receptor occupancy of BUP and NTX from blood and brain concentrations 
When the BUP/NTX combination was administered 10 minutes before a cocaine or 
morphine drug prime, reinstatement was blocked. In order to establish the plasma and brain 
concentrations of BUP and NTX that would have been present during the reinstatement 
test, a separate cohort of rats were administered with 0.3 mg/kg BUP and 1.0 mg/kg NTX, 
and drug concentrations after 30 minutes were measured. The primary metabolites of BUP 
and NTX (norbuprenorphine and 6β-naltrexol) were also assayed but were below the limit of 
quantitation in plasma and brain samples. From the BUP and NTX concentrations the mu 
and kappa receptor occupancies of each drug could be estimated using their equilibrium 
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dissociation constants (table 3.3). The amount of drug bound to the receptor has an 
insignificant effect on circulating concentrations; receptor occupancy calculations for mu 
and kappa were therefore considered separately. 
 
Table 3.3: Plasma and brain concentrations of BUP and NTX and estimated receptor 
occupancies. BUP and NTX were administered simultaneously intraperitoneally. Plasma 
and brain samples were taken 30 minutes later and BUP and NTX levels measured. Using 
the plasma and brain concentrations, and literature affinity values of both BUP and NTX, 
mu and kappa receptor occupancy levels were determined. All data shown as mean ± 
SEM. 
























Plasma 56 ± 4 38 ± 3 8 ± 1 285 ± 19 62 ± 4 91 ± 6 
Brain  83 ± 14 45 ± 8 12 ± 2 313 ± 19 55 ± 3 88 ± 5 
 
These data suggest that at the time of the drug prime, more than 95% of available mu 
receptors were occupied either by BUP or NTX. This is consistent with Greenwald et al. 
(2014) who found that when more than 90 % of mu receptors were occupied (following 
administration of BUP in man) the subjective effects of “higher-than-usual” doses of abused 
opioids were blocked.  
 
The optimal relative receptor occupancies for this therapeutic application are not yet 
known. The results shown here indicate that when ~45% of the mu receptors in the brain 
are occupied by BUP and ~55% are occupied by NTX, neither aversion nor reward is 
experienced (chapter 2). Furthermore, at the doses administered here, these relative 
receptor occupancies were sufficient to block a cocaine or morphine prime. 
 
Lastly, these data indicate that more than 95% of available kappa receptors in the brain 
were occupied by BUP or NTX. Therefore, as well as blocking mu receptors, the 






A caveat of the receptor occupancy calculations is that only absolute brain levels were 
measured rather than free concentrations of each drug. A high proportion of the compounds 
may be in the lipid compartment and unavailable for receptor binding. The brain levels 
measured here were far in excess of the equilibrium constant values, so using free 
concentrations would be unlikely to have an impact on total receptor occupancy. However, if 
the proportion of drug bound was very different for BUP and NTX, this would of course be 
expected to influence the predictions of relative receptor occupancies. 
 
As mentioned briefly in chapter 2, it is not known to what extent the results observed here in 
a rat model will translate into a clinical situation. Some ways in which the CPP-extinction-
reinstatement model lacks construct validity are presented below. 
 
Firstly, the timeframe of the CPP method used here is vastly different from the clinical 
situation. In this work, the rats received 3 doses of cocaine, or 3 doses of morphine; this is 
clearly not equivalent to frequent use of a drug of abuse over many years. Similarly, the 
drug-free extinction period here was 1 or 2 weeks, in contrast to the years of abstinence that 
can precede relapse in man. 
 
A second important difference between the reinstatement model in rodents and the clinical 
situation is that extinction occurs for different reasons (abstinence is imposed or abstinence 
is chosen). Epstein et al. (2006) believes this to be the single biggest conceptual difference 
between the animal and human situation, though it is not yet known if this difference 
translates into reinstatement/relapse outcomes. Likewise, a human self-initiates drug use in 
the event of a lapse, whereas the rodent is administered the priming dose by the 
experimenter (Aguilar et al. 2009).  
 
Lastly, the magnitude of relapse/reinstatement response is believed to decrease over time in 
humans, but not in rodents (Epstein et al. 2006). As for the results of chapter 2, the findings 
presented here would ideally be confirmed in human patients.  
4. Conclusions of the chapter 
In summary, it has been shown that a combination of 0.3 mg/kg BUP and 1.0 mg/kg NTX, 
administered intraperitoneally in Sprague Dawley rats, results in high occupancy levels of 
both mu and kappa receptors, and so acts as a functional mu/kappa receptor antagonist. It 
was demonstrated that 0.3 mg/kg BUP and 1.0 mg/kg NTX blocked drug-primed 
reinstatement to cocaine-seeking, and attenuated drug-primed reinstatement to morphine-
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seeking. These data add to the growing evidence that a BUP/NTX combination may be 
effective in a polydrug abuse situation. In chapter 4, the delivery of BUP and NTX via the 
transdermal route will be addressed. 
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Chapter 4: Feasibility of iontophoretic transdermal delivery of  




NTX is currently available as an oral tablet (as Revia®), while BUP is formulated as a 
sublingual tablet (as Subutex®). Delivering NTX and BUP in a combination oral tablet would 
be difficult because of BUP’s low oral bioavailability due to first pass effect (McQuay & 
Moore 1995). Unfortunately, delivery of the combination as a sublingual tablet might be 
difficult because of NTX’s low bioavailability by this route, probably due to the poor 
permeability of the drug (Lewis & Lloyd-Jones 1987).  
 
Transdermal formulation could provide an advantageous platform for the delivery of the two 
drugs together. Transdermal delivery could result in reduced opportunity for abuse/diversion, 
increased patient adherence, and avoidance of daily fluctuations in plasma concentrations. 
Iontophoresis offers greater control over delivery rates compared to passive delivery (Harper 
Bellantone et al. 1986). Furthermore, it is expected to be a more suitable delivery approach 
for NTX, which has low passive fluxes (Hammell et al. 2004 & 2005), possibly due to its 
relative hydrophilicity. The objectives of this chapter were to determine if BUP and NTX 
could be delivered together by transdermal iontophoresis, and to assess their relative 
delivery efficiencies.  
 
Mechanisms of iontophoretic transport 
During iontophoresis, molecules move across the skin via three mechanisms: 
electrorepulsion (ER), electroosmosis (EO) and passive diffusion. 
 
1. Electrorepulsion 
The movement of ions during iontophoresis is driven by the electrochemical reactions at the 
electrodes. The reactions shown here (Equation 4.1) take place when silver/silver chloride 
electrodes are used; these are considered the best option for use in iontophoresis (Phipps et 
al. 1989).  
Equation 4.1 
 
anode:  Ag + Cl-  ➝ AgCl(s) + e-    
cathode:  AgCl(s) + e




When current is passed, electroneutrality is maintained by movement of ions across the skin 
(Phipps et al. 1989). An anion can move toward the anode, or a cation can move toward the 




Figure 4.1: Schematic representation of the movement of ions in an iontophoretic patch 
system on the skin. Redrawn from Kalia et al. 2004. In this example, the drug is positively 
charged, therefore is delivered from the anode. Ions present at the anode and cathode 
compartments would be from a buffer for example. 
 
For every one electron that moves round the circuit, one (singly-charged) ion will move, thus 
there is finite movement of ions. Therefore, competition to carry the current exists between 
co-ions (ions of same polarity) and between counter-ions (ions of opposite polarity) (Burnette 
& Ongpipattanakul 1987; Pikal & Shah 1990a & b). Which ions in the system move is 
determined by their relative mobilities, and by their relative abundances (Riviere & Heit 1997; 
Mudry et al. 2007). Smaller ions (smaller hydrodynamic radius) are more mobile than larger 
ions (Riviere & Heit 1997). Singly-charged ions are more efficiently delivered than multiply-
charged ions (Phipps et al. 1989); for one doubly-charged ion to be transported, two 
electrons must pass round the circuit. Furthermore, under normal circumstances, the skin is 
negatively charged, so all things being equal, cations will move across the skin in larger 
numbers than anions (Burnette & Ongpipattanakul 1987). Note the contrast between the 
situation of iontophoresis and the situation of passive delivery. In passive delivery, the flux of 
drug A would not be expected to be influenced by the concentration of drug B in the donor 
solution. In iontophoresis, two drugs of the same sign of charge (both cations or both anions) 
are expected to compete for charge carrying. This is a fundamental difference between 
passive delivery and iontophoresis (Riviere & Heit 1997). 
 
How good an ion is at competing for charge (and therefore how efficiently it can be 
delivered) can be quantified by calculating its transport number. Transport number is simply 
the fraction of the total current transported by that ion, and therefore has a theoretical 
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maximum of 1. For example, if for every 4 electrons that pass round the circuit, one (singly-
charged) drug ion crosses the skin, the transport number of the drug is 0.25. In reality, 
transport numbers for drug molecules will generally be small, with the vast majority of the 
charge being carried by other smaller, more mobile ions present in the system.  
 
Competition between co-ions in the system means that increasing the molar fraction of an 
ion results in increasing flux of that ion (Marro et al. 2001c; Kalia et al. 2004, Phipps & Gyory 
1992). This is illustrated in figure 4.2 where, as the concentration of the co-ion (in this case 
Na+, from sodium chloride) in the donor decreases, the flux (and therefore the transport 
number) of lidocaine increases.  
 
Figure 4.2: Transport number as a function of molar fraction (Mudry et al. 2006a, data 
generated in vitro using pig skin). LH+ is lidocaine hydrochloride. Lidocaine is delivered at 
lower efficiency than the small inorganic ions because it is larger size (234 Da) and therefore 
lower mobility. Reproduced with kind permission from Elsevier. 
 
Clearly, the highest transport number will be observed in the ‘single-ion situation’, when the 
drug is the only ion of its polarity (cation or anion) in the donor compartment and the molar 
fraction is therefore 1 (Mudry et al. 2006a). Note that in the single-ion situation, changing the 
concentration of the drug in the donor will not affect flux (because molar fraction is always 1). 
This is important because it means that, in contrast to passive delivery, maximal flux can be 
achieved with drug concentrations below saturation (Marro et al. 2001b). That said, the 
single-ion situation is unlikely to occur in a commercial product, because stabilisers, 
preservatives, buffers, or viscosity agents are likely to be present.  
 
The pH of the donor affects ER by determining the ionisation of the drug as obviously, only 
ionised drug is transported by ER (Merino et al. 1999; Lopez et al. 2001). Therefore, 
judicious selection of pH can, to a certain extent, be used to increase the proportion of 
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charge that is carried by the drug molecules, and thus the efficiency of drug delivery. Other 
strategies to increase the flux of drug include choosing larger (therefore less mobile) buffer 
co-ions, and increasing the molar fraction of the drug in the donor solution. Increasing the 
molar fraction of the drug can be achieved by increasing the drug concentration, or by 
decreasing background co-ion concentrations. Competition between drug ions and counter-
ions is not as easy to manipulate. In the case of a drug delivered from the anode, the most 
important counter-ion is subdermal chloride (Phipps et al. 1989); in the case of a drug 
delivered from the cathode, the most important counter-ion is subdermal sodium. Clearly 
there is no control over the subdermal compartment, and this places a limit on how efficient 
iontophoresis can ever be.  
 
The last point to make about ER, and the most intuitive, is that iontophoretic flux increases 
proportionally with current intensity (Kalia et al. 2004), as predicted by Faraday’s law. 
 
Equation 4.2 
   J =      I x t 
 z x F  
 




When current is passed across the skin, a convective solvent flow, known as EO, is 
established (Pikal & Shah 1990a & b; Burnette & Ongpipattanakul 1987; Luzardo-Alvarez et 
al. 1998). This solvent flow occurs due to the skin; the net negative charge of the skin under 
normal conditions makes it permselective to cations. EO occurs in the anode-to-cathode 
direction, and so drug delivery from the anode is ‘helped’ by EO. EO acts on all molecules 
present at the anode, including uncharged ones. The volume of EO solvent flow is 
dependent on buffer type, ionic concentration, and pH (Tamada & Comyns 2005), but the 
volume of convective solvent flow that occurs during iontophoresis is generally in the region 
of 1 to 2 µl/h/cm2 (Kim et al. 1993; Marro et al. 2001a; Dubey & Kalia 2014). It is possible to 
directly measure movement of water between compartments of an iontophoretic cell either 
by using a cell linked to a capillary tube (Pikal & Shah 1990a) or by measurement of tritiated 
water (Kim et al. 1993). However, it is more common to use the flux of a marker such as 
mannitol or acetaminophen as an indicator of ‘apparent solvent flow’. These molecules are 
suitable as markers because they are uncharged and have negligible passive flux (Dubey & 
Kalia 2014).  
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The relative contributions of ER and EO to total iontophoretic flux depend on the permeant, 
and upon the experimental conditions (Merino et al. 1999; Tamada & Comyns 2005). 
Obviously, EO is likely to be the largest contributing factor to flux for large uncharged 
molecules, whilst ER is likely to be the largest contributing factor to flux for small, charged 
ions (Riviere & Heit 1997; Marro et al. 2001b). Unlike ER, the effect of molecular size on 
electroosmotic transport is not fully established, yet there is some experimental evidence 
suggesting that electroosmotic transport decreases as molecular weight increases (Yoshida 
& Roberts 1993, Djabri et al. 2015). 
 
Although under normal conditions EO occurs in the anode-to-cathode direction (Delgado-
Charro & Guy 1994; Burnette & Ongpipattanakul 1987; Pikal & Shah 1990a), the direction of 
the solvent flow can change if the charge on the skin is altered. The charge on the skin can 
be altered either by changing the pH (Kim et al. 1993; Merino et al. 1999; Marro et al. 
2001a), or by accumulation of cations in the skin (Delgado-Charro & Guy 1995; Schuetz et 
al. 2005; Dubey & Kalia 2014). The effect of pH will be discussed first. 
 
As mentioned, under physiological conditions the skin carries a net negative charge, 
believed to correspond to acid residues. As the pH is lowered, these groups become less 
ionised and the overall negative charge is less. The isoelectric point of human skin (the pH 
at which the skin carries no net charge), is close to pH 4.5 (Marro et al. 2001a). At pHs 
below the isoelectric point, the skin carries a net positive charge, and the direction of EO is 
reversed. This is illustrated in figure 4.3, which shows the effect of pH on anode-to-cathode 
EO and on cathode-to-anode EO.   
 
Figure 4.3: Effect of pH on EO. The magnitude of mannitol flux (mean ± standard deviation) 
after 6 h of iontophoresis across human skin in vitro depends on the pH. The experiments 
were carried out in symmetrical conditions (the same background electrolyte was used on 
both sides of the skin). Transport in the anode-to-cathode direction (filled circles) is 
compared to that in the cathode-to-anode direction (open circles). Redrawn from Marro et al. 
(2001a). 
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Interestingly, it can be seen that EO occurs simultaneously in the anode-to-cathode direction 
and in the cathode-to-anode direction. To explain this observation, it has been suggested 
that there are (at least) 2 populations of channels, differing in polarity of charge, or pore size, 
or charge density (Pikal 2001). However, there is no direct experimental evidence for this 
hypothesis. 
 
The second mechanism by which the charge on the skin and thus the direction of EO can be 
altered is by accumulation of cations in the skin itself. Figure 4.4 shows a clear and dramatic 




Figure 4.4: Anodal (□) and cathodal (■) mannitol flux (mean ± standard deviation) in the 
absence or presence of the cationic peptide nafarelin in the anodal compartment was 
measured across hairless mouse skin. Taken from Delgado-Charro & Guy (1995) and 
reproduced with kind permission from Elsevier. 
 
  
3. Passive diffusion 
Of course, passive diffusion still occurs during iontophoresis (Riviere & Heit 1997) though 
obviously in a system optimised for iontophoresis the contribution to total flux from passive 
diffusion is likely to be small. A typical observation in vitro is that after a period of 
iontophoresis, passive flux is often higher than pre-iontophoresis levels (Pikal & Shah 1990b; 
Thysman et al. 1994b; Santi & Guy 1996b), however, the relevance of this effect in vivo is 
unclear. 
 
Passive fluxes across skin from a saturated aqueous solution can be usefully predicted from 
the logP and molecular weight of the permeant (Potts & Guy 1992). However, prediction of 
iontophoretic flux is not as straightforward (Yoshida & Roberts 1992). Prediction of the 
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electrorepulsive component of iontophoretic flux of ions is possible if their charge, and their 
concentrations and mobilities in the skin are known (Mudry et al. 2006a). Obviously this 
latter information is not readily available. Furthermore, the magnitude of the solvent flow, and 
its contribution to total iontophoretic transport is not easily predicted. Consequently, total 
iontophoretic flux is generally established empirically. In this chapter the influence of some 
formulation and iontophoretic parameters on the delivery of BUP and NTX was examined, 
and is reported in the following four sections: 
 
 Section A: Feasibility study 
 Section B: Effect of pH on iontophoresis of NTX and BUP 
 Section C: Effect of drug concentration in the donor on iontophoresis of NTX and 
BUP 
 Section D: Effect of current density on iontophoresis of NTX and BUP 
 
2. Methods and materials 
 
Materials 
Buprenorphine hydrochloride (BUP) was from Reckitt and Colman (UK). Naltrexone 
hydrochloride (NTX), acetaminophen (ACM), Tris base, Tris hydrochloride, sodium chloride, 
silver, silver chloride and trifluoroacetic acid were from Sigma (UK). Organic solvents were 
from Fisher (UK). The dorsal pig skin was collected from a local abbatoir, dermatomed 
(Zimmer®, US), to a nominal thickness of 750 µm, frozen within 24 hours of slaughter, and 
thawed before use.  
 
Iontophoresis 
Excised dorsal pig skin was placed across the aperture of a side-bi-side cell and held 
together in a clamp (figure 4.5). The cell had two compartments, enabling the outer surface 
of the skin to be bathed in donor solution and the subdermal side to be bathed in receiver 
solution. Both compartments were stirred by magnetic bars. A power supply (Kepco, UK) 
was connected to a silver/silver chloride anode and cathode prepared in-house (Green 
1996). The anode was in the donor compartment and the cathode was in the receiver 
compartment. A fixed current was passed for 6 hours, during which the receiver was 
sampled every hour for analysis by high performance liquid chromatography (HPLC). In a 






Figure 4.5. Photographs of a glass diffusion cell in a clamp, and a pair of Ag/AgCl 
electrodes. The surface of the electrode on the left is largely silver, so can be used as an 
anode; the surface of the electrode on the right is largely silver chloride so can be used as a 
cathode. The electrodes are placed in the vertical ports of the diffusion cell. The lateral ports 
of the diffusion cell can be used to sample the receiver compartment. 
 
Section A: Feasibility study  
The side-bi-side cells used in this section allowed 0.95 cm2 of skin to be exposed and 
available for drug transport. The volume of the donor solution was 1.3 ml, the volume of the 
receiver solution was 1.8 ml. The donor solution was Tris/TrisHCl buffer pH 6 (60 mM Tris 
hydrochloride chloride & 0.4 mM Tris base), containing 1 mg/ml BUP with either 0, 0.55, 5.5, 
or 55 mg/ml NTX. The receiver solution was phosphate buffered saline pH 7.4 (8 g NaCl, 0.2 
g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 per litre of water). A direct, constant current of 0.38 
mA was passed. Each hour 1 ml of receiver solution was removed for analysis and replaced 
with fresh buffer. A passive (no current) experiment was also performed during which the 
receiver was only sampled at 3 and 6 hours. 
 
Four different donor solutions were tested. The concentration of NTX was varied, while the 
concentration of BUP was held constant. The table below describes the experiments 
presented in this section. 
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Table 4.1: Summary of the initial experiments carried out to assess the relative transdermal 
fluxes of NTX and BUP, and the effect of the concentration of NTX in the donor solution. 
NTX in donor 
(mg/ml) 






1.0 60 mM  
Tris HCl, 














Section B: Effect of pH  
The side-bi-side cells used in this section allowed 0.95 cm2 of skin to be exposed and 
available for drug transport. The volume of both the donor and receiver solutions was 3.5 ml. 
The donor solution was 0 or 1 mg/ml BUP, 0.1415 mg/ml NTX and 0.5 mg/ml ACM prepared 
in 60 mM TrisHCl (pH was adjusted to 4, 5 or 6 with Tris base, NaOH or HCl). The receiver 
solution was 60 mM TrisHCl (pH adjusted to 4, 5 or 6 with Tris base, NaOH or HCl). For pH 
6 only, a passive (no current) experiment was also performed; during which the receiver was 
only sampled at 3 and 6 hours. 
 
A fixed current of 0.285 mA was passed for 6 hours, during which the receiver was sampled 
every hour for analysis by HPLC. The receiver was completely refreshed 3 times (at 1, 2, 
and 3 hours), at the remaining samples, 1 ml was sampled from the receiver and 
replenished. The donor was completely refreshed at 1, 2 and 4 hours. The complete 
refreshing of the donor and receiver solutions was performed to minimise pH drifts that might 
occur due to components of the skin leaching out during the experiment. During the passive 
experiment, the receiver was only sampled at 3 and 6 hours. The table below describes the 
experiments presented in this section. 
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Table 4.2: Summary of the experiments on the effect of pH on the iontophoresis of NTX and 
BUP. 





pH of donor 
(60 mM 
TrisHCl) 





0.14 1.0 4 4 
0.285 mA  
(0.3 mA/cm2) 
0.14 1.0 5 5 
0.14 1.0 6 6 
0.14 0 6 6 
0.14 1.0 5 5 Passive 
 
 
Section C: Effect of drug concentration  
The side-bi-side cells used in this section allowed 0.95 cm2 of skin to be exposed and 
available for drug transport. The volume of both the donor and receiver solutions was 3.5 ml. 
The donor solution was 0.5, 1 or 2.5 mg/ml BUP, 0.1415 mg/ml NTX and 0.5 mg/ml ACM 
prepared in 60 mM TrisHCl. pH was adjusted to 5 with NaOH or HCl. The receiver solution 
was 60 mM TrisHCl (pH adjusted to 5 with NaOH or HCl). A fixed current of 0.285 mA was 
passed for 6 hours, during which the receiver was sampled every hour for analysis by HPLC. 
The receiver was completely refreshed 3 times (at 1, 2, and 3 hours), at the remaining 
samples, 1 ml was sampled from the receiver and replenished. The donor was completely 
refreshed at 1, 2 and 4 hours. The table below describes the experiments presented in this 
section. 
 
Table 4.3: Summary of the experiments on effect of concentration of BUP in the donor 
solution. *Data from section B are shown for comparison in this section and in section D. 
NTX in donor  
as mg/ml (or molar 
fraction) 
BUP in donor  





0.14 (0.006) 0.5 (0.016)   
0.285 mA  
(0.3 mA/cm2) 
0.14 (0.006)* 1.0 (0.032)* 
Tris pH 5,  
60 mM 
Tris pH 5,  
60 mM 




Section D: Effect of current density  
In this section a set of side-bi-side cells were used which allowed a ‘large’ (3.80 cm2) area of 
skin to be exposed and available for transport. The results were then compared to a 
‘standard’ set of cells which allowed only 0.95 cm2 of skin to be exposed (data from section 
B). The volume of the donor and receiver solutions in the standard cell was 3.5 ml. The 
volume of the donor and receiver solutions of the large cell was 8 ml. The donor solution was 
1 mg/ml BUP, 0.1415 mg/ml NTX and 0.5 mg/ml ACM prepared in 60 mM TrisHCl. pH was 
adjusted to 5 with NaOH or HCl. The receiver solution was 60 mM TrisHCl (pH adjusted to 5 
with NaOH or HCl). A fixed current of 0.285 mA was passed for 6 hours, during which the 
receiver was sampled every hour for analysis by HPLC. The donor and receiver were 
completely refreshed 3 times (at 1, 2 and 4 hours, and 1, 2 and 3 hours respectively). At the 
remaining hourly samples, 1 ml was sampled from the receiver and replenished.  
 
Although two sizes of skin were used in this section, the same size area was tape-stripped in 
both cases (0.785 cm2) so that amount of drug recovered would be directly comparable. The 
table below describes the experiments presented in this section. 
 








Current density  
(current intensity) 




Tris pH 5 
60 mM 
Tris pH 5 








3. Results and Discussion 
 
Section A: Feasibility study 
The objective of these experiments was to determine the feasibility of iontophoresis as a 
technique to deliver therapeutic amounts of BUP and NTX through skin. For the initial 
experimental conditions of the feasibility study, a donor solution with drug concentrations 
close to the observed maximum aqueous solubilities was selected (1 mg/ml and 55 mg/ml 
for BUP and NTX respectively, at pH 6). A pH of 6 was selected as a starting point because 
at this pH NTX and BUP, as weak bases with pKas around 8, are both positively charged, 
and have acceptable aqueous solubility. Furthermore, at pH 6, EO would be expected to 
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contribute to overall drug flux. The results obtained can be seen in tables 4.5 and 4.6 and 
figures 4.6 and 4.7.  
 
As expected, iontophoresis dramatically increased flux of both compounds compared to 
passive diffusion (600-fold for NTX and 40-fold for BUP). The highest iontophoretic fluxes of 
BUP observed here were not as high as previously reported by Fang et al. (2002), which 
was 10.1 µg/h/cm2. However, this may be explained by their use of nude mouse skin, as 
rodent skin is generally considered to be more permeable than pig skin. The fluxes of NTX 
observed here were several fold higher than the highest NTX fluxes previously reported; 
Wermeling et al. (2008) and Ghosh et al. (2013) used microneedle technology and reported 
fluxes of 14.7 µg/h/cm2 and 16.4 µg/h/cm2 respectively.  
 
Table 4.5: Iontophoretic and passive fluxes (mean ± standard deviation) of NTX and BUP 
across excised pig skin as a function of NTX concentration in the donor solution. The 
background electrolyte in all donor solutions was Tris buffer pH 6. Receiver solution was 
PBS pH 7.4. Current intensity was 0.38 mA over an area of 0.95 cm2. 




6 h cumulative  
delivery (µg) 
Flux at 6h (µg/h) 
6 h cumulative 
delivery (µg) 
Flux at 6h (µg/h) 
55 & 1 4 1223 ± 97 272 ± 42 0.49 ± 0.29 0.22 ± 0.10 
5.5 & 1 4 416 ± 169 113 ± 43 0.86 ± 0.56 0.38 ± 0.22 
0.55 & 1 10 100 ± 20 24 ± 3 6.29 ± 5.25 2.04 ± 1.29 
0 & 1 4 - - 6.31 ± 2.98 1.90 ± 0.68 




Figure 4.6: Iontophoretic flux (mean + standard deviation) of NTX (left) and BUP (right). 
Donor solutions were pH 6 and contained 0, 0.55, 5.5 or 55 mg/ml NTX and 1 mg/ml BUP (n = 
4, 10, 4 and 4 respectively). Note the 100-fold difference in the y axes. 
 
As expected, increasing the concentration of NTX in the donor solution increased flux of NTX 
and decreased flux of BUP. The flux of BUP is influenced by the amount of NTX in the system 
due to competition for charge-carrying between these co-ions (Mudry et al. 2006a and b). As 
the concentration of NTX in the donor solution is increased, the drug carries a larger share of 
the available charge in the system, it follows that another ion/s must carry less charge. 
Unfortunately, the amount of charge carried by the counter-ion chloride is relatively constant 
in this type of system. This was illustrated by Mudry (2006b) who measured the fluxes of 
sodium, lithium, ammonium and potassium delivered from the anode. The only counter-ion 
present in the cathodal compartment was chloride (present as MgCl2). It was shown that 
altering the concentrations of lithium, ammonium and potassium in the anode compartment 
(while keeping the concentration of sodium fixed) altered their fluxes, but at the expense of 
sodium flux, not at the expense of chloride flux. When considering the data presented here, it 
follows that as the concentration of NTX in the donor solution increases and the flux of NTX 
increases, it is the flux of bulky BUP and not the flux of small mobile chloride (in the cathode-
to-anode direction) or Tris+ (in the anode-to-cathode direction) that will ‘lose out’. 
 
The highest flux of BUP, and the delivery ratio of the two drugs closest to the 3:1 NTX:BUP 
aim determined in chapter 2, were achieved using a donor solution containing 0.55 mg/mL 
NTX and 1 mg/mL BUP; the fluxes were 24 and 2 µg/h at 6 hours respectively. The transport 
number of a drug gives a measure of its ability to compete as a charge-carrier. The transport 
number of BUP in the ‘best’ donor solution (0.55 mg/mL NTX and 1 mg/mL BUP) was 2.9 x 
10-4 (table 4.6). This is consistent with previously reported values for transport numbers of 
BUP: 5 x 10-4 (Robson 1988, using a citrate-phosphate buffer pH 5), 9 x 10-4 (Bose et al. 
2001, using a citrate buffer donor solution pH 4.0), and 10 x 10-4 (Fang et al. 2002, using a 
citrate-phosphate buffer pH 5). The detail provided in these three previous studies was not 
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sufficient to calculate the molar fraction of BUP in the donor solutions for comparison with the 
results presented here. The transport number of NTX in the ‘best’ donor was 0.0045; no 
comparison iontophoretic data for NTX has been published. To clarify, the vast majority of 
charge is carried by ions other than NTX or BUP, specifically by Tris cations in the anode-to-
cathode direction, and by chloride anions in the cathode-to-anode direction. 
 
Table 4.6: Molar fraction in the donor and transport number of NTX and BUP. All donor 
solutions were pH 6. Current intensity was 0.38 mA over an area of 0.95 cm2. 
NTX & BUP 
(mg/ml) 
NTX BUP 
Molar fraction Transport number Molar fraction Transport number 
55 & 1 0.702 0.0507 0.0096 3.1 x 10
-5
 
5.5 & 1 0.191 0.0211 0.0259 5.3 x 10
-5
 
0.55 & 1 0.023 0.0045 0.0313 2.9 x 10
-4
 








Figure 4.7: Transport number of NTX (left; n = 10, 4 and 4) and BUP (right; 4, 4, 10, 4) as a 
function of their molar fractions in the donor solutions. Transport number is the fraction of 
current that the drug carries, and is normally expected to be linearly related to molar fraction 
of the drug in the donor solution. All donor solutions were pH 6. Current intensity was 0.38 
mA over an area of 0.95 cm2. Values are mean ± standard deviation.  
 
Figure 4.7 shows that for NTX, there is a linear relationship between molar fraction of the 
drug in the donor solution and transport number (R2 = 0.996). BUP transport number also 
increases with BUP molar fraction, but not in a linear fashion (R2 = 0.636). A non-linear 
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relationship between transport number and molar fraction has been observed for cations 
such as propranolol (Marro et al. 2001b) and apomorphine (van der Geest et al. 1997). 
However, the transport number normally reaches a plateau as molar fraction increases, as 
opposed to increasing as seen in this case. The non-linear relationship observed here might 
reflect the very low molar fractions used (up to only 0.03). Previous studies demonstrating a 
linear relationship between molar fraction on transport number have often used much higher 
molar fractions; for example, Mudry et al. (2006a) examined the behaviour of lidocaine over 
a range of molar fractions from 0.25 up to 1. It might be the case that the relationship 
between molar fraction and transport number does not follow this same behaviour when 
looking at changes of very low (or very high) molar fractions. 
 
The slope of the regression of the molar fraction and transport number is a measure of the 
ability of the ion to compete for charge-carrying, and has been linked to aqueous mobility; a 
higher slope value indicates a higher efficiency and a more mobile species (Mudry et al. 
2007). The slope for NTX was 0.075 ± 0.007 (significantly different from zero). As the 
relationship between molar fraction and transport number for BUP was not linear, two slope 
values were calculated, one for molar fractions 0.0075 to 0.0239, and one for molar fractions 
0.0239 to 0.0315. The two slope values were 0.0022 ± 0.0004 and 0.0070 ± 0.002 
respectively. Taking either of these values, it is clear that NTX is a far greater charge carrier 
than BUP. This is perhaps due to NTX’s lower molecular weight and greater hydrophilicity.  
 
In summary, iontophoresis dramatically increased flux of both compounds compared to 
passive diffusion. The relationship between molar fraction of the drug in the donor solution 
and transport number may allow the iontophoretic fluxes of NTX and BUP to be manipulated 
by altering their relative concentrations in the donor solution. 
 
The target delivery rates calculated in chapter 1 were 15.2 μg/cm2/hr for NTX and 2.2 
μg/cm2/hr for BUP. The target for NTX was far exceeded here; at 6 hours a flux of 1287 
μg/cm2/hr was observed (1223 ± 97 μg/hr across 0.95 cm2 of skin). The target for BUP was 
met here; at 6 hours a flux of 2.15 μg/cm2/hr was observed (2.04 ± 1.29 μg/hr across 0.95 
cm2 of skin). Iontophoresis may therefore be a promising route for delivering NTX and BUP 
through the skin. 
 
The target fluxes for NTX and BUP predicted in chapter 1 were based on literature values of 
clearance and therapeutic plasma concentrations, therefore are only an approximation. 
Furthermore, it is unknown how well the in vitro iontophoretic fluxes reported here predict in 
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vivo iontophoresis fluxes. Therefore, efforts to better understand how to manipulate the 
relative fluxes of the two drugs were continued in subsequent sections. 
 
Section B: Effect of pH 
The effect of pH on the iontophoretic delivery of BUP and NTX was studied next. The effect 
of pH in an iontophoretic system can be complex due to simultaneous effects on the drug 
and skin charge. This is illustrated by experiments using 5-fluorouracil, a weak acid (Merino 
et al. 1999). At pH 8.5, 5-fluorouracil is largely negatively charged, and flux is predominantly 
in the cathode-to-anode direction, as expected as the drug is transported in this direction by 
ER. At pH 6, 5-fluorouracil was 99 % unionised, therefore negligible ER occurred. The 
contribution to total flux from EO therefore increased, and flux in the anode-to-cathode 
direction dominated. At pH 3, the net charge on the skin is positive, and EO is in the 
cathode-to-anode direction. Therefore 5-fluorouracil flux was again predominantly in the 
cathode-to anode direction (as at pH 8.5) but now due to EO. 
 
A study by Lopez et al. (2001) using 5-aminolevulinic acid illustrates a similar point. EO 
(indicated by the flux of mannitol) increased dramatically from pH 4 to pH 7.4, as expected. 
The contribution to total flux of EO was, however, offset, by a decrease in the contribution 
from ER, as the fraction of 5-aminolevulinic acid in the cationic form decreased at the same 
time. Overall, total flux of 5-aminolevulinic acid at pH 4 and 7.4 was not different. 
 
A pH range of 4 to 6 was chosen here. The lower limit of this range was selected because 
prolonged exposure to pHs lower than 4 may cause skin irritation. The upper limit of this 
range was selected because at pHs higher than 6, the aqueous solubility of BUP drops 
dramatically (table 4.7). Furthermore, although EO would be expected to increase as the pH 
was increased from 4 to 6, no further benefit would be expected at pHs higher than pH 6 
(Marro et al. 2001a), probably because the skin is already maximally negatively charged at 
close to pH 6. Conversely, it was expected that ER contribution to total flux would be 
greatest at the lower pH, due to a higher ionised fraction of drug at pH 4 than at pH 6 
(Siddiqui et al. 1989; Kalia et al. 2004). 
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Table 4.7: Percentage ionisation and aqueous solubility of NTX and BUP as a function of 
pH. BUP solubility values are experimental, and are taken from Robson (1988). NTX 
solubility values are predicted and were generated using MarvinSketch 6.3.1. The 
percentage of drug ionised was calculated from pKa values for NTX and BUP of 8.13 and 
8.37 respectively. 
  NTX BUP 





 water (mg/ml) 
4  100.0 378 100.0 19.0 
5  100.0 378 100.0 11.9 
6  99.6 378 99.8 1.4 
7.4  91.1 23.3 94.6 0.045 
 
As well as the amount of drug that reached the receiver compartment, in this and 
subsequent sections, the amount of drug in the stratum corneum (the outer non-viable layer 
of skin) was also quantified. Measuring the concentration of drug in the skin itself is more 
common when delivering drugs that act locally, and not drugs that act systemically, as BUP 
and NTX do. These measurements were included here because there was an expectation 
that BUP might form a reservoir in the skin during transdermal delivery. This possibility was 
indicated by work by Bose et al. (2001), who observed a significant release of BUP from the 
skin upon termination of iontophoresis, though the amount of BUP in the skin was not 
directly measured in their study.  
 
In order to assess the potential impact of a BUP reservoir on EO, and consequently on the 
fluxes of the two drugs, apparent convective solvent flow was now also measured. This was 
achieved by measuring the transdermal iontophoretic flux of an uncharged marker added to 
the donor solution. Acetaminophen (ACM), was chosen for this purpose. It has negligible 
passive flux, and is neutral over the pH range used here thus is not transported by ER, so is 
commonly used as a marker of EO (Dubey & Kalia 2014). 
 
The objective of the experiments in this section was to determine the influence of pH on the 
flux of NTX and BUP, on EO, and on the amount of drug in the skin. The results are shown 
in tables 4.8, 4.9 and 4.10 and figures 4.8 to 4.11. 
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Table 4.8: Iontophoretic and passive fluxes of NTX, BUP and the marker ACM as a function 
of pH. Donor and receiver solution were both Tris buffer. Current intensity was 0.285 mA 
over an area of 0.95 cm2. Letters in superscript indicate pairs of values significantly different 
(one-way ANOVA followed by Bonferroni post-tests, p < 0.05). 







































































































Figure 4.8: Iontophoretic fluxes of NTX (left) and BUP (right) as a function of time and pH of 
donor solution. All donor solutions contained 0.14 mg/ml NTX and 1.0 mg/ml BUP. pH of 
donor and receiver was 4, 5 or 6 (n = 6, 6 and 6). Data have been nudged to facilitate 
visualisation. All values are mean ± standard deviation.  
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The transport numbers of NTX and BUP were 0.001 and 0.0004 respectively at pH 6 (table 
4.9) despite NTX being present in the donor at a concentration 7 times lower than BUP. When 
the transport number of the ion of interest is high, ER dominates, and the contribution of EO is 
small; for ions with a small transport number, EO assumes a much greater significance 
(Luzardo-Alvarez et al. 1998). It follows that the contribution of EO to total flux is less 
important for NTX than it is for BUP, and any change in EO will have a comparatively greater 
effect on the total flux of BUP. As a general rule, electrical mobility will decrease with 
molecular weight and as a consequence, the electroosmotic contribution should become 
increasingly important for larger molecules (Guy et al. 2000). 
 
Table 4.9: Transport numbers of NTX and BUP as a function of pH. 
 
Transport number  
of NTX 
Transport number  
of BUP 
pH 4 7.5 x 10-4 4.9 x 10-4 
pH 5 7.0 x 10-4 2.6 x 10-4 
pH 6 8.2 x 10-4 4.5 x 10-4 
pH 6 no BUP 10.0 x 10-4 n/a 
 
No effect of pH on flux was observed for either NTX or BUP. As mentioned, increasing pH 
was expected to result in: 
1) a decrease in the ER contribution to the flux of NTX and BUP, as the percentage of drug 
present in the ionised fraction decreased (Siddiqui et al. 1989; Kalia et al. 2004) and 
2) an increase in the EO contribution to the flux of NTX and BUP as the permselectivity of 
the skin increased (Marro et al. 2001a).  
 
The lack of effect of pH on flux observed here cannot be explained by these two (opposing) 
factors cancelling each other out, as it had been for the 5-aminolevulinic acid work (Lopez et 
al. 2001). Lopez et al. saw a clear increase in EO with increasing pH, as indicated by the flux 
of the marker mannitol. However, that was not the case for the data presented here, and 
surprisingly, no effect of pH on the flux of ACM was observed. To explain why no influence 




Figure 4.9: Flux (mean ± standard deviation) of ACM as a function of pH. ACM is a marker of 
EO convective flow. All donor solutions contained 0.14 mg/ml NTX and 1.0 mg/ml BUP. pH 
of donor and receiver was 4, 5 or 6 (n = 6, 6 and 6). Data have been nudged to facilitate 
visualisation. 
 
NTX did not accumulate in the stratum corneum (NTX was not quantifiable beyond tape 1). In 
contrast, the amount of BUP recovered from the stratum corneum was large compared to the 
amount that reached the receiver compartment. For example, at pH 6, the total amount of 
BUP that crossed into the receiver solution was 4.8 ± 2.8 µg and the amount of BUP 
recovered from the stratum corneum was 151 ± 137 µg (192 ± 175 µg/cm2). To put the 
amount of BUP in the stratum corneum observed here in context, Curdy et al. (2001) 
recovered 49 µg/cm2 of piroxicam from the stratum corneum following cathodal iontophoretic 
delivery in vivo in man. Jadoul et al. (1995) reported recovering 0.1 µg/cm2 fentanyl, and 0.25 
µg/cm2 thyrotropin releasing hormone, from the stratum corneum following anodal 
iontophoretic delivery in rat skin in vitro. 
 
The accumulation of BUP in the stratum corneum was pH-dependent (table 4.10). The mass 
of BUP recovered from the stratum corneum was 5 times higher at pH 6 than at pH 4 (table 
4.10).  The depths of stratum corneum reached for pH 4, 5 and 6 were 4.8 ± 1.8 µm, 5.2 ± 2.7 
µm, and 7.2 ± 2.2 µm. These depths are not statistically different. Nevertheless, in case the 
depth sampled influenced the amount of BUP recovered in the stratum corneum, the results 
were also reported as concentration of drug in the stratum corneum; the concentration of BUP 
in the stratum corneum was three times higher at pH 6 than at pH 4. It has been previously 
reported that passive BUP partitioning into isolated human stratum corneum was pH-
dependent (Robson 1988). For example, the log of the stratum corneum–aqueous buffer 
distribution ratio of BUP (as the hydrochloride) increased from 0.5 at pH 4 to 2.5 at pH 7.4. 
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Table 4.10: Effect of pH on accumulation of BUP in the stratum corneum (NTX not 
quantifiable in stratum corneum beyond tape 1). Mean ± standard deviation. 
pH of donor 
and receiver 
BUP in tapes (µg) 
Stratum corneum 
removed (µg) 
Concentration of  

































As each tape was extracted and analysed separately, the distribution profile of BUP in the 
stratum corneum can be plotted (figure 4.10). The profiles show a typical decrease in drug in 
the stratum corneum with increasing depth. The average depth of stratum corneum sampled 
was 6 µm, out of an available total thickness of porcine stratum corneum of around 10 μm 




Figure 4.10: Amount of BUP in stratum corneum as a function of depth, following 6 hours of 
iontophoresis. All donor solutions contained 0.14 mg/ml NTX and 1.0 mg/ml BUP. Donor 
solution and receptor solution were pH 4 (left) or pH 6 (right), n = 6 and 6. 
 
Tape-stripping following the passive experiment yielded little BUP (3 ± 1 µg). Importantly, 
this low amount recovered for the passive experiment indicates that BUP recovered from the 
stratum corneum after iontophoresis was not simply residual donor solution on the surface of 
 94 
the skin. NTX in the stratum corneum was below limit of quantification following the passive 
experiment. 
 
The difference between the amounts of BUP and NTX in the stratum corneum may reflect 
the fact that NTX was present in the donor at a concentration 7 times lower than BUP. 
Alternatively, it may be because NTX is less lipophilic than BUP therefore less attracted to 
the lipid environment of the stratum corneum. Delgado-Charro and Guy (1994) commented 
that as well as an electrostatic attraction between a positively charged drug and the 
negatively charged sites in the skin, some lipophilicity of the drug also appears necessary for 
accumulation to occur. NTX and BUP are both similarly positively charged at this pH, but 
only BUP accumulates in the skin. Lastly, it is possible that the difference in recovery of NTX 
and BUP from the stratum corneum is a reflection of different pathways taken through the 
skin by these two drugs. Curdy et al. (2001) suggested that permeants which travel via the 
follicular route and move faster through the stratum corneum would be expected to found in 
the stratum corneum at lower concentrations. Correspondingly, Curdy et al. (2001) inferred 
that if a permeant is found in the stratum corneum it must be at least partly transported via 
the intercellular route. 
 
Influence of accumulated BUP on EO and on flux of NTX  
An explanation for the surprising absence of effect of pH on EO is now offered. It was 
hypothesised that at pH 6, the skin depot of BUP was neutralising negative charges on the 
skin and suppressing EO. Suppression of EO by accumulation of a cation in the skin has 
been previously reported for the peptide nafarelin (Delgado-Charro et al. 1995; Santi & Guy 
1996a). To test whether BUP was causing suppression of EO, iontophoresis was performed 
(at pH 6 only) in the absence of BUP. Note that removal of BUP from the donor solution 
increased the molar fraction of NTX by only 3%, therefore, any change in flux of NTX 
associated with ion competition would not be expected to be measurable. The results are 
shown in figure 4.11. 
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Figure 4.11: Flux of ACM (left) and flux of NTX (right) in the absence and presence of 1 
mg/ml BUP in the donor. Both donor solutions contained 0.14 mg/ml NTX and the pH of the 
donor solution and the receptor solution was pH 6 (n = 6 and 6). Data shown are mean + 
standard deviation. 
 
Significantly higher fluxes of ACM were indeed observed in the absence of BUP. This 
observation supports the hypothesis that BUP suppresses EO. At pH 6, the observed 
accumulation of BUP in the skin may be cancelling the negative charges in the skin that 
normally generate EO flow.  
 
Significantly higher fluxes of NTX were also observed in the absence of BUP. The increase 
in NTX flux (21 %) is smaller than the increase in ACM flux (64 %). This is because, unlike 
ACM, NTX total flux is composed of contributions from ER as well as from EO.  
 
Having demonstrated that BUP inhibits EO, and thereby inhibits flux of NTX, it was inferred 
that BUP also inhibits its own flux. Furthermore, it is expected that any reduction in EO will 
have a greater impact on the flux of BUP than on the flux of NTX. That is because BUP is 
less efficient at competing to carry charge than NTX (as indicated by lower transport 
numbers than NTX), therefore the relative contribution of EO to total flux of BUP will be 
greater than the relative contribution of EO to total flux of NTX (Luzardo-Alvarez et al. 1998, 
Guy et al. 2000). 
 
To the author’s knowledge, it has not been previously reported that during simultaneous 
iontophoretic delivery of two drugs, one drug could alter the flux of the other drug, by a 
mechanism not related to ion competition. Thysman et al. (1994a) studied the iontophoretic 
flux of two drugs delivered from the anode in succession (calcitonin for 1 hour followed by 
metroprolol for 6 hours). It was shown that delivery of calcitonin altered the skin in a way that 
reduced the subsequent flux of metroprolol. According to Thysman, this effect might be 
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explained by physical blocking of ‘skin channels’ or ‘pores’ by calcitonin, but the authors did 
not explore changes in EO. 
 
In summary, BUP accumulates in the stratum corneum in a pH-dependent fashion, reducing 
EO, probably by cancelling the net negative charge of the skin. Consequently, BUP limits its 
own flux, as well as negatively impacting on the flux of NTX.  
 
Section C: Effect of drug concentration 
The effect of drug donor concentration during iontophoresis is usually predictable, with flux 
proportional to molar fraction of drug in the donor (Phipps & Gyory 1992; Marro et al. 2001c; 
Kalia et al. 2004). However, this is not always the case (Hoogstraate et al. 1994; Merino et 
al. 2008; Dubey & Kalia 2014). In section A, the concentration of BUP in the donor solution 
was constant, and the concentration of NTX in the donor solution was varied. In this section, 
the concentration of NTX in the donor solution was kept constant and the concentration of 
BUP in the donor solution was varied.  
 
The objective of these experiments was to determine the influence of BUP concentration in 
the donor on flux of NTX and BUP, on EO and on amount of drug in the stratum corneum 
and the viable tissue. Tables 4.11 and 4.12 and figures 4.12 and 4.13 show the results.  
 
Despite a five-fold increase in the concentration (and molar fraction) of BUP in the donor 
solution, no increase in the flux of BUP was observed. This can be explained by the auto-
inhibition of BUP demonstrated in the previous section.  
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Table 4.11: Iontophoretic fluxes of BUP, NTX and ACM as a function of different 
concentrations of BUP in the donor. The background electrolyte of the donor and receiver 
solutions was Tris buffer pH 5. Current intensity was 0.285 mA over an area of 0.95 cm2. 
Mean ± standard deviation. Letters in superscript indicate pairs of values are significantly 
different (one-way ANOVA followed by Bonferroni post-tests, p < 0.05). 
Donor (mg/ml)  BUP NTX ACM 
NTX BUP n 
Flux at 6 h 
(µg/h) 
Flux at 6 h 
(µg/h) 
Flux at 6 h 
(µg/h) 



































Figure 4.12: Flux of NTX (left) and BUP (right) as a function of BUP molar fraction in the 
donor. The background electrolyte in both the donor solution and the receptor solution was 
60 mM Tris pH 5. Donor solutions contained 0.14 mg/ml NTX, either 0.5, 1.0 or 2.5 mg/ml 
BUP (n = 4, 6 and 4 respectively), and 0.5 mg/ml ACM. Mean ± standard deviation. 
 
As the concentration of BUP in the donor solution was increased, the amount of BUP 
accumulated in the skin increased (figure 4.13, right panel). In this section, as well as the 
amount of BUP in the stratum corneum, the amount of drug in the underlying viable skin 
tissue was quantified. A similar amount of BUP was recovered from the viable tissue and the 
stratum corneum, though obviously the concentration of BUP in the viable tissue was much 
lower, as the thickness of the stratum corneum is ~10 µm and the thickness of the viable 
tissue was ~750 µm. The lower concentration of BUP in the viable tissue most likely reflects 
slow partitioning of this lipophilic drug from the stratum corneum into a comparatively 
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aqueous environment. Interestingly, and as already seen in section B, the amount of BUP in 
the skin is not a good predictor of BUP transdermal flux. NTX was quantifiable in the viable 
skin tissue, but as expected, no effect of concentration of BUP on amount of NTX in the 
viable tissue was observed.  
 
In agreement with the results in the previous section, increasing the concentration of BUP in 
the donor solution decreased the flux of NTX. The decrease in NTX flux cannot be explained 
by simple ion competition; the molar fraction of NTX in the donor solution was only 
decreased by 6 % when the concentration of BUP was increased from 0.5 mg/ml to 2.5 
mg/ml and so cannot account for the observed 57 % decrease in NTX flux. Instead, the 
decrease in NTX can be explained by an effect on EO. 
 
The flux of ACM (the marker of EO) decreased with increasing concentration of BUP in the 
donor; EO decreased by 60% when the concentration of BUP in the donor was increased 
from 0.5 mg/ml to 2.5 mg/ml (figure 4.13, left panel). This is not an effect of ionic strength; 
the background electrolyte in the donor is 60 mM, increasing the concentration of BUP from 
0.5 to 2.5 mg/ml is only an increase of 4 mM. Rather, the effect of BUP concentration on EO 
is most likely the result of the accumulation of BUP in the skin, cancelling the negative 




Figure 4.13: Flux of ACM (left), and amount of BUP and NTX in the skin (right) as a function 
of BUP molar fraction in the donor. The background electrolyte in both the donor solution 
and the receptor solution was 60 mM Tris pH 5. Donor solutions contained 0.14 mg/ml NTX, 
either 0.5, 1.0 or 2.5 mg/ml BUP (n = 4, 6 and 4 respectively), and 0.5 mg/ml ACM. Mean ± 
standard deviation. 
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Table 4.12: Amount of BUP and NTX (mean ± standard deviation) in the skin as a function of 
BUP donor concentration. Letters in superscript indicate pairs of values significantly different 














































































In summary, a clear auto-inhibition of BUP flux was seen: despite a 5-fold increase in BUP 
donor concentration, no increase in flux of BUP was observed. In other words, the effect of 
increasing BUP molar fraction was counteracted by a decreasing contribution of EO.  
 
In an iontophoretic system that behaves ‘conventionally’, flux can be increased by 
manipulating the molar fraction of drug in the donor. This can be done either by increasing 
the concentration of the drug in the donor, or by decreasing the concentration of other ions 
present in the buffer. It was demonstrated in this section that this first option did not result in 
increased flux of BUP. The second option of reducing the concentration of the Tris buffer in 
the donor solution was not pursued, for the following reasons. Firstly, a minimal 
concentration of chloride ions is required for the electrochemistry at the anode, and 
secondly, reducing the concentration of the buffer would reduce the buffer capacity. 
Therefore, in the next section, the less well explored strategy of manipulating current density 
was considered. 
 
Section D: Effect of current density 
The effect of altering current density, while fixing current intensity, has been investigated by 
Lopez-Castellano et al. (1999) using propranolol, a lipophilic cation that inhibits its own flux 
in a concentration-dependent manner (Hirvonen & Guy 1997). Although the amount of drug 
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delivered during iontophoresis is normally linearly proportional to current intensity (Burnette 
& Ongpipattanakul 1987; Phipps et al. 1989; Pikal 2001), Lopez-Castellano et al. 
hypothesised that if the drug was spread out over a larger area it might have less impact on 
the EO contribution to iontophoretic flux. It was hoped here that this same strategy might 
result in a lower BUP depot per unit area of skin and therefore higher EO and, potentially, 
higher BUP flux.  
 
The objective of these experiments was to determine the influence of current density on flux 
of NTX and BUP, on EO, and on the amount of drug in the skin. Experiments were therefore 
here carried out in which the current intensity was fixed but the area of exposed skin was 
increased, thus the current density was decreased. Tables 4.13 and 4.14 and figures 4.14 
and 4.15 show the results. 
 
Table 4.13: Iontophoretic fluxes of NTX, BUP and ACM under ‘standard’ or ‘low’ current 
density conditions. Current intensity was 0.285 mA over an area of 0.95 cm2 or 3.80 cm2. 
The background electrolyte for the donor and receiver solutions was Tris buffer pH 5.Mean ± 
standard deviation. Letters in superscript indicate pairs of values significantly different (t-test, 
p < 0.05).  



























































It was hypothesised that a lower current density might result in lower accumulation of BUP in 
the skin which in turn might result in less inhibition of EO by BUP. Indeed, the flux of ACM 





Figure 4.14: Iontophoretic fluxes of NTX, BUP and ACM as a function of current density. 
Both the donor solution and the receiver solution were pH 5. All donor solutions contained 
0.14 mg/ml NTX and 1.0 mg/ml BUP (n = 6 and 4 for standard and low current density). 
Values are mean + standard deviation. 
 
However, the difference in apparent EO observed did not translate into a statistically 
different flux of BUP, presumably because BUP flux is the sum of contributions from both ER 
and EO. Similarly, NTX was not influenced by the change in apparent EO. Lowering current 
density even further (whilst fixing current intensity) might give rise to higher fluxes of drug. 
However, considering a 4-fold decrease in current density only resulted in a ~ 50 % boost to 
EO such as strategy would require very large patch sizes in patients, rendering this 
approach impractical. 
 
Table 4.14: Amount of BUP in the stratum corneum following iontophoresis using standard 
(0.3 mA/cm2) or low (0.075 mA/cm2) current density. The area tape stripped was 0.785 cm2 
in both cases. NTX not quantifiable past tape 1. Mean ± standard deviation. Letters in 
superscript indicate pairs of values are significantly different (t-test, p < 0.05).  
Current density 
(mA/cm2) 
Amount of BUP  
in the  
stratum corneum (µg) 
Stratum corneum  
removed (µg) 
Concentration of  




























Figure 4.15: Distribution profiles of BUP in the stratum corneum following iontophoresis 
using standard (0.3 mA/cm2; left panel) or low (0.075 mA/cm2; right panel) current density. 
Both the donor solution and the receiver solution were pH 5. All donor solutions contained 
0.14 mg/ml NTX and 1.0 mg/ml BUP (n = 6 and 4 for standard and low current density). 
 
The explanation for the higher flux of ACM observed at the lower current density is not 
obvious. It had been hypothesised that current density would influence amount of BUP in the 
skin, which would in turn influence inhibition of EO. However, no significant effect of current 
density on the amount recovered nor concentration of BUP in the stratum corneum was 
observed (table 4.14 and figure 4.15). The explanation for the higher flux of ACM observed 
at the lower current density may lie in differences in the amount of BUP in the underlying 
viable tissue, which was not assayed here.  
 
Although lowering current density was not successful at reducing the concentration of BUP 
in the stratum corneum, or at boosting BUP flux, these data do show that fluxes of BUP and 
NTX are determined by current intensity (over the range of current density investigated 
here), this would at least allow for titration of dose. This was as expected; even compounds 
with documented ‘anomalous’ behaviour, like nafarelin and ropinirole, obey this rule 
(Delgado-Charro et al. 1995; Luzardo-Alvarez et al. 2001). 
4. Conclusions of the chapter 
The transdermal flux of both drugs was dramatically increased by iontophoresis compared to 
the passive control. Varying the concentration of NTX in the donor solution (in the range 0.55 
to 55 mg/ml) when the concentration of BUP was fixed resulted in a predictable change in 
the flux of NTX, as explained by ion competition. The observed flux of NTX was far higher 
than the predicted target, whilst the flux of BUP met the predicted target. Further 
experiments therefore used lower donor concentrations of NTX.  
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During iontophoresis a skin depot of BUP was formed. The magnitude of the reservoir was 
proportional to the concentration of BUP in the donor and was greater at pH 6 than at pH 4. 
The mechanism of formation of the depot cannot be known from these data, but is likely a 
consequence of both an electrostatic attraction between BUP and the skin, and the low 
partitioning of lipophilic BUP out of the stratum corneum into the relatively aqueous 
environment of the viable tissue beneath (Riviere & Heit 1997; Hirvonen & Guy 1997). The 
BUP depot was associated with a decrease in anode-to-cathode EO, presumably by 
neutralising negative charges on the skin. Interestingly, this effect was accompanied not only 
by significant auto-inhibition of BUP flux but also by a decreased NTX flux. 
 
This anomalous behaviour complicates optimisation of this iontophoretic drug combination. A 
less common strategy of reducing current density was therefore investigated, and though a 
significant effect on apparent EO was observed, this approach was unsuccessful at reducing 
the depot or at increasing the flux of BUP. 
 
The work presented in this chapter demonstrates that the simultaneous iontophoresis of two 
cations may result in complicated transport interactions beyond those expected through 
transport number competition. Nevertheless, iontophoresis appears to be a promising 
approach for delivering NTX and BUP through the skin. 
 
For the majority of the experiments performed in this chapter the receiver solutions used 
were matched to the buffers used in the donor solutions. In chapter 5, further 
characterisation and optimisation of the system was carried out using a receiver solution 
more comparable to the in vivo situation.  
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Chapter 5: Characterisation of iontophoretic transdermal delivery of buprenorphine 





In chapter 4 it was established that both NTX and BUP could be delivered by transdermal 
iontophoresis. However, delivery of BUP was significantly less efficient than delivery of NTX. 
It was established that BUP accumulates in the skin, and by its influence on EO, reduces its 
own flux, as well as that of NTX. Therefore, the aim of this chapter was to further understand 
the anomalous iontophoretic behaviour of BUP. 
 
Furthermore, in this chapter a receiver solution of a physiological pH was adopted, in order 
to closer mimic the in vivo situation. In chapter 4, the importance of pH in an iontophoretic 
system was described, and it was stated that pH affects various factors simultaneously. For 
example, the pH of the donor solution can change the percentage of the drug which is 
ionised, which modifies the aqueous solubility. The percentage of drug which is ionised also 
influences the total drug flux, because obviously only ionised drug is transported by 
electrorepulsion (ER) (Siddiqui et al. 1989). In the introduction of this chapter, the specific 
importance of the composition of the receiver solution, including the effect of pH, will be 
discussed. The accumulation of drug in the skin, current profile effects and lastly molar 
fraction effects are also briefly discussed. 
 
Influence of receiver solution on iontophoresis 
The composition of the receiver solution can influence the iontophoretic flux of a drug, via 
the separate mechanisms of ER and electroosmosis (EO). The effect on ER will be 
discussed first. Mudry et al. (2006a) demonstrated that the flux of lithium from the anode was 
influenced by the anion (chloride, acetate, or gluconate) used in the receiver solution. The 
flux of lithium was highest when the receiver solution contained gluconate, and lowest when 
the receiver solution contained chloride. This observation can be explained by the difference 
in the aqueous mobility of the three anions, which are 8.1 x 10-4, 4.2 x 10-4 and 2.5 x 10-4 
cm2/s.V for chloride, acetate and gluconate respectively. There is competition for charge-
carrying between lithium in the donor (transported in the anode-to-cathode direction), and 
the anion in the receiver solution (transported in the cathode-to-anode direction); chloride is 
better at competing with lithium for charge-carrying than gluconate is. 
 
There are very few drug delivery studies which specifically examine the effect of receiver 
solution composition on EO. However, drug extraction studies offer useful insight into the 
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influence on EO of the composition of the subdermal electrolyte solution. Transdermal 
extraction of lithium (Leboulanger et al. 2004), phenylalanine (Merino et al. 1999) and 
glucose (Tamada & Comyns 2005) has been investigated for therapeutic monitoring 
purposes. The compounds are extracted using iontophoresis; as the aim is to transport the 
permeant out of the body instead of into the body, the term ‘reverse iontophoresis’ is 
commonly used. In the case of glucose, which is neutral, transport out of the skin into a 
collection chamber is effectively driven exclusively by EO. Several studies have therefore 
been carried out with the objective of selecting optimal electrolyte solutions for collection 
chambers to maximise extraction efficiencies. These reverse iontophoresis experiments 
showed that the following factors influence EO: 
 
1. Type of ion. Tamada & Comyns (2005) measured iontophoretic extraction of glucose (an 
indicator of EO) in vivo in man, and showed that the extraction of glucose was more than 
twice as efficient into a collection chamber containing citrate buffer compared to into a 
collection chamber containing bicarbonate buffer (both solutions were pH 6.5 and were 
closely matched in ionic strength). No clear explanation of this effect of buffer type on EO 
has yet been proven, but it is hypothesised that different buffer molecules have a different 
ability to shield the skin’s negative charges (Santi & Guy 1996a). 
 
2. Ionic strength. Tamada & Comyns (2005) observed that lower ionic strengths in the 
collection chamber resulted in higher flux of glucose.  Again, this effect may be related to the 
shielding of the negative charges in the skin, which would be expected to increase with 
buffer concentration. An inverse relationship between ionic strength and EO was also 
observed by Santi & Guy (1996b) who measured outward flux of mannitol (another marker of 
EO) in vitro. 
 
3. pH. Lastly, Tamada & Comyns (2005) reported that higher pH in the collection chamber 
(pH 7.5 versus pH 6.5, and pH 6.5 versus 4.5) resulted in greater flux of glucose. The finding 
that higher pH in the receiver results in greater anode-to-cathode EO is supported by work 
from Kim et al. (1993). Several other researchers have shown in ‘symmetrical’ set-ups (i.e., 
the donor solution and receiver solution were prepared using identical background 
electrolyte) that higher pH results in greater EO (Luzardo-Alvarez et al. 1998; Marro et al. 
2001a); Kim et al. however, demonstrated that the same effect could be observed by 
changing the pH of only the receiver compartment. Keeping all other parameters fixed, and 
using a donor solution of pH 4, the flux of mannitol from the anode was observed to be more 
than three times greater when a receiver solution of pH 7.4 was used compared to a receiver 




Additionally, the choice of receiver solution may influence the chemical and physical stability 
of a drug during an experiment. For example, Delgado-Charro & Guy (1995) showed an 
apparent increase in the rate of degradation of nafarelin (a peptide) during the experiment 
when the pH of the receiver was increased from pH 5 to pH 6 or 7. Lastly, experimental 
artefacts such as loss of drug from the receiver solution due to adsorption to the glass 
surfaces of the apparatus can also be effected by choice of receiver solution.  
 
Skin accumulation 
In chapter 4, it was observed that BUP accumulates in the stratum corneum and viable 
tissue during iontophoresis. Some accumulation of drug in the stratum corneum is relatively 
common during passive delivery and is particularly well documented for topical steroids 
(Surber et al. 1990; Roberts et al. 2004). The accumulation of BUP in the skin is important 
for the following reasons. If BUP moved into the skin and remained there it would not reach 
the subdermal compartment (in vivo) to become bioavailable. Alternatively, BUP in the skin 
might be released into the systemic circulation after removal of a patch by a patient; this 
effect has been documented for fentanyl patches (Grond et al. 2000). A key principle of this 
combination product is that BUP, an opioid agonist, should not be delivered without the 
antagonist NTX (NTX does not form a reservoir in the skin). Lastly, as shown in section B 
and C of the previous chapter, the BUP depot inhibits EO and consequently has a negative 
impact on flux. 
 
Accumulation of a cationic drug in the skin can mean that the conventional linear relationship 
between molar fraction and flux (Phipps & Gyory 1992) is not observed. For example, 
Luzardo-Alvarez et al. (2001) performed iontophoresis of ropinirole and found that increasing 
the concentration of ropinirole in the donor such that molar fraction was increased more than 
four-fold did not result in a significant increase in the flux of ropinirole. This observation was 
explained by a reduced contribution from EO (as indicated by mannitol flux) as the 
concentration of ropinirole in the donor solution was increased. This effect has been termed 
‘auto-inhibition’. 
 
Similar behaviour has been documented for peptides (Hoogstraate et al. 1994; Delgado-
Charro & Guy 1994; Delgado-Charro & Guy 1995; Delgado-Charro et al. 1995; Rodriguez-
Bayon & Guy 1996; Schuetz et al. 2005; Cazares-Delgadillo et al. 2007; Dubey & Kalia 
2014) as well as small drug molecules (table 5.1). BUP is within the same range of 
lipophilicity as the other drugs known to auto-inhibit (BUP logP 2.63). That does not mean 
that BUP is ‘too lipophilic’ for iontophoresis; lidocaine hydrochloride (logP 2.3) and fentanyl 
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hydrochloride (logP of 3.8) are also within this range, and both have been formulated into 
commercial iontophoresis products. However, the duration of iontophoresis for both lidocaine 
and fentanyl is relatively short (less than 30 minutes per session). 
 
Table 5.1: Small drug molecules observed to inhibit their own flux during transdermal 
iontophoresis, shown with their molecular weights and logP values. 
Compound Authors and year Molecular weight logP 
Propranolol 
Hirvonen & Guy 1997; 
Marro et al. 2001b 
259 3.21 
Timolol Hirvonen & Guy 1997 316 1.91 
Metoprolol Hirvonen & Guy 1997 272 1.88 
Ropinirole 
Luzardo-Alvarez et al. 
2001 
260 2.70 
Quinine Marro et al. 2001b 324 3.44 
Nortriptyline 
hydrochloride 
Merino et al. 2008 298 4.54 
 
Accumulation of drug in the skin has been attributed to electrostatic attraction between the 
skin and the drug (all the compounds in table 5.1 are delivered as cations), and to a certain 
level of lipophilicity of the drug (Hirvonen & Guy 1997; Raiman et al. 2003). Furthermore, as 
a drug moves across the skin, in vitro or in vivo, it may encounter a pH gradient. Therefore 
its ionisation and water solubility may change, resulting in accumulation in the skin 
(Thysman et al. 1994a).  In vivo, the pH of the skin changes from about 4.2 at the skin 
surface to pH 7.3 in the aqueous viable tissue (Sage 1997). 
 
Current profile effects 
Contribution to total flux from ER can be optimised by increasing the transport number, for 
example by manipulation of the drug molar fraction of the donor solution. Contribution to total 
flux from EO can be optimised by increasing convective solvent flow, for example by 
manipulation of the pH. After exploring these options in this and the previous chapter, the 
current profile, which can influence both ER and EO, was here considered. 
 
During an iontophoresis session the current can be (deliberately) turned off for short periods. 
For example, current could be switched off for 10 minutes out of every hour. This will be 
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referred to as ‘pulsatile iontophoresis’. The original rationale for pulsatile iontophoresis was 
to counter iontophoresis-induced skin irritation, by allowing depolarisation of the skin (Okabe 
et al. 1986) though there is not clear published evidence of such an effect. Later, it was 
suggested that the depolarisation associated with an off period might result in release of 
drug accumulated in the skin (Yoshida & Roberts 1992; Thysman et al. 1994b). Lastly, 
pulsatile iontophoresis has been used to deliver bursts of drug to mimic the natural cycles in 
blood concentration of some hormones. Some previous studies employing pulsatile 
iontophoresis are shown in table 5.2. 
 
Table 5.2: Some previous studies which have performed pulsatile iontophoresis, meaning an 




Details Rationale Timings Outcome 
Miller et 
al. 1989 
Anodal delivery of 
gonadotropin-
releasing hormone. 
Hairless mouse,  
AgCl electrodes 
To mimic natural 





















To mimic natural 
pulsatile pattern of 
plasma levels 
5 min on, 
55 min 
off, for 6 h 
No comparison 








Anodal delivery of 
nafarelin. Hairless 
mouse skin,  
AgCl electrodes 
Release of drug 
reservoir from skin 
6 h on,  
6 h off,  







Anodal and cathodal 
extraction of 
mannitol. Hairless 
mouse skin, AgCl 
electrodes 
















Anodal and cathodal 
extraction of 
glucose. Human in 
vivo,  
AgCl electrodes 













This limited set of studies broadly shows that cumulative drug delivered is a function of total 
current passed, as expected in accordance with Faraday’s law. That said, the precise effect 
of pulsatile iontophoresis is likely to depend on the permeant involved, and on the current 
profile (Hirvonen et al. 1995). 
 
The current profile can also be modified by intermittently reversing the polarity of the 
electrodes. This strategy was proposed by Lattin and Spevak (1983) as a way to extend the 
lifetime of an iontophoretic delivery device. They observed that an electrode has a finite 
lifetime, due to electrochemical factors, or due to drug depletion. Therefore, the lifetime of a 
delivery device could be doubled simply by placing drug at both electrodes, and running 
each electrode in turn as the delivery electrode, either each until exhaustion, or in 5 minute 
cycles, for example. The previously mentioned possibility of reduction of skin irritation due to 
depolarisation of the skin would also apply. Despite these possible advantages, the effect of 
reversing polarity (RP) is not well explored (table 5.3). 
 
Table 5.3: Some previous studies using RP iontophoresis, meaning that the polarity of the 
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Every 6h 
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The possible benefits of placing drug at both the anode and the cathode, and delivering from 
each simultaneously, is hinted at in work by Lopez et al. (2003). The flux of zwitterionic 
aminolevulinic acid delivered from both electrodes simultaneously during direct, constant 
current iontophoresis was greater than the flux from either electrode alone. 
 
Both pulsed iontophoresis and RP might be expected to result in some mobilisation of the 
BUP reservoir in the skin (Delgado-Charro & Guy 1995). RP was investigated in this thesis 
because in contrast to pulsatile delivery, during RP iontophoretic delivery occurs 
continuously.  
 
As a cation, BUP is delivered by ER from the anode. Delivery of BUP from the cathode is 
therefore termed ‘wrong-way iontophoresis’ (Pikal 2001). It was hypothesised that during the 
(wrong-way) cathodal period of RP, BUP could be released from the skin either passively or 
aided by EO (Delgado-Charro & Guy 1995). It has been shown previously that if an 
accumulation of lipophilic cations is large enough, it can not only cancel the negative 
charges of the skin, but actually confer a net positive charge to it; consequently, EO in the 
cathode-to-anode direction becomes dominant (Delgado-Charro & Guy 1994). Though it was 
shown in sections B and C of chapter 4 that BUP reduced EO in the anode-to-cathode 
direction, it was not known to what extent EO in the cathode-to-anode direction was 
occurring. EO in the cathode-to-anode direction was not measured in those experiments 
because of the analytical difficulty of analysing very low concentrations of ACM in the donor 
solution in the presence of 1 mg/ml BUP.  
 
Figure 5.1 illustrates the theoretical mechanisms influencing BUP flux under a regimen of 
RP. Up to now, experiments in this thesis have been carried out using a 2-compartment cell 
with the anode in the donor compartment and the cathode in the receiver compartment. In 
this section it was necessary to use a 3-compartment cell. A central compartment containing 








Figure 5.1: Illustration of the movement of BUP during iontophoresis when the polarity of the 
electrodes is reversed every 2 hours. Experiments were performed in a 3-compartment cell, 
with the receiver solution in the central compartment. During 0-2 hours, BUP is delivered 
from the anode and begins to accumulate in the skin on the left. During 2-4 hours, BUP is 
delivered from the anode and begins to accumulate in the skin on the right. Simultaneously, 
BUP in the skin on the left can move into the central subdermal compartment due to passive 
diffusion and the influence of cathode-to-anode EO. During 4-6 hours, BUP is delivered from 
the anode. Simultaneously, BUP in the skin on the right can move into the central subdermal 
compartment due to passive diffusion and the influence of cathode-to-anode EO. 
 
Effect of molar fraction 
In the last section of this chapter, the effect of molar fraction of drug in the donor on flux is 
revisited. In section A of chapter 4, it was shown that changing the concentration of NTX in 
the donor concentration over the range 0.55 to 55 mg/ml while keeping the concentration of 
BUP fixed had a predictable effect; flux of NTX was proportional to NTX molar fraction. This 
is explained by co-ion competition and is consistent with studies of co-delivery of sodium and 
lidocaine (Mudry et al. 2006b) and calcium and hydromorphone (Phipps & Gyory 1992). 
Subsequently, in section C of chapter 4, it was shown that BUP behaved anomalously, and 
BUP flux did not increase despite a 5-fold increase in BUP concentration in the donor. The 
molar fraction study in this chapter varies from the previous chapter in two ways. Firstly, 
having established that NTX is very efficiently delivered by iontophoresis and that far lower 
donor concentrations than originally tested are required, a concentration range of 0.07 to 
0.14 mg/ml NTX was used. Secondly, the previous data for NTX and BUP were collected 
under different experimental conditions (different current densities and different receptor 




In this chapter, the combined iontophoretic delivery of NTX and BUP in a situation closer to 
physiological conditions was assessed, to improve prediction of their behaviour in vivo. In 
order to increase the efficiency of delivery of BUP, and to characterise and try to minimise 
the effect of the BUP reservoir, the following experimental conditions were tested: 
 
 Section A: Effect of receiver solution  
 Section B: Post-iontophoretic release of drug from the skin 
 Section C: Effect of reversing polarity (RP) on iontophoresis of NTX and BUP 
 Section D: Effect of drug concentration in the donor on iontophoresis of NTX and 
BUP 
 
2. Methods and materials 
 
The materials and general description of iontophoresis are identical to the previous chapter; 
refer to page 79. 
 
Section A: Effect of receiver solution 
The side-bi-side cells used in this section allowed 0.95 cm2 of skin to be available for drug 
transport. The volume of both the donor and receiver solutions was 3.5 ml. The donor 
solution was 1 mg/ml BUP, 0.1415 mg/ml NTX and 0.5 mg/ml ACM prepared in 60 mM 
TrisHCl. pH was adjusted to 5 with NaOH or HCl. The first receiver solution tested was 
phosphate buffered saline pH 7.4 (PBS, 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g 
KH2PO4 per litre of water). Subsequently, three other receiver solutions were also tested 
(see table 5.5). The anode was in the donor compartment and the cathode was in the 
receiver compartment. 
 
A direct, constant current of 0.285 mA was passed for 6 hours, during which the receiver 
was sampled every hour for analysis by HPLC. The receiver was completely refreshed 3 
times (at 1, 2, and 3 hours), at the remaining samples, 1 ml was sampled from the receiver 
and replenished. The donor was completely refreshed at 1, 2 and 4 hours. The complete 
refreshing of the donor and receiver solutions was performed to minimise any pH drift that 
might occur due to components of the skin leaching out during the experiment. The table 







Table 5.4. Summary of the experimental conditions used to demonstrate the effect of 
receiver solution on iontophoresis of NTX and BUP.  
Donor 
Current intensity  
(current density) 
At end of 6h 
0.14 mg/ml NTX  
1.0 mg/ml BUP  
& 0.5 mg/ml ACM 
 in 60 mM Tris 
pH 5.0 
0.285 mA  
(0.3 mA/cm2) 
Tape stripping  
for receiver solutions  
A and B only (defined  
in table 5.5) 
 
 
Table 5.5. Composition of the receiver solutions used in this section. (Receiver solution A 





















 pH 7.4 
- - 15 138 153 
C 
Tris pH 7.4 








- - - 138 138 
 
 
Section B: Post-iontophoretic release of drug from the skin 
The side-bi-side cells used in this section allowed 0.95 cm2 of skin to be available for drug 
transport. The volume of both the donor and receiver solutions was 3.5 ml. The donor 
solution was 1 mg/ml BUP, 0.1415 mg/ml NTX and 0.5 mg/ml ACM prepared in 60 mM 
TrisHCl. pH was adjusted to 5 with NaOH or HCl. The receiver solution for the first 6 hours 
was PBS pH 7.4. 
 
A direct, constant current of 0.285 mA was passed for 6 hours, during which the receiver 
was sampled every hour for analysis by HPLC. The receiver was completely refreshed 3 
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times (at 1, 2, and 3 hours), at the remaining samples, 1 ml was sampled from the receiver 
and replenished. The donor was completely refreshed at 1, 2 and 4 hours. At 6 hours, when 
the current was switched off, all drug was removed from the donor chamber by rinsing, and 
replaced with PBS pH 7.4, and the receiver solution was exchanged for 60 mM TrisHCl 
buffer pH 4.0 (see discussion). The receiver was then sampled at 7, 8, 9, 23 and 24 hours. It 
follows that any drug detected in the receiver at these times must have originated in the skin 
itself. The table below describes the experiment presented in this section. 
 
Table 5.6: Summary of the experiment to observe post-iontophoretic passive release of 
NTX, BUP and ACM. 
Donor (for first 6 
hours) 
Receiver 
(for first 6 
hours) 
Receiver 




At end of 6h 
0.14 mg/ml NTX  
1.0 mg/ml BUP & 
0.5 mg/ml ACM 
 in 60 mM Tris 
pH 5.0 
PBS 
 pH 7.4 
Tris  
pH 4.0 
0.285 mA  
(0.3 mA/cm2) 
Passive release 




Section C: Effect of reversing current polarity 
In this section, a 3-compartment cell (PermeGear, US) was used (see figure 5.2). A central 
compartment held the receiver solution, whilst there were 2 outer electrode chambers. As 
previously, the cell was held together in a clamp; 0.95 cm2 of each piece of skin was 
exposed. The volume of each of the three chambers was 3.5 ml. The donor solution was 0.5 
mg/ml BUP, 0.1415 mg/ml NTX and 0.5 mg/ml ACM prepared in 60 mM TrisHCl pH 5.0 (pH 




Figure 5.2: Photograph of a 3-compartment cell. The central compartment is the receiver 
compartment, the two outer compartments are the electrode compartments.  
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In one set of experiments, the polarity of the electrodes was reversed every 2 hours. For 
example, the electrode that ran as an anode for 0-2 hours ran as a cathode for 2-4 hours. 
The choice of a 2 hour period between polarity reversals was arbitrary. The duration of the 
experiment was extended to 8 hours (from 6 hours in previous sections) to enable equal 
sessions of each electrode acting as an anode and as a cathode. The electrode 
compartment which started as the anode was denoted as ‘+/-‘, and the electrode which 
started as the cathode was denoted as ‘-/+’. Donor solution was placed in both electrode 
compartments. 
 
As a control, a second experiment was run where the polarity was not changed during the 
experiment (‘standard’ iontophoresis). In these cells, donor solution was only placed in the 
anodal compartment, whilst the cathode compartment contained Tris 60 mM pH 5.0. No 
difference in flux was expected by using a 3-compartment set-up rather than a 2-
compartment set-up (Harper Bellantone et al. 1986). This control was performed to measure 
fluxes over 8 hours, to match the duration of the RP experiment; previous experiments were 
6 hours in duration. 
 
A direct, constant current of 0.285 mA was passed for 8 hours, during which the receiver 
was sampled every hour for analysis by HPLC. The receiver was completely refreshed 3 
times (at 1, 2, and 3 hours), at the remaining samples, 1 ml was sampled from the receiver 
and replenished. Both the donor solutions were completely refreshed at 1, 2 and 4 hours. In 
this section, tapes were grouped together as follows for extraction: 1, 2, 3-5, 6-8 and 9-12. 




Table 5.7. Summary of the experiments on the effect of intermittent reversing of the polarity 
of the electrodes. 





Electrode chamber A 
0.14 mg/ml NTX, 0.5 mg/ml BUP 
& 0.5 mg/ml ACM 





Electrode chamber B 
60 mM Tris 
pH 5.0 
0.14 mg/ml NTX 
0.5 mg/ml BUP 
in 60 mM Tris 
pH 5.0 
At end of 8h Tape-stripping then tissue extraction 
 
 
Section D: Effect of concentration of drug in the donor solution 
Excised dorsal pig skin was stretched across the aperture of a 2-compartment side-bi-side 
glass cell (PermeGear, US) held together in a clamp; 0.95 cm2 of skin was exposed. The 
outer surface of the skin was bathed in donor solution (3.5 ml). The underside of the skin 
was bathed in receiver solution (3.5 ml). Both compartments were stirred by magnetic bars. 
The anode was placed in the donor chamber, the cathode was placed in the receiver 
chamber. The donor solution was 0.5 or 1 mg/ml BUP, 0.07 or 0.1415 mg/ml NTX and 0.5 
mg/ml ACM prepared in 60 mM TrisHCl. pH was adjusted to 5 with NaOH or HCl. The 
receiver solution was PBS pH 7.4. 
 
A direct, constant current of 0.285 mA was passed for 6 hours, during which the receiver 
was sampled every hour for analysis by HPLC. The receiver was completely refreshed 3 
times (at 1, 2, and 3 hours), at the remaining samples, 1 ml was sampled from the receiver 
and replenished. The donor was completely refreshed at 1, 2 and 4 hours.  The table below 








Table 5.8. Summary of the experiments on the effect of concentration of NTX and BUP in 







At end  
of 6h 






















Analytical and statistical methods are identical to the previous chapter; refer to pages 80-82.  
 
3. Results and Discussion 
 
In chapter 4, the experiments in sections B, C and D were performed using a so-called 
symmetrical set-up, with identical background electrolyte solutions used in the donor and 
receiver compartments of each cell. This set-up is common, particularly when examining the 
effect of pH, as it can facilitate interpretation of the results (Sieg et al. 2004). However, an 
influence of receiver solution on the system, specifically an effect of the pH, may be 
expected. For that reason, in this chapter it was preferred to use a receiver solution that 
would closer mimic the in vivo situation; the effect of this was assessed. Thereafter, the 
strategy of intermittent reversal of the polarity of the electrodes was examined. Lastly, the 
effect of independently varying the concentration of NTX and BUP in the donor solution is 
reported. 
Section A: Effect of receiver solution  
The importance of an appropriately selected receiver solution in passive skin experiments 
has been described (Bronaugh & Stewart 1984; Scott & Ramsey 1987; Kou et al. 1993). The 
effect of receiver solution, and particularly the solubility of the permeant in the receiver 
solution, on iontophoretic flux, where passive diffusion and partitioning are not the major 
driving forces, is less often discussed (Phipps & Gyory 1992). The challenge resides in 
establishing the key parameters that determine the iontophoretic flux in vitro, to achieve 
better prediction of in vivo fluxes. In the case of lipophilic compounds such as BUP, an 




In the case of BUP, previous researchers have taken different approaches to this problem. 
Robson (1988) and Wang et al. (2009) (both passive) used receiver solutions containing 
50% ethanol. This obviously increases the solubility of BUP in the receiver, but may 
overestimate drug flux, as ethanol permeates into the skin during the experiment, and 
reduces the skin’s barrier function. For example, Kou et al. (1993) showed a 10-fold increase 
in the passive flux of nicardipine following inclusion of 50 % ethanol in the receiver. Similarly 
Hirvonen et al. (1996) showed a doubling of the passive flux of mannitol following the 
inclusion of 90% ethanol in the receiver solution. Roy et al. (1994, passive), Stinchcomb et 
al. (1996, passive), Bose et al. (2001, iontophoresis), and Fang et al. (2002, iontophoresis) 
addressed the issue by using receiver solutions with pH 6 or 6.4 as the solubility of BUP 
increases with decreasing pH. The concern is that those pHs were chosen arbitrarily; the 
interstitial fluid of the subdermal environment is close to pH 7.4.  
 
The first receiver solution tested in this chapter was PBS pH 7.4. It is commonly used as a 
receiver solution in both passive and iontophoretic skin permeation experiments. It has a pH 
relevant to the physiological situation, it is not expected to alter the barrier function of the 
skin, and lastly, it has physiological levels of chloride. As chloride is the main endogenous 
anion competing for charge-carrying when delivering a positively charged drug, use of a 
receiver solution that does not contain chloride would be likely to greatly overestimate 
cationic drug flux (Burnette & Ongpipattanakul 1987; Mudry et al. 2006a). The objective of 
this experiment was to determine the effect, if any, of switching to a receiver solution of PBS 




Figure 5.3: Iontophoretic fluxes (mean + standard deviation) of BUP, NTX and ACM. 
Receiver solution was either Tris pH 5 or PBS pH 7.4 (n = 6 and 6). All other parameters 
were identical. The donor solution was 0.14 mg/ml NTX, 1.0 mg/ml BUP and 0.5 mg/ml 




A clear effect of receiver solution on BUP flux was observed (figure 5.3). The flux of BUP 
into a PBS receiver solution was significantly lower (p < 0.05) than into Tris buffer. This 
result was not expected. It had been anticipated that if anything, the flux of BUP might be 
higher with PBS pH 7.4 compared to Tris pH 5 because of an expected increase in the 
contribution from EO at the higher pH (Kim et al. 1993).  
 
The decrease in BUP flux associated with the use of a PBS receiver solution could not be 
explained by absence of sink conditions. Sink conditions are defined as ≥ 10-fold difference 
between observed concentration of the drug in the receiver solution, and the maximum 
aqueous solubility of the drug in the receiver solution. The solubility of BUP in PBS pH 7.4 is 
45 µg/ml (Robson 1988), while sample concentrations were all < 1 µg/ml.  
  
Additionally, in contrast to sections B and C of chapter 4 the flux of BUP was not reduced 
due a lower EO flow as ACM fluxes were not significantly different for the two receiver 
solutions used. Furthermore, neither the amount of BUP recovered, nor the concentration of 
BUP in the stratum corneum (table 5.9) were significantly different for the two receiver 
solutions. 
 
Table 5.9: Amount of BUP recovered from the stratum corneum. Receiver solution was 
either Tris pH 5 or PBS pH 7.4. No NTX was quantifiable beyond tape 1. Values are mean ± 
standard deviation. 
Receiver solution 
BUP recovered  
from tapes (µg) 
Stratum corneum 
removed (µg) 
Concentration of BUP 
in stratum corneum 
(µg/mg) 




















gure 5.4: Amount of BUP in the stratum corneum (mean + standard deviation) as a function 
of depth. The donor solution was 0.14 mg/ml NTX, 1.0 mg/ml BUP and 0.5 mg/ml ACM, in 
60mM Tris pH 5.0. The current intensity was 0.285 mA. Left: receiver solution was Tris 
buffer pH 5 (n = 6). Right: receiver solution was PBS pH 7.4 (n = 6). 
 
Therefore, overall, no immediate explanation for the observed difference in BUP fluxes for 
the two receiver solutions was apparent. The two receiver solutions compared here differ in 
buffer type, ionic strength, and pH, all of which can have an influence on iontophoretic flux 
(Riviere & Heit 1997; Tamada & Comyns 2005). Therefore, three more receiver solutions (C, 
D and E, defined in table 5.10) were tested in an attempt to understand the observed 
difference. Figure 5.5 and table 5.10 show the results. 
 
The first hypothesis to explain the reduction in BUP flux observed upon adopting a receiver 
solution of PBS was that it was an effect of buffer type. To test this idea, a receiver solution 
with the same pH and very similar ionic strength to PBS (receiver solution B), but with a Tris 
buffer system, was prepared (receiver solution C). However, there was no indication that 
buffer type was important; BUP flux using receiver solution C was close to when using PBS 





Table 5.10: Fluxes of NTX, BUP and ACM into different receiver solutions. All other 
parameters were identical. Donor solution was 0.14 mg/ml NTX, 1.0 mg/ml BUP and 0.5 
mg/ml ACM, in 60mM Tris pH 5.0. The current intensity was 0.285 mA. 


































































































Figure 5.5: Fluxes of BUP, NTX and ACM (mean + standard deviation) into different receiver 
solutions. The donor solution was 0.14 mg/ml NTX, 1.0 mg/ml BUP and 0.5 mg/ml ACM, in 
60mM Tris pH 5.0 (n = 6, 6, 2, 5, and 4). 
 
The second hypothesis to explain the reduction in BUP flux observed upon adopting a 
receiver solution of PBS was that it was an effect of increased counter-ion competition. The 
previously used Tris buffer had only 60 mM chloride, whereas PBS contains 138 mM 
chloride. Chloride in the receiver solution is a counter-ion that competes with BUP (and NTX) 
to carry charge. To test this hypothesis, receiver solution D (phosphate buffer pH 7.4 but 
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with no sodium chloride) was prepared. Again, the flux of BUP using receiver D was very 
similar to that observed when using PBS; the different level of chloride did not seem to effect 
the behaviour of BUP. In contrast, the flux of NTX was higher using receiver solution D than 
any other tested. This could be explained by the following 2 factors: 
 
1.The absence of chloride ions in receiver solution D. In the absence of chloride, phosphate 
is the major anion in the receiver fluid, but as it is larger and less mobile than chloride, it is 
less good at competing with NTX for the available charge (Phipps & Gyory 1992). It was not 
the aim of this section to investigate competition with counter-ions, but this data does 
highlight how the efficiency of iontophoretic delivery of cations will always be limited by the 
presence of ubiquitous endogenous chloride in the subdermal compartment in vivo (Mudry et 
al. 2006a). Furthermore, it is expected that less mobile ions (such as BUP), respond 
proportionally less than more mobile ions (such as NTX) to changes in the composition of 
counter-ions in the receiver solution (Mudry 2006c). 
 
2. The low ionic strength (15 mM) of receiver solution D. An inverse relationship between 
ionic strength and EO has been documented (Tamada & Comyns 2005). The corresponding 
increase in the flux of ACM is consistent with the increased flux of NTX being driven by EO. 
 
Lastly, receiver solution E (sodium chloride only) was prepared; this is commonly used as a 
receiver solution. Unexpectedly, the flux of BUP returned to the levels previously observed 
with Tris buffer, and was 10 times higher than with PBS pH 7.4. Receiver solution E was 
unbuffered and had a pH of 6. Higher pHs are expected to result in a greater contribution to 
flux from EO via an effect on skin charge (Marro et al. 2001b). However, as well as effecting 
the skin, the pH also effects the drug, and the aqueous solubility of BUP drops dramatically 
between pH 5.0 and pH 7.4 (from 12 mg/ml to 0.045 mg/ml, Robson 1988). It was 
hypothesised therefore, that the low fluxes observed into PBS pH 7.4 were due to BUP 
favouring the lipid environment of the skin over the aqueous receiver solution, and therefore 
only partitioning into the receiver solution very slowly. If this is the case, a significant amount 
of BUP should accumulate in the skin that did not partition into the receiver solution. This 
hypothesis was explored in section B. 
 
Section B: Post-iontophoretic release of drug from the skin 
To test whether BUP, which has pH-dependent aqueous solubility, can move freely into a 
Tris buffer of pH 5, but not into PBS pH 7.4, an experiment was carried out in which post-
iontophoresis fluxes were measured. ‘Post-iontophoretic flux’ is simply the flux of drug that 
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occurs after the current is terminated (Thysman et al. 1994; Santi & Guy 1996a; Bose et al. 
2001). 
 
Post-iontophoretic flux has been measured to monitor passive desorption of a drug from the 
skin. This can be achieved by termination of the current, removal of drug from the donor 
compartment, and continued sampling of the receiver solution (Delgado-Charro & Guy 
1995). Post-iontophoretic flux has also been used to measure an iontophoresis-induced 
increase in passive permeability of the skin. This can be achieved by monitoring the post-
iontophoresis fluxes of water (Kim et al. 1993), or mannitol (Kim et al. 1993; Santi & Guy 
1996b) for example.  
 
Post-iontophoretic flux was measured in this section to see the effect of pH of the receiver 
solution on passive release of NTX and BUP from the skin into the receiver chamber. A 
standard 6 hour experiment was performed, but at 6 hours, current was terminated, donor 
solution was removed from the donor compartment, and replaced with buffer only (PBS pH 
7.4). The receiver solution was replaced with Tris buffer 60 mM pH 4.0. This was chosen 
because it was anticipated that BUP would be able to move freely into this receiver solution. 
At pH 4.0, the aqueous solubility of BUP is ~19 mg/ml (Robson 1988). Table 5.11 and figure 
5.6 show the results. 
 
Table 5.11: Amount of NTX, BUP and ACM permeated during iontophoresis, and 
subsequently released passively from the skin itself (mean ± standard deviation). The donor 
solution was 0.14 mg/ml NTX, 1.0 mg/ml BUP and 0.5 mg/ml ACM, in 60mM Tris pH 5.0. 
The current intensity was 0.285 mA. The receiver solution between 0-6 hours was PBS pH 
7.4 and the receiver solution between 6-24 hours was Tris pH 4.0. 







Flux at 6 





Flux at 6  





Flux at 6 
or 24 h 
(µg/h) 
Iontophoresis 
0 to 6 hours 
6 8.4 ± 1.6 2.6 ± 0.5 0.7 ± 0.4 0.4 ± 0.2 1.8 ± 0.4 0.5 ± 0.1 
Post-
iontophoresis 
6 to 24 hours 






Figure 5.6: Iontophoretic fluxes (0-6 hours), and post-iontophoretic fluxes (6-24 hours) of 
BUP and NTX (mean + standard deviation, n = 6). The dotted line indicates termination of 
current, removal of donor solution, and switching to a receiver solution (pH 4.0) in which 
BUP is relatively soluble.  
 
As expected, from 6 hours onwards the release of NTX from the skin slowed, presumably as 
the amount of NTX in the skin was depleted. In striking contrast, the rate of release of BUP 
from the skin into the receiver solution actually increased when the current was switched off. 
To reiterate, there was no drug in the donor compartment after 6 hours, so fluxes represent 
drug being released from the skin. These data confirm that a substantial amount of BUP 
deposits in the skin during iontophoresis, and that BUP distributed into the receiver solution 
far more easily when Tris pH 4.0 was used than when PBS pH 7.4 was used. This provides 
a credible explanation for the low flux of BUP with a receiver solution of pH 7.4 compared to 
a receiver solution of pH 5.0 observed in section A. 
 
It is possible that slow partitioning of BUP into a receiver solution of PBS pH 7.4 might result 
in underestimation of in vivo fluxes. To minimize underestimation of BUP fluxes, the drug in 
the viable tissue at the end of the experiment was determined from this point.  
 
Ideally, the suitability of any receiver solution used in vitro would be confirmed by 
demonstrating correlation with in vivo drug fluxes. Such a ‘back-to-front’ approach was taken 
by Gyory et al. (1997) when investigating the iontophoretic delivery of fentanyl. It was 
reported that an excellent in vivo: in vitro correlation was achieved by selecting the 
appropriate receiver solution, and that the ionic strength of the receiver solution was of 




Section C: Reversing polarity  
During this experiment BUP and NTX were present in both donor compartments, and the 
polarity was reversed every 2 hours. Therefore, BUP and NTX were delivered by anodal 
iontophoresis (as until now) and simultaneously by cathodal (wrong-way) iontophoresis. It 
was hypothesised that the delivery of BUP could take place not only from the donor solution 
but additionally from any skin reservoir built up in the previous two hour period. The objective 
of these experiments was to determine the influence of RP on the flux of NTX and BUP, on 
EO, and on the amount of drug in the skin. Tables 5.12, 5.13 and 5.14, and figures 5.7 and 
5.8 show the results. 
 
Table 5.12: Amount of NTX recovered (mean ± standard deviation) from the viable skin 
following 8 hours of either standard iontophoresis, or after reversing the polarity of the 
electrodes every 2 hours over an 8 hour period. No NTX was quantifiable beyond tape 1. 
Letters in superscript indicate pairs of values are significantly different (one-way ANOVA 
followed by Bonferroni post-tests, p < 0.05). 
 
NTX in viable skin  
(µg) 
Total NTX in skin 
(µg) 






















Table 5.13: Amount of BUP (mean ± standard deviation) recovered from the skin following 
iontophoresis with standard iontophoresis for 8 hours, or after reversing the polarity of the 
electrodes every 2 hours over an 8 hour period. Letters in superscript indicate pairs of values 
are significantly different (one-way ANOVA followed by Bonferroni post-tests, p < 0.05). 
 
BUP in viable skin  
(µg) 




removed (µg)  
 
 +/- -/+ +/- -/+  
Total BUP 












































It was hoped that employing RP would reduce the depot of BUP in the skin. Indeed, under 
the RP regimen BUP was found at lower amounts (p < 0.05) in the viable skin, and in the 
stratum corneum of the +/- skin site (the chamber that acted first as the anode). However, 
bearing in mind that when employing RP two skin sites instead of one contained drug, there 
was no difference in total BUP in the skin compared to standard iontophoresis. Interestingly, 
the skin site that started as the anode (+/-) contained significantly less (p < 0.05) BUP and 
NTX than the skin site that started as the cathode (-/+). It is possible that during 6-8 hours, 
some drug moved from the +/- skin into the receptor solution by passive diffusion. 
 
 
Figure 5.7: Total recovery of BUP and NTX (mean + standard deviation) from the skin 
following standard iontophoresis (SI, n = 3) or a regimen of reversing polarity (RP, n = 3); 
+/- denotes the skin compartment initially providing anodal delivery of the drugs; -/+ 
denotes the skin compartment initially providing cathodal delivery of the drugs. 
 
In this experiment, ACM was only placed in one donor chamber – the chamber that acted 
first as the anode (the +/- chamber). Therefore the flux of ACM between 0-2 hours was a 
measure of anode-to-cathode EO, and flux of ACM between 2-4 hours was a measure of 





Figure 5.8: Iontophoretic fluxes (mean + standard deviation) of BUP and NTX (left) and 
ACM (right) under standard iontophoresis or under a regimen of reversing polarity (n = 3 
and 3), as a function of time. The donor solution was 0.14 & 0.5 mg/ml NTX & BUP 
respectively, and 0.5 mg/ml ACM, in 60mM Tris pH 5.0. The current intensity was 0.285 
mA. The vertical dotted lines indicate reversal of the polarity of the electrodes every 2 
hours.  
 
It had been anticipated that a ‘saw-tooth’ pattern might have been generated, as observed 
by Santi & Guy (1996b) when measuring the extraction of mannitol into the two electrode 
compartments while reversing the polarity of the electrodes every 15 minutes. No clear 
pattern of that type was observed here (figure 5.8), implying either that anodal and 
cathodal EO were similar in magnitude, or that flux of ACM driven by EO did not respond 
immediately when the polarity was changed. Indeed, Kim et al. (1993) reported that 
passive fluxes of mannitol and water, driven by iontophoresis-induced permeability of the 
skin, were observed for several hours after termination of current.  
 
The flux of ACM was lower during the RP regimen than during standard iontophoresis. One 
explanation for this is that reversing the polarity every 2 hours was too frequent and did not 
allow time to EO to ‘get going’. However, this explanation is not consistent with the 
responsiveness of mannitol flux to polarity reversal observed in the Santi & Guy work 
(1996b), nor with the observation that the GlucoWatch®, a device for diabetic patients that 
utilised EO to extract glucose across the skin (Sieg et al. 2005), reversed polarity every 20 
minutes, and was able to extract glucose (by EO alone) in line with blood concentrations. 
However, those experiments were not influenced by confounding effects on EO as 
observed here with BUP. Furthermore, mannitol and glucose are both more hydrophilic 
than ACM (ACM logP 0.46, 151 Da), and therefore less likely to partition in the skin. If ACM 
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partitions in the skin, flux of ACM may underestimate EO, or be subject to a time lag. In 
section B of this chapter it was observed that 3.2 µg of ACM accumulated in the skin in 6 
hours; compared to 1.8 µg of ACM carried across the skin into the receiver solution over 
the same period. This is a possible limitation of ACM as a marker of EO, and may 
contribute to the lack of saw-tooth effect observed here. In any case, there is no evidence 
that cathode-to-anode EO was occurring, or that BUP was delivered by cathode-to-anode 
EO. 
 
Disappointingly, the fluxes of BUP and NTX at 8 hours were significantly lower under the 
RP regimen than under standard iontophoresis. It had been postulated that EO in the 
cathode-to-anode direction might contribute to total flux; no evidence of such an effect was 
observed. This finding is not inconsistent with other studies (Hirvonen et al. 1995; Delgado-
Charro & Guy 1995) who concluded that total transport was determined by the duration of 
current passed in the conventional anode-to-cathode direction. 
 
Most likely, this was a consequence of flux under the RP regimen being subject to two 
successive lag times, one for each skin site. This is illustrated in tables 5.15 and 5.16. 
Using the observed fluxes from the standard iontophoresis experiment, the flux under a 
regimen of reversing polarity if drug was only delivered from the anode was predicted. 
Predicted and observed final fluxes were in close agreement. This indicates that the 
cumulative drug delivered is controlled by the current passed from the anode; no 
advantage of RP over standard iontophoresis has been demonstrated. 
 
Table 5.14: Iontophoretic fluxes of NTX, BUP and ACM (mean ± standard deviation) with 
standard iontophoresis or with intermittent reversing of the polarity of the electrodes. Donor 
was 0.14 mg/ml NTX, 0.5 mg/ml BUP and 0.5 mg/ml ACM in in 60mM Tris pH 5.0. The 
receiver solution was PBS pH 7.4. Values are mean ± standard deviation. Letters in 
superscript indicate pairs of values are significantly different (t-test, p < 0.05). 















































































Table 5.15: Predicted contributions to total NTX flux from +/- (the electrode that started as 
the anode) and -/+ (the electrode that started as the cathode). Prediction based on 
observed data from standard iontophoresis. For site +/- the first 2 hours of iontophoresis is 
exactly the same as for the control experiment. During 2-4 hours, when the polarity is 
reversed, if drug is only transported from the anode, no flux will be observed. During 4-6 
hours, the polarity is reversed again, and this is akin to 2-4 hours of the control experiment. 
 















Total flux   
0 to 2 
hours 
0.62 0.62 0 0.62 0.31 ± 0.16 
2 to 4 
hours 
2.24 0 0.62 0.62 1.25 ± 0.23 
4 to 6 
hours 
3.07 2.24 0 2.24 1.98 ± 0.24 
6 to 8 
hours 
3.69 0 2.24 2.24 2.34 ± 0.17 
 
Table 5.16: Predicted contributions to total BUP flux from +/- (the electrode that started as 
the anode) and -/+ (the electrode that started as the cathode). Prediction based on 
observed data from standard iontophoresis. For site +/- the first 2 hours of iontophoresis is 
exactly the same as for the control experiment. During 2-4 hours, when the polarity is 
reversed, if drug is only transported from the anode, no flux will be observed. During 4-6 

















Total flux  
0 to 2 
hours 
0.04 0.04 0.00 0.04 0 
2 to 4 
hours 
0.25 0.00 0.04 0.04 0 
4 to 6 
hours 
0.70 0.25 0.00 0.25 0.18 ± 0.07 
6 to 8 
hours 





In the experimental design used here it is not known from which electrode compartment 
BUP and NTX found in the receiver originate, this could be achieved by the use of radio-
labelled drug added to one electrode compartment only. 
 
Section D: Effect of drug concentration in the donor solution 
When co-ions are present in the donor it is expected that the flux of a drug will be 
proportional to the concentration of that drug in the donor solution (Phipps & Gyory 1992; 
Marro et al. 2001b; Mudry et al. 2006b). NTX seems to obey this rule, whereas BUP does 
not.   
 
The aim of this section was to establish the effect of drug concentration in the donor on flux 
of NTX and BUP, on EO, and on the amount of drug in the skin, in order to enable rational 
optimisation of the system by selection of an appropriate donor solution. The concentration 
of BUP was held constant while the concentration of NTX was varied, and then the 
concentration of NTX was held constant while the concentration of BUP was varied. The 
fluxes of BUP, NTX and ACM, and drug recovered from the skin, are shown in tables 5.17 
and 5.18 and figures 5.9 and 5.10.  
 
Table 5.17: Iontophoretic fluxes of NTX, BUP and ACM (mean ± standard deviation) as a 
function of donor composition. The background electrolyte in all donor solutions was 60mM 
Tris pH 5.0. All donor solutions contained 0.5 mg/ml ACM. The current intensity was 0.285 
mA. Values are mean ± standard deviation. Letters in superscript indicate pairs of values 
are significantly different (one-way ANOVA followed by Bonferroni post-tests, p < 0.05). 
mg/ml  BUP NTX ACM 
NTX BUP  n 



















































































Figure 5.9: Iontophoretic fluxes of NTX, BUP and ACM (mean + standard deviation) as a 
function of donor composition (n = 8, 7 and 9). The background electrolyte in all donor 
solutions was 60mM Tris pH 5.0. All donor solutions contained 0.5 mg/ml ACM. The current 
intensity was 0.285 mA. 
 
Table 5.18 shows the recovery of the two drugs from skin and tapes as the concentration of 
drug in the donor solution was varied. As seen in section 2 of chapter 4, the amount of BUP 
found in the skin increased with the concentration of BUP in the donor, while the amount of 
NTX recovered from the skin was not influenced by donor concentration (of BUP or NTX) 
over this range. 
 
Table 5.18: Amount of BUP and NTX recovered from the skin (mean ± standard deviation) 
as a function of donor composition. Letters in superscript indicate pairs of values are 
significantly different (one-way ANOVA followed by Bonferroni post-tests, p < 0.05). 
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Figure 5.10: Amount of NTX and BUP recovered from the skin (mean + standard deviation) 
as a function of donor composition (n = 5-8, 7 and 3). The background electrolyte in all donor 
solutions was 60mM Tris pH 5.0. All donor solutions contained 0.5 mg/ml ACM. The current 
intensity was 0.285 mA. 
 
As shown in chapter 4, but now confirmed using a more physiologically relevant receiver 
solution, BUP does not follow the conventional pattern expected of a drug in an iontophoretic 
system, and a linear relationship between the concentration of BUP in the donor and the flux 
of BUP was not observed. In fact, when NTX donor concentration was fixed, BUP flux was 
higher (p < 0.05) from a donor containing 0.5 mg/ml BUP than from a donor containing 1.0 
mg/ml BUP. Likewise, apparent EO and flux of NTX were decreased (p < 0.05) by an 
increase in BUP donor concentration. Conversely, the amount of NTX in the donor did not 
influence the flux of BUP. When BUP concentration in the donor was fixed, NTX followed the 
conventional rules of iontophoresis and NTX flux increased with NTX concentration in the 
donor. 
4. Conclusions of the chapter 
In order to closer mimic the in vivo situation, a receiver solution of PBS pH 7.4 was adopted 
in this chapter. It was observed that using PBS pH 7.4 instead of Tris HCl pH 5.0 (whilst 
fixing all other parameters) had a non-significant effect on all outcomes, except on the flux of 
BUP, which decreased 5-fold. This was attributed to the pH-dependence of BUP aqueous 
solubility and resulting slow partitioning of BUP from the skin into a receiver solution of pH 
7.4. 
 
The large influence of receiver solution on flux observed in section A shows how care must 
be taken when predicting in vivo fluxes from in vitro data. Furthermore, quantification of the 
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amount of drug in the stratum corneum and in the viable tissue at the end of an 
iontophoresis experiment can increase understanding of drug behaviour. The significant 
reservoir of only BUP represents a challenge for this application that will need to be solved 
before assessing this system in vivo. 
 
A strategy of reversing the polarity of the electrodes was investigated. This approach was 
successful at lowering the amount of BUP recovered from each skin site compared to a 
standard iontophoresis control. However, under the reversing polarity regimen, as drug 
accumulates in the skin at both electrodes the total amount of drug recovered from the skin 
was not different from the control; no benefit to a patient would be expected. Reversing the 
polarity of the electrodes did not result in increased flux of NTX or BUP.  
 
The amount of BUP in the skin increased with the concentration of BUP in the donor. The 
BUP depot was associated with a decrease in anode-to-cathode EO, presumably by 
neutralising negative charges on the skin. Confirming the findings of the previous chapter, a 
significant ‘auto-inhibition’ of BUP flux was observed, as well as a decreased NTX flux. 
When BUP donor concentration was fixed, the effect of NTX donor concentration on NTX 
flux was predictable.  
 
It has been shown previously that two co-ions delivered simultaneously by iontophoresis can 
each influence the flux of the other, through ion competition effects. This is often shown with 
small inorganic cations such as lithium, sodium and potassium (Mudry et al. 2006a and b). 
To the author’s knowledge, that one cationic drug (BUP) may negatively influence the 
simultaneous iontophoretic flux of another cationic drug (NTX) via an effect on EO has not 
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Chapter 6. General Discussion and Conclusions 
 
In this thesis, experiments were undertaken to assess the viability of an iontophoretic 
transdermal patch delivering BUP and NTX together as a relapse prevention therapy. 
The work presented falls into two halves, the pharmacological action of the BUP/NTX 
combination, and its transdermal delivery. 
 
1.0 mg/kg (but not 0.3 mg/kg) NTX blocked the rewarding properties of 0.3 
mg/kg BUP. A range of ratios (between 5:1 and 1:10 NTX:BUP, table 2.1) had been 
previously reported in rodent studies to achieve blocking of BUP’s mu agonsim. We 
found that blocking was achieved with a ratio of 3:1 NTX:BUP. Our data suggest that 
the previous clinically administered ratio of 10:1 NTX:BUP may have been an 
overcautious approach.  
 
0.3 mg/kg BUP with 3.0 mg/kg NTX (but not the same dose of NTX alone) was 
aversive. The issue of aversion is important because the main drawback of a NTX-
alone therapy is that patient adherence is low (Kirchmayer et al. 2002) and there is a 
common conception that this is due at least in part to NTX producing a general 
dysphoria (Miotto et al. 2002). However, our results indicate that NTX alone is not 
aversive. NTX provides good blockade of heroin, therefore understanding the precise 
nature of the reported patient dislike for NTX could help to improve use of this drug. 
 
If the aversion observed following administration of 0.3 mg/kg BUP with 3.0 mg/kg 
NTX is not a simple mu antagonist effect, it might be explained by BUP activity at the 
NOP receptor. There is great interest in the NOP receptor as it is believed to have 
‘anti-addictive’ properties (Marquez et al. 2008; Bebawy et al. 2010). The hypothesis 
of Canestrelli et al. (2014) is that when BUP is administered in combination with a mu 
antagonist (naloxone was used in their study), BUP’s activity at the NOP receptor 
becomes apparent. Their hypothesis was supported by the observation that an NOP 
antagonist eliminated the aversive effect of BUP and naloxone; a similar test could 
be performed for BUP and NTX. The importance of the NOP receptor for BUP activity 
is still unclear, as binding affinity (measured in vitro) is relatively low. 
 
0.3 mg/kg BUP with 1.0 mg/kg NTX blocked drug-primed reinstatement to 
morphine- and cocaine-seeking. It is intuitive that the BUP/NTX combination 
should block reinstatement following a morphine prime, so long as the correct ratio 
and dose were selected. However, the mechanism by which the combination blocks 
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drug-primed reinstatement to cocaine is not clear, and the data presented here do 
not offer any answers. Following the same rationale as suggested for investigation of 
the aversive effects of the combination, BUP/NTX could be administered together 
with an NOP antagonist before presenting the drug prime. This might clarify if the 
NOP action of BUP contributes at all to the efficacy of the combination.  
 
Interestingly, a large (300 patients, 11 sites) clinical study investigating the ability of 
BUP and NTX to reduce cocaine use has been initiated (design described in Mooney 
et al. 2013) despite the lack of knowledge of the pharmacological mechanisms 
involved. However, understanding the mechanism is likely to be important for 
optimising the therapy, and would certainly provide valuable insight to researchers 
designing novel single compound alternatives to BUP and NTX for use in relapse 
prevention (Kumar et al. 2014; Casal-Dominguez et al. 2014). 
 
A final comment on the data presented in the first half of the thesis is that the 
similarity between the results for morphine-conditioned rats and cocaine-conditioned 
rats is not necessarily expected. Morphine and cocaine belong to very different 
classes of drug; they are a sedative and a stimulant respectively. The similarity 
observed counters the expectations of Tzschentke (2014) who stated that “when 
considering approaches to anti-abuse treatments, each drug class probably needs to 
be considered separately, as a drug that may be effective in supporting opioid 
abstinence would not necessarily be expected to reduce craving for cocaine as well”. 
 
In the second half of the thesis it was shown that NTX is efficiently delivered by 
iontophoresis. In fact, the concentration of NTX in the donor solution was reduced 
almost 400-fold from that first tested in order to match the requirements of this 
application. NTX’s suitability for iontophoresis was largely expected considering its 
physicochemical properties.  
 
The iontophoretic flux of BUP reported here is not superior to the passive flux 
of BUP from marketed passive patches. The rationale for iontophoresis of BUP 
was not to increase its flux compared to passive delivery, but to co-deliver it with NTX 
(to reduce abuse liability) and to increase control over input rates.  
 
BUP accumulates in the skin, more so with higher pH and with higher BUP 
concentration in the donor. More BUP was recovered from the skin at pH 6 than at 
pH 4, implying that aqueous solubility is a bigger influence on accumulation than 
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electrostatic interaction with the skin (BUP is a weak base with pKa ~8). The 
presence of BUP in the system retarded the convective solvent flow that 
normally boosts drug transport when delivering cations, and so reduced total 
flux of BUP and NTX. This unusual effect has been observed previously for some 
small drug molecules and peptides, and can be ‘managed’ by keeping the 
concentration of the drug in the donor low. 
 
Therapeutically relevant transdermal fluxes were observed for both BUP and NTX. 
However, the in vitro set-up does not mimic the presence of a functioning cutaneous 
blood supply, and therefore may not exactly predict in vivo transdermal fluxes. As 
NTX and BUP are both already marketed and known to be safe, it could be 
appropriate to go directly to tests in man (as opposed to in vivo testing in rodents, for 
example), for in vivo measurement of BUP and NTX plasma and stratum corneum 
concentrations. However, as BUP is a schedule 3 controlled drug, it is anticipated 
that it would be difficult to obtain consent for this work. 
 
It is not known if a 24-hour-a-day iontophoresis system is feasible. None of the 
devices for iontophoretic delivery that have been licensed are intended for prolonged 
delivery. For example, dexamethasone administration is commonly performed for 20 
minutes per session, and sumatriptan patches are only intended for up to 4 hours of 
use. The current density that can be tolerated for 24 hours is not clearly defined; 
Teillaud (1997) suggested 0.1 to 0.15 mA/cm2 might be the maximum. However, skin 
response in healthy humans measured over a 24 hour period of iontophoresis (0.2 
mA/cm2 current density) was ‘well tolerated’ and only modest transient skin redness 
was observed (unpublished results by Maibach 1994, cited in Sage 1997). Ultimately, 
the maximum tolerable current density may depend on the nature of the electrode 
patch, for example on the type of hydrogel used (Nogueiras-Nieto et al. 2013). 
Furthermore, the practical consideration of battery life over longer periods of time 
may limit this application. A patch needing to be replaced more frequently than every 
24 hours would lose one of the advantages of the transdermal route over oral tablets. 
 
It was not the purpose of this thesis to compare the behaviour of a lipophilic and a 
hydrophilic weak base in a single transdermal iontophoresis system, however, NTX 
and BUP are similar in several physicochemical properties: the pKa of the two 
molecules are very similar, they are structurally related (see figure on page 21), and 
in the same size range, but differ in lipophilicity and water solubility. Therefore the 
observed differences in accumulation in skin, and in ability to alter the properties of 
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NTX is suited to iontophoretic delivery but BUP iontophoretic delivery may be more 
problematical. Two alternative transdermal options arise; firstly, development of a 
novel single compound alternative to BUP and NTX, with appropriate 
physicochemical properties for iontophoresis, or secondly, passive delivery of BUP 
with another mu antagonist with physicochemical properties more suited to passive 
delivery than NTX.  
 
The findings of chapters 2 and 3 are useful regardless of the drug delivery route 
envisaged for patients. Whilst it is believed that the transdermal route offers genuine 
advantages for this combination, other drug delivery options such as an injectable 
depot, or sublingual or oral tablets should not be ruled out. BUP delivery by the oral 
route was rejected in favour of the sublingual route at least in part because low oral 
BUP bioavailability made this option costly (Sigmon et al. 2006). However, BUP 
became generic in 2009; perhaps BUP by the oral route could be re-examined. It is 
not yet known whether the far greater cost of a transdermal (iontophoretic) patch 
compared to an oral tablet is justifiable in terms of benefit to the patient. 
 
If it is the lipophilicity of BUP that makes it accumulate in the skin during 
iontophoresis, and behave in an anomalous manner, that provides an interesting link 
between the two halves of the thesis; the relative lipophilicity of BUP has been said to 
have an important influence on its pharmacology (Lewis 1985) and on its 
pharmacokinetics (Robinson 2002). 
 
Intriguingly, the NTX/BUP combination has also been proposed as a therapy for 
smoking cessation, alcohol dependence, weight loss and depression (McCann 2008; 
Almatroudi et al. 2015). The findings of chapter 2 and chapters 4 and 5 are equally 
applicable to these other therapeutic applications.  
 
Overall, the combination holds great promise for relapse prevention, but the choice of 








The mu-opioid receptor agonism of 0.3 mg/kg BUP was blocked by 1.0 mg/kg NTX, 
when administered via the intraperitoneal route in Sprague Dawley rats. At this 
delivery ratio, the combination was non-rewarding and non-aversive. Co-
administration of 0.3 mg/kg BUP and 1.0 mg/kg NTX blocked drug-primed 
reinstatement to cocaine-seeking, and attenuated drug-primed reinstatement to 
morphine-seeking. 
 
The transdermal iontophoretic flux of NTX was higher than the predicted target, 
whilst the flux of BUP was close to the predicted target. Varying the concentration of 
NTX in the donor solution when the concentration of BUP was fixed resulted in a 
predictable change in the flux of NTX, as explained by ion competition. 
 
During iontophoresis a depot of BUP formed in the skin. The amount of drug 
recovered from the skin was proportional to the concentration of BUP in the donor 
and increased with pH. BUP caused a concentration-dependent decrease in anode-
to-cathode EO, probably by neutralising negative charges on the skin. Auto-inhibition 
of BUP flux and a decreased flux of NTX was observed. This anomalous behaviour 
complicates optimisation of this drug combination, but iontophoresis still appears to 
be a feasible approach for delivering NTX and BUP through the skin. 
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1 413 559 445 372 
2 480 534 355 730 
3 517 625 306 516 
4 441 604 547 603 
5 369 616 541 265 
6 551 632 390 741 
7 312 623 487 636 
8 467 552 516 761 
9 382 501 520 330 
10 374 521 529 556 
11 449 511 577 567 
12 365 466 575 557 
Mean 427 562 482 553 
SEM 20 16 26 47 
 
Table A3: CPP data from chapter 3. Control cocaine drug-prime. Corrected time 






1 560 616 597 514 
2 450 542 496 385 
3 504 570 590 566 
4 436 531 279 511 
5 539 624 495 149 
6 329 363 381 427 
7 430 710 709 385 
8 333 364 353 131 
9 460 606 194 212 
Mean 449 547 455 365 
SEM 27 39 13 13 
 
Table A4: CPP data from chapter 3. Blocking of cocaine drug-prime with BUP/NTX. 









1 304 543 328 651 
2 517 617 591 620 
3 437 635 328 445 
4 463 759 550 371 
5 460 519 583 654 
6 437 655 470 640 
7 475 608 699 865 
8 356 516 446 858 
9 471 628 481 571 
10 493 669 375 643 
11 340 634 630 300 
12 507 580 384 731 
13 432 600 655 814 
14 337 495 229 187 
Mean 431 604 482 596 
SEM 18 19 38 55 
 
Table A5: CPP data from chapter 3. Control morphine drug-prime. Corrected time 






1 336 554 447 633 
2 377 615 531 654 
3 304 626 319 128 
4 531 692 476 470 
5 335 675 278 115 
6 476 572 301 791 
7 374 497 355 485 
8 434 645 664 740 
Mean 396 610 421 502 
SEM 28 23 47 92 
 
Table A6: CPP data from chapter 3. Blocking of morphine drug-prime with BUP/NTX.  








Data from chapter 4 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
3 0.15 0.00 0.00 0.00 0.04 0.08 
6 0.09 0.08 0.01 0.03 0.05 0.04 
Table A7: Passive flux of BUP (µg/h) from 0.55:1 (ratio NTX:BUP) 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
3 0.00 0.00 0.00 0.00 0.0 0.0 
6 0.09 0.06 0.00 0.00 0.04 0.04 
Table A8: Passive flux of NTX (µg/h) from 0.55:1 (ratio NTX:BUP) 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.11 0.08 0.00 0.00 0.05 0.06 
4 0.14 0.13 0.00 0.00 0.07 0.08 
5 0.17 0.22 0.09 0.13 0.15 0.06 
6 0.29 0.33 0.12 0.15 0.22 0.10 
Table A9: Iontophoretic flux of BUP (µg/h) from 55:1 (ratio NTX:BUP) 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 21 46 22 35 31 12 
2 111 170 106 140 132 29 
3 253 287 220 242 251 28 
4 299 269 274 271 278 14 
5 294 248 249 249 260 23 
6 322 272 219 275 272 42 





Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.04 0.00 0.01 0.02 
3 0.04 0.04 0.16 0.01 0.06 0.07 
4 0.11 0.09 0.32 0.04 0.14 0.12 
5 0.37 0.18 0.42 0.09 0.26 0.16 
6 0.37 0.34 0.67 0.14 0.38 0.22 












Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 1 3 9 1 3 4 
2 33 30 67 13 36 23 
3 68 71 103 29 68 31 
4 92 78 127 41 85 36 
5 181 101 121 47 113 56 







Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.14 0.03 0.07 
2 0.06 0.21 0.05 0.77 0.27 0.34 
3 0.39 0.58 0.33 1.69 0.75 0.64 
4 1.66 1.23 1.28 2.47 1.66 0.57 
5 1.46 1.62 0.97 2.75 1.70 0.75 
6 1.57 1.89 1.28 2.84 1.90 0.68 





Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.13 0.14 0.08 0.14 0.39 0.26 0.19 0.11 
3 0.36 0.35 0.23 0.48 0.77 0.44 0.44 0.18 
4 0.55 0.37 0.33 0.65 1.17 0.68 0.63 0.30 
5 0.74 0.49 0.41 0.70 1.68 0.78 0.80 0.46 
6 0.85 0.56 0.51 0.62 1.69 0.82 0.84 0.44 
Table A16: Fluxes (µg/h) of acetaminophen. Donor and receiver of pH 4. 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.40 0.22 0.34 0.96 0.90 0.94 0.63 0.34 
3 1.43 1.01 1.22 2.12 2.00 2.04 1.64 0.48 
4 2.31 1.67 1.82 2.87 2.76 3.10 2.42 0.58 
5 2.98 2.15 2.30 3.08 3.56 3.64 2.95 0.62 
6 3.15 2.64 2.68 2.56 3.49 3.62 3.02 0.46 
Table A17: Fluxes (µg/h) of naltrexone. Donor and receiver of pH 4. 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.34 0.06 0.14 
3 0.15 0.00 0.00 0.32 0.00 1.12 0.27 0.44 
4 0.52 0.00 0.00 1.37 1.20 2.46 0.93 0.95 
5 1.35 0.13 0.46 2.45 2.56 3.50 1.74 1.32 
6 2.36 0.42 0.87 2.87 4.10 5.16 2.63 1.83 








Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.17 0.10 0.07 0.26 0.00 0.13 0.12 0.09 
3 0.40 0.29 0.17 0.58 0.17 0.33 0.32 0.15 
4 0.69 0.51 0.35 0.89 0.30 0.57 0.55 0.22 
5 0.77 0.68 0.41 1.08 0.47 0.80 0.70 0.24 
6 0.83 0.83 0.48 1.17 0.57 0.82 0.78 0.24 
Table A20: Fluxes (µg/h) of acetaminophen. Donor and receiver of pH 5. 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.64 0.15 0.13 0.63 0.00 0.00 0.26 0.30 
3 1.59 0.72 0.55 1.72 0.00 0.69 0.88 0.66 
4 2.63 1.53 1.29 2.81 1.03 1.30 1.76 0.76 
5 3.49 2.35 1.78 3.38 1.83 2.20 2.51 0.75 
6 3.81 2.66 1.90 3.49 2.28 2.63 2.79 0.72 
Table A21: Fluxes (µg/h) of naltrexone. Donor and receiver of pH 5. 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
4 0.56 0.00 0.00 0.55 0.00 0.00 0.18 0.29 
5 1.51 0.00 0.00 1.94 0.00 0.46 0.65 0.86 
6 2.38 1.08 0.64 2.88 0.60 0.76 1.39 0.99 






Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.22 0.42 0.18 0.16 0.21 0.35 0.26 0.11 
3 0.47 0.85 0.47 0.45 0.55 0.89 0.61 0.20 
4 0.74 1.59 0.70 0.62 0.69 1.06 0.90 0.37 
5 0.87 1.11 0.93 0.71 1.17 1.36 1.03 0.23 
6 0.86 1.45 0.97 0.76 1.02 1.51 1.10 0.31 
Table A24: Fluxes (µg/h) of acetaminophen. Donor and receiver of pH 6. 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.47 0.83 0.40 0.57 0.51 0.53 0.55 0.15 
3 1.49 1.92 1.15 0.46 1.60 1.60 1.37 0.51 
4 2.40 4.04 2.08 2.42 2.17 2.08 2.53 0.75 
5 2.87 2.60 2.81 2.67 2.72 2.60 2.71 0.11 
6 3.04 3.75 2.88 3.24 3.63 3.29 3.31 0.33 
Table A25: Fluxes (µg/h) of naltrexone. Donor and receiver of pH 6. 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.00 0.39 0.29 0.00 0.11 0.18 
4 0.67 2.33 0.41 0.92 0.81 0.45 0.93 0.71 
5 0.65 2.36 0.60 1.78 1.84 1.00 1.37 0.72 
6 1.01 4.21 0.54 2.79 3.54 2.02 2.36 1.43 









Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.06 0.00 0.11 0.00 0.04 0.05 
2 0.53 0.23 0.56 0.27 0.40 0.17 
3 1.19 0.55 1.19 0.70 0.91 0.33 
4 1.68 0.94 1.67 1.12 1.35 0.38 
5 1.98 1.13 1.77 1.44 1.58 0.37 
6 1.99 1.38 2.00 1.68 1.76 0.29 
Table A28: Fluxes (µg/h) of acetaminophen. Donor and receiver of pH 6, no BUP. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.85 0.53 0.85 1.10 0.83 0.23 
3 2.03 1.77 2.08 2.41 2.07 0.26 
4 3.22 2.98 3.23 3.52 3.24 0.22 
5 4.01 3.70 3.73 4.36 3.95 0.31 
6 3.73 3.58 4.15 4.43 3.97 0.39 





Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.12 0.37 0.22 0.11 0.21 0.12 
3 0.33 0.61 0.41 0.35 0.42 0.13 
4 0.60 0.71 0.77 0.47 0.64 0.13 
5 0.73 0.84 0.92 0.70 0.80 0.10 
6 0.91 0.82 1.14 0.84 0.93 0.15 
Table A30: Fluxes (µg/h) of acetaminophen. 0.14 & 0.5 mg/ml NTX & BUP. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.43 0.37 0.00 0.20 0.23 
2 0.86 1.74 1.19 1.02 1.20 0.38 
3 1.93 2.81 2.31 2.08 2.28 0.39 
4 2.79 3.05 3.08 2.60 2.88 0.23 
5 3.54 3.68 3.52 3.55 3.57 0.07 
6 4.04 3.17 3.67 3.44 3.58 0.37 
Table A31: Fluxes (µg/h) of naltrexone. 0.14 & 0.5 mg/ml NTX & BUP. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.72 0.00 0.00 0.18 0.36 
2 0.30 1.38 0.14 0.00 0.46 0.63 
3 0.80 3.05 0.60 0.42 1.22 1.23 
4 1.49 4.57 1.32 0.97 2.08 1.67 
5 2.45 6.21 2.02 1.69 3.09 2.11 
6 3.02 5.96 2.85 2.21 3.51 1.67 










Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.30 0.13 0.05 0.12 0.13 
3 0.14 0.41 0.23 0.10 0.22 0.14 
4 0.21 0.42 0.32 0.15 0.28 0.12 
5 0.38 0.52 0.56 0.32 0.45 0.12 
6 0.36 0.40 0.40 0.31 0.37 0.04 
Table A34: Fluxes (µg/h) of acetaminophen. 0.14 & 2.5 mg/ml NTX & BUP. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.29 0.83 0.86 0.57 0.64 0.27 
3 1.11 1.84 1.74 1.53 1.55 0.32 
4 1.97 2.48 2.20 2.28 2.23 0.21 
5 2.65 2.74 3.06 2.57 2.76 0.22 
6 2.34 2.68 2.08 2.23 2.33 0.26 
Table A35: Fluxes (µg/h) of naltrexone. 0.14 & 2.5 mg/ml NTX & BUP. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.45 0.43 0.00 0.22 0.25 
3 0.15 2.57 0.87 0.33 0.98 1.10 
4 0.51 4.45 1.88 1.05 1.98 1.74 
5 1.52 5.45 3.85 1.98 3.20 1.81 
6 2.01 5.74 5.43 2.47 3.91 1.94 








Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.24 0.00 0.32 0.25 0.20 0.14 
3 0.69 0.55 0.60 0.49 0.58 0.08 
4 1.34 0.87 1.26 0.44 0.98 0.41 
5 1.23 1.00 0.95 0.93 1.03 0.14 
6 1.44 1.23 1.27 0.69 1.16 0.32 
Table A38: Fluxes (µg/h) of acetaminophen. Low current density. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.51 0.31 0.21 0.25 
3 0.44 0.73 3.05 0.95 1.29 1.19 
4 1.31 1.48 1.73 0.94 1.37 0.34 
5 1.58 1.69 2.57 1.95 1.95 0.44 
6 2.30 2.51 3.66 1.72 2.55 0.81 
Table A39: Fluxes (µg/h) of naltrexone. Low current density. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.00 0.00 0.00 0.00 
4 0.33 0.47 1.53 0.00 0.58 0.66 
5 0.22 1.07 2.45 1.69 1.36 0.95 
6 0.82 1.71 2.59 1.77 1.72 0.72 







Data from chapter 5 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.11 0.05 0.06 0.00 0.00 0.00 0.04 0.05 
3 0.28 0.16 0.23 0.21 0.22 0.26 0.23 0.04 
4 0.45 0.29 0.40 0.29 0.35 0.46 0.37 0.08 
5 0.54 0.33 0.51 0.48 0.51 0.68 0.51 0.11 
6 0.34 0.58 0.56 0.47 0.53 0.58 0.51 0.09 
Table A42: Fluxes (µg/h) of acetaminophen. Receiver solution B (PBS pH 7.4). 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.36 0.18 0.14 0.00 0.00 0.00 0.11 0.14 
3 1.16 0.67 0.74 0.49 0.49 1.05 0.77 0.28 
4 2.19 1.50 1.55 1.24 1.12 2.08 1.61 0.44 
5 2.89 1.52 2.14 1.96 1.86 2.75 2.19 0.53 
6 1.71 2.76 2.50 1.99 2.06 2.71 2.29 0.43 
Table A43: Fluxes (µg/h) of naltrexone. Receiver solution B (PBS pH 7.4). 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.12 0.00 0.42 0.00 0.00 0.00 0.09 0.17 
3 0.33 0.12 0.58 0.00 0.00 0.00 0.17 0.24 
4 0.48 0.00 0.63 0.27 0.00 0.00 0.23 0.28 
5 0.48 0.00 0.60 0.23 0.00 0.00 0.22 0.27 
6 0.57 0.00 0.35 0.32 0.00 0.00 0.21 0.24 







Hours Cell 1 Cell 2 
1 0.00 0.00 
2 0.09 0.30 
3 0.26 0.58 
4 0.40 0.70 
5 0.33 0.81 
6 0.38 0.71 
Table A46: Fluxes (µg/h) of acetaminophen. Receiver solution C (Tris pH 7.4). 
 
 
Hours Cell 1 Cell 2 
1 0.00 0.00 
2 0.00 0.71 
3 0.73 1.63 
4 1.29 2.27 
5 1.35 3.02 
6 1.67 3.18 
Table A47: Fluxes (µg/h) of naltrexone. Receiver solution C (Tris pH 7.4). 
 
 
Hours Cell 1 Cell 2 
1 0.00 0.00 
2 0.00 0.00 
3 0.00 0.00 
4 0.00 0.00 
5 0.00 0.00 
6 0.00 0.32 





Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.28 0.15 0.20 0.61 0.00 0.25 0.23 
3 0.63 0.46 0.59 1.14 0.12 0.59 0.37 
4 0.98 0.76 1.05 1.44 0.27 0.90 0.43 
5 1.42 1.02 1.69 1.91 0.48 1.30 0.57 
6 1.59 1.25 2.01 2.07 0.61 1.51 0.60 




Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.53 0.51 0.72 2.05 0.00 0.76 0.77 
3 2.13 1.96 2.60 4.39 0.28 2.27 1.47 
4 3.64 3.40 4.18 5.79 0.94 3.59 1.75 
5 5.20 4.44 5.35 6.91 1.57 4.70 1.96 
6 5.45 5.21 6.09 6.97 2.06 5.16 1.86 




Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
6 0.32 0.37 0.00 0.00 0.00 0.14 0.19 






Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.09 0.30 0.34 0.41 0.28 0.14 
3 0.27 0.61 0.56 0.72 0.54 0.19 
4 0.48 0.74 0.67 0.89 0.70 0.17 
5 0.60 0.99 0.71 0.89 0.80 0.17 
6 0.51 0.90 0.70 0.92 0.76 0.19 
Table A52: Fluxes (µg/h) of acetaminophen. Receiver solution E (NaCl only). 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.25 0.63 1.26 0.83 0.44 0.27 
3 1.06 1.35 2.23 1.95 1.20 0.20 
4 2.07 1.63 3.00 2.78 1.85 0.32 
5 2.78 2.45 3.14 2.64 2.62 0.23 
6 2.21 2.35 3.04 2.88 2.28 0.10 
Table A53: Fluxes (µg/h) of naltrexone. Receiver solution E (NaCl only). 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.93 0.62 0.39 0.47 
4 0.00 0.00 2.25 1.52 0.94 1.13 
5 0.00 0.72 3.26 2.27 1.56 1.48 
6 0.20 0.91 4.25 2.73 2.02 1.83 







Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.16 0.11 0.10 0.00 0.12 0.20 0.12 0.07 
3 0.29 0.25 0.28 0.17 0.28 0.43 0.28 0.09 
4 0.39 0.34 0.39 0.24 0.44 0.52 0.39 0.09 
5 0.42 0.60 0.50 0.38 0.49 0.65 0.51 0.10 
6 0.48 0.61 0.56 0.37 0.56 0.53 0.52 0.08 
7 0.53 0.63 0.61 0.54 0.75 0.63 0.61 0.08 
8 0.43 0.51 0.45 0.45 0.57 0.51 0.49 0.05 
9 0.34 0.36 0.35 0.39 0.50 0.42 0.39 0.06 
23 0.11 0.07 0.12 0.11 0.15 0.12 0.11 0.02 
24 0.05 0.11 0.06 0.11 0.09 0.10 0.09 0.03 
Table A55: Fluxes (µg/h) of acetaminophen. Post-iontophoretic release. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.43 0.59 0.31 0.26 0.36 0.43 0.40 0.11 
3 1.13 1.55 1.18 0.94 1.14 1.46 1.23 0.23 
4 1.81 2.30 1.75 1.37 1.65 1.90 1.80 0.31 
5 2.16 3.44 2.27 1.86 2.15 2.42 2.38 0.55 
6 2.52 3.47 2.63 2.32 2.33 2.18 2.57 0.47 
7 2.50 2.94 2.42 2.45 2.53 2.39 2.54 0.20 
8 1.77 2.19 1.80 1.82 1.87 1.82 1.88 0.15 
9 1.41 1.53 1.46 1.56 1.62 1.51 1.51 0.08 
23 0.49 0.41 0.48 0.56 0.57 0.46 0.49 0.06 
24 0.12 0.05 -0.01 0.15 0.20 0.26 0.13 0.10 
Table A56: Fluxes (µg/h) of naltrexone. Post-iontophoretic release.  
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
4 0.17 0.11 0.12 0.00 0.00 0.00 0.07 0.08 
5 0.34 0.36 0.25 0.00 0.00 0.27 0.20 0.16 
6 0.49 0.60 0.49 0.14 0.29 0.26 0.38 0.17 
7 1.16 1.44 1.26 0.55 0.82 1.02 1.04 0.32 
8 1.32 1.63 1.35 0.53 0.80 1.04 1.11 0.40 
9 1.56 1.89 1.57 0.69 0.97 1.43 1.35 0.44 
23 1.42 1.77 1.65 0.88 1.01 1.35 1.35 0.35 
24 1.87 1.83 1.68 1.26 1.01 1.66 1.55 0.34 





Hours Cell 1 Cell 2 Cell 3 Mean SD 
1 0.00 0.00 0.14 0.05 0.08 
2 0.13 0.00 0.30 0.14 0.15 
3 0.13 0.23 0.45 0.27 0.16 
4 0.21 0.25 0.51 0.32 0.16 
5 0.31 0.30 0.49 0.36 0.11 
6 0.33 0.39 0.46 0.39 0.06 
7 0.47 0.54 0.56 0.52 0.05 
8 0.68 0.60 0.65 0.64 0.04 
Table A58: Fluxes (µg/h) of acetaminophen. 3 compartment control. 
 
Hours Cell 1 Cell 2 Cell 3 Mean SD 
1 0.20 0.17 0.28 0.22 0.05 
2 0.70 1.03 1.35 1.03 0.33 
3 1.52 1.95 2.28 1.92 0.38 
4 2.28 2.75 2.66 2.56 0.25 
5 2.74 3.02 2.79 2.85 0.15 
6 2.99 3.56 3.36 3.30 0.29 
7 3.44 3.60 2.97 3.34 0.33 
8 3.97 4.05 4.13 4.05 0.08 
Table A59: Fluxes (µg/h) of naltrexone. 3 compartment control. 
 
Hours Cell 1 Cell 2 Cell 3 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.21 0.07 0.12 
3 0.00 0.00 0.55 0.18 0.32 
4 0.00 0.25 0.72 0.32 0.36 
5 0.38 0.56 1.00 0.65 0.32 
6 0.47 0.75 1.05 0.76 0.29 
7 0.59 1.10 1.00 0.90 0.27 
8 0.90 1.38 1.52 1.27 0.33 
Table A60: Fluxes (µg/h) of buprenorphine. 3 compartment control.  
xxx 
 

















1 2.3 6.1 3.5 8.6 2.3 5.8 
2 4.4 4.0 4.5 3.2 3.1 2.4 
3-5 6.4 9.3 5.7 6.3 4.3 4.3 
6-8 9.3 6.0 7.6 4.4 6.3 3.7 












 7.8  7.9  9.0 
 






Hours Cell 1 Cell 2 Cell 3 Mean SD 
1 0.00 0.09 0.00 0.03 0.05 
2 0.00 0.00 0.00 0.00 0.00 
3 0.14 0.12 0.00 0.09 0.08 
4 0.11 0.09 0.00 0.07 0.06 
5 0.07 0.04 0.11 0.08 0.03 
6 0.20 0.14 0.08 0.14 0.06 
7 0.25 0.16 0.11 0.17 0.07 
8 0.16 0.11 0.11 0.12 0.03 
Table A62: Fluxes (µg/h) of acetaminophen. Reversing polarity. 
 
Hours Cell 1 Cell 2 Cell 3 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 
2 0.81 0.79 0.25 0.62 0.32 
3 1.35 1.37 0.77 1.16 0.34 
4 1.60 1.16 1.26 1.34 0.23 
5 2.01 1.56 1.72 1.77 0.23 
6 2.46 2.32 1.78 2.19 0.36 
7 2.34 2.32 1.74 2.13 0.34 
8 2.65 2.39 2.58 2.54 0.14 
Table A63: Fluxes (µg/h) of naltrexone. Reversing polarity. 
 
Hours Cell 1 Cell 2 Cell 3 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.00 0.00 0.00 
4 0.00 0.00 0.00 0.00 0.00 
5 0.00 0.21 0.16 0.12 0.11 
6 0.27 0.31 0.10 0.23 0.11 
7 0.27 0.35 0.31 0.31 0.04 
8 0.38 0.39 0.22 0.33 0.10 

















Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Cell 7 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.12 0.09 0.39 0.16 0.18 0.19 0.12 0.18 0.10 
3 0.30 0.27 0.83 0.41 0.41 0.36 0.32 0.41 0.19 
4 0.49 0.42 1.09 0.65 0.73 0.58 0.62 0.65 0.22 
5 0.59 0.52 1.35 0.83 0.77 0.77 1.02 0.84 0.28 
6 0.67 0.57 1.38 1.04 1.08 1.05 1.29 1.01 0.30 
Table A70: Fluxes (µg/h) of acetaminophen. 0.14 mg/ml NTX & 0.5 mg/ml BUP. 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Cell 7 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.40 0.19 0.66 0.68 1.03 0.97 0.56 0.64 0.29 
3 1.26 0.78 1.40 1.77 2.14 1.99 1.72 1.58 0.47 
4 1.99 1.50 2.08 2.82 3.46 3.12 2.70 2.53 0.69 
5 2.54 1.91 2.68 3.42 3.51 3.32 3.61 3.00 0.63 
6 2.44 2.20 2.93 3.92 4.24 4.24 3.64 3.37 0.85 
Table A71: Fluxes (µg/h) of naltrexone. 0.14 mg/ml NTX & 0.5 mg/ml BUP. 
 
 
Hours Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Cell 7 Mean SD 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
4 0.00 0.00 0.20 0.21 0.44 0.24 0.00 0.16 0.17 
5 0.38 0.16 0.56 0.40 0.59 0.80 0.42 0.47 0.20 
6 0.44 0.21 0.73 0.67 0.87 0.84 0.50 0.61 0.24 
Table A72: Fluxes (µg/h) of buprenorphine. 0.14 mg/ml NTX & 0.5 mg/ml BUP. 
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